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Abstract 
The secretory pathway Ca2+-ATPase (SPCA) provides the Golgi apparatus with a 
luminal Ca2+ store, which is used to modulate the activity of Ca2+-dependent enzymes 
involved in controlling the secretory pathway and post-translational modification of 
proteins. This Ca2+ store controlled by SPCA is also believed to be agonist-releasable. 
Regucalcin (RGN), (also known as senescence marker protein 30 (SMP30)) is 
believed to be a Ca2+-binding protein expressed in an age-dependent manner, whereby 
its protein levels decrease in a number of organs as aging progresses. It has been 
suggested to be able to affect the activities of the sarco/endo-plasmic reticulum Ca2+-
ATPase (SERCA), as well as other Ca2+-dependent enzymes. On the other hand, 
RGN’s ability to bind Ca2+ has been argued against and this protein has been shown 
to modulate the activities of enzymes not involved in Ca2+ homeostasis, as well as 
have intrinsic enzymatic activity in itself as a gluconolactonase.  
 It was of interest in the present studies to examine how SPCA can be regulated 
and how RGN can contribute to the regulation of Ca2+ homeostasis within intact cells. 
As a result, the following novel attributes of SPCA and RGN were shown: (1) SPCA 
expression and activity are sensitive to glucose homeostasis in rat vascular smooth 
muscle cells (VSMCs); (2) hSPCA1d activity can be inhibited without altering 
hSERCA2b activity by using bis-phenol and 2-APB; (3) TFP and TBBPA affect both 
hSPCA1d and hSERCA2b activities to the same degrees, while cADPR and NAADP 
have no effect on hSPCA1d (and possibly hSERCA2b in the case of cADPR) activity; 
(4) RGN mRNA expression can be found in some specialised cell types of the male 
rat reproductive system; and (5) human RGN over-expression can influence Ca2+ 
mobilisation stimulated by 1µM thapsigargin and 10µM histamine, possibly via 
alteration of SERCA expression. The present study has also made available a custom-
made recombinant form of rat RGN and anti-RGN polyclonal antibodies.  
 It can be strongly suggested that SPCA plays a role in diabetes because of its 
sensitivity to glucose concentrations, coupled with its involvement in the secretory 
pathway and ability to influence vasopressin response in VSMCs. Bis-phenol has now 
been quantitatively shown to be a potent and specific inhibitor of SPCA, giving it 
great potential to be used as a pharmacological tool for future research on this Ca2+-
ATPase. For RGN, it appears promising that this cytosolic protein has a role to play in 
male fertility, while its role in Ca2+ homeostasis is likely to involve modulating ER 
Ca2+ storage capacity and strength of Ca2+-mediated hormone response.      
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CHAPTER 1.  
INTRODUCTION 
 
1.1. Ca2+ in Cells (An Overview) 
1.1.1. The Importance of Cellular Ca2+ 
Ca2+ homeostasis is an essential part of maintaining normal function of a eukaryotic 
cell by contributing to a diverse number of processes that span its entire life cycle. It 
has two general biochemical functions, which are to act as either a structural stabiliser 
or cofactor upon binding to a protein (Williams, 2006). The processes in which Ca2+ 
is important can be both specialised to a specific cell type or exist for housekeeping 
purposes in all cells. Examples of such processes include initiating skeletal muscle 
contraction upon Ca2+ binding to troponin C (Cohen et al., 1980) and activation of a 
multitude of kinases by the Ca2+-calmodulin complex (CaM) (Swulius and Waxham, 
2008).  
There are two aspects of Ca2+ homeostasis that make it possible for this cation 
to be able to contribute to a vast number of different processes. Firstly, it is controlled 
by a large number of different proteins, which are found in the form of transporters, 
enzymes and modulators, and altogether give a “toolkit” for intracellular Ca2+ 
handling (Berridge et al., 2003). The second is that Ca2+ is distributed into discrete 
pools within a cell with the use of membrane-bound organelles as specialised storage 
compartments (Michelangeli et al., 2005). The maintenance of different Ca2+ 
concentrations ([Ca2+]) by components of the aforementioned toolkit at these different 
pools create ionic gradients, which can be used to re-distribute Ca2+ around different 
parts of a cell rapidly when required. This results in significantly large changes in 
[Ca2+] between the organelles, extracellular space and cytoplasm. Along with Ca2+, all 
cells have Ca2+-dependent proteins, which are also segregated into discrete 
intracellular environments, and those with non-complementary organelle- or process-
specific functions are kept apart from each other.  Changes in the distribution of Ca2+ 
act as switches, which either turn on or off the activity of different sets of Ca2+-
dependent proteins to give a change in the number and type of Ca2+-dependent 
processes that take place in a cell within a given time.  
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1.1.2. Ca2+ Distribution Within a Cell 
The movement of Ca2+ in a cell to the right place and at the right time is key. For 
instance, too little Ca2+ in the cytoplasm of spermatozoa could prevent the acrosome 
reaction from taking place (Yanagimachi and Usui, 1974, Breitbart, 2002). On the 
other hand, too much Ca2+ in the cytoplasm of hippocampal neurons can cause cell 
death instead of mediating the normal signalling pathways associated with glutamate 
stimulation (Randall and Thayer, 1992). Thus Ca2+ movement needs to be tightly 
controlled. The use of a large number of Ca2+ channels, exchangers and pumps, as 
well as discrete Ca2+ stores, (figure 1.1.2.1) give this control (Michelangeli et al., 
2005).  
There are two main routes of Ca2+ transit in a cell, which are that between the 
cytoplasm and organelles, and between the cytoplasm and extracellular space. Both of 
these routes run bi-directionally. The movement of Ca2+ into the cytoplasm leads to 
the initiation and propagation of major signalling pathways, whereas the movement of 
Ca2+ out of the cytoplasm results in their termination. Caspase-dependent apoptosis is 
an example of a process that requires the flow of Ca2+ into the cytoplasm to take place 
(Orrenius et al., 2003). Ca2+ movement between the cytoplasm and organelles is 
required for processes specific to the latter, whereby an example would be the 
requirement of Ca2+ by dehydrogenases in the citric acid cycle that takes place in the 
mitochondria (Traaseth et al., 2004).  
 
1.1.3. Ca2+ Channels, Pumps & Exchangers  
Many of the Ca2+ transporters known to exist in cells are shown in figure 1.1.2.1. The 
movement of Ca2+ from the extracellular space into the cytoplasm is controlled by 
three main types of channel proteins, namely voltage-operated Ca2+ channels (VOCs), 
receptor-operated Ca2+ channels (ROCs), and store-operated Ca2+ channels (SOCs) 
(Bootman et al., 2001). Members of these three types of Ca2+ transporters are all 
located at the plasma membrane. Two other proteins, which are the Na+/Ca2+ 
exchanger (NCX, also known as NCE) and the plasma membrane Ca2+-ATPase 
(PMCA), promote Ca2+ movement in the opposite direction and are also located at the 
plasma membrane (Michelangeli et al., 2005). These proteins work together to 
maintain a [Ca2+] of >1mM at the extracellular space and approximately 0.1µM in the 
cytoplasm, giving a 10,000-fold difference on either side of the plasma membrane and 
thus a very steep Ca2+ gradient in a resting cell (Rizzuto and Pozzan, 2006). 
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Figure 1.1.2.1. Ca2+ Channels, Exchangers & Pumps in a Cell 
 
The diagram shows the organelles (N – nucleus, G – Golgi apparatus, ER – 
endoplasmic reticulum, M – mitochondria, V – vacuoles, L – lysosomes, SR – 
sarcoplasmic reticulum) that can act as Ca2+ stores within a cell and their 
associated Ca2+ transporters (Michelangeli et al., 2005). 
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The proteins required for the transit of Ca2+ from the inside of their storage organelles 
into the cytoplasm are the second messenger-operated Ca2+ channels (SMOCs), which 
include the inositol-1,4,5-triphosphate receptor (IP3R), ryanodine receptor (RyR) and 
potentially the nicotinic acid adenine dinucleotide phosphate receptor (NAADPR) 
(the latter of which has been recently identified as a two-pore channel (TPC) (Calcraft 
et al., 2009)). The opposite movement along this route is directed by a different set of 
transporters, which include the H+/ Ca2+ exchanger (HCX, also known as HCE), the 
mitochondrial Ca2+ uniporter (MCU), and the sarcoplasmic/endoplasmic reticulum 
(SR/ER) Ca2+-ATPase (SERCA) (Michelangeli et al., 2005). The magnitude of 
difference in [Ca2+] between the cytoplasm and lumens of different organelles vary. In 
a resting cell, cytosolic [Ca2+] is approximately 0.1µM (Badminton et al., 1996), 
while the approximate luminal [Ca2+] in the nucleus, ER, Golgi apparatus, and 
mitochondria are 0.1µM (Badminton et al., 1996), 0.5mM (Pinton et al., 1998), 
0.3mM (Pinton et al., 1998) and 0.1µM (Vay et al., 2009), respectively. These values 
were determined using Ca2+-sensitive aequorin proteins, which were expressed 
specifically at the organelles measured for their luminal [Ca2+] in human cervix 
carcinoma (HeLa) cells.  
 
1.1.4. Patterns & Rhythms of Ca2+ Signalling 
The co-operation of all the transporters mentioned above is required to adjust and 
balance Ca2+ gradients in a cell. Typically, when a cell is in its resting state, a high 
[Ca2+] is located at the extracellular space and within organelles, and this is balanced 
with a low [Ca2+] in the cytoplasm. A dynamic redistribution of Ca2+ occurs between 
these three compartments when a cell is stimulated (e.g. by a hormone or 
neurotransmitter).  
Segregation of Ca2+ inside a cell is not just from the use of different organelles 
as their stores. Ca2+ microdomains also exist, which are local build-ups of Ca2+ at the 
points of its entry into and out of the cytoplasm. These can vary in their location, size 
and number within a cell. They come in the form of sparklets, sparks, blinks, syntillas 
and puffs, but can sometimes be referred to more generally as Ca2+ spikes (Berridge, 
2006). Ca2+ microdomains are formed by SMOCs and via Ca2+ influx across the 
plasma membrane. The RyRs are responsible for sparks, blinks and syntillas, and the 
IP3Rs give puffs. One type of microdomain, the sparklet, is formed by VOCs. The key 
  6 
purpose of forming Ca2+ microdomains, like multiple membrane-bound Ca2+ stores, is 
to keep different Ca2+-controlled processes isolated to specific regions of a cell. For 
example, syntillas have been observed to form at nerve terminals and are used for 
stimulating neurotransmitter release, which is a process that can only occur at this part 
of hypothalamic neuronal cells (De Crescenzo et al., 2004). All types of Ca2+ 
microdomains are transient events (except when large numbers of Ca2+ puffs are 
formed to create global (i.e. whole cell) Ca2+ changes), which presumably help to 
keep different processes spatially and temporally separated by reducing the chance of 
different sets of Ca2+ changes merging together. A disruption of time and space 
confinement of different sets of Ca2+ microdomains can lead to disease, such as 
alcoholic pancreatitis (Petersen et al., 2006).  
 
1.1.5. Ca2+ Stores in Organelles 
Organelles that act as intracellular Ca2+ stores include the nucleus, mitochondria and 
SR/ER. One of the first observations that led to the recognition of the nucleus as a 
Ca2+ store was from experiments with nuclei isolated from calf thymus (Naora et al., 
1961). Since then, nuclear Ca2+ stores have been suggested to have a number of uses, 
ranging from regulation of gene expression to activation of kinases (Gomes et al., 
2006). Early observations of mitochondria being able to internalise Ca2+ included that 
from experiments with rat kidney (Deluca and Engstrom, 1961), and subsequently the 
purpose of mitochondrial Ca2+ storage has been linked to apoptotic cell death as well 
as other processes (Duchen et al., 2008). The observation of SR’s ability to contribute 
to muscle contraction by utilising its internal source of Ca2+ (Weber et al., 1963) was 
one of the first to support SR/ER’s role as an intracellular Ca2+ store. Now it is well 
established that Ca2+ in the ER is required for various functions, including the folding 
and secretion of proteins (Burdakov et al., 2005).    
 
1.2. The Golgi Apparatus (An Intracellular Ca2+ Store) 
1.2.1. Structure & Function of the Golgi Apparatus 
The Golgi apparatus (as shown in figure 1.2.1.1) was an entity discovered by (and 
subsequently named after) Camillo Golgi from his work done on Purkinje cells 
(Droscher, 1998). It is an intracellular structure composed of stacks of membranous 
disks, which are individually called cisterna and each have a lumen containing various 
structural and enzymatic proteins. The cisternae are organised into three parts, which 
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Figure 1.2.1.1. Images of the Golgi Apparatus 
 
The Golgi apparatus is depicted here in the form of (A) an original drawing by 
Camillo Golgi as a structure next to the nucleus in each of nine cells (Bentivoglio, 
1998), (B) an electron microscopy photograph as the structure labelled “G” 
(Donohoe et al., 2006), (C) a three-dimensional model with its different 
compartments represented in different colours (Mogelsvang et al., 2004), and (D) 
fluorescence microscopy photographs of a vascular smooth muscle cell as the yellow 
structure labelled by immunohistochemistry (Michelangeli et al., 2005).  
 
A B 
C 
 
D 
 
  8 
are known as the cis-, medial- and trans- Golgi. The cis- and trans- parts make up the 
ends of the Golgi apparatus whilst the medial- part is positioned between them (Marsh 
and Howell, 2002). The Golgi apparatus is best known for its role in the post-
translational modification and transport of newly synthesised proteins. It is also 
capable of synthesising lipids and distributing them around the cell (Slomiany et al., 
1993). This organelle is now also believed to contribute to cell signalling, with 
reasons for this including the finding of pro-apoptotic factors at its membrane (Hicks 
and Machamer, 2005), the contents of phosphoinositide-modifying enzymes (used for 
lipid signalling) in its lumen (De Matteis et al., 2005) and its ability to act as a Ca2+ 
store (Dolman and Tepikin, 2006). 
 
1.2.2. The Golgi Apparatus & Ca2+ Homeostasis 
One of the first links made between the Golgi apparatus and Ca2+ homeostasis came 
from experiments that showed the structural integrity of the former within rat 
parathyroid glands is dependent on the [Ca2+] in their surrounding medium (Roth and 
Raisz, 1964). Another study showed microsomes derived from rat parotid and 
submaxillary glands are capable of transporting Ca2+ and required ATP to do so. Most 
of the Ca2+ uptake observed from these membranes was suggested to have come from 
the Golgi apparatus and, from this, it was hypothesised that Ca2+ in this organelle 
could play a role in protein secretion (Selinger et al., 1970). Previous research had 
already shown Ca2+ is required for agonist-stimulated secretion of enzymes (Hokin, 
1966). Following this, Ca2+-activated ATPase activity in the Golgi apparatus was 
found to exist in hamster chromaffin cells and it was noted to be distinct from ATPase 
activities detected at the plasma membrane and mitochondria (Benedecz et al., 1972).  
 
1.2.3. Ca2+ Storage in the Golgi Apparatus: Secretory Cells   
One of the earliest direct demonstrations of ATP-dependent Ca2+ uptake at the Golgi 
apparatus was done using bovine mammary glands, from which the kinetics and ATP 
dependence of this activity were observed to be similar to that found at the SR of 
skeletal muscle (Baumrucker and Keenan, 1975). The same observation was later 
made in murine mammary tissue (Watters and Neville, 1981). Other tissue types that 
have been used in early studies to show the Golgi apparatus is a functional Ca2+ store 
include mice pituitary gland (Klein et al., 1972) and rat intestines (Freedman et al., 
1977). However, it should be noted that these studies used early (and thus not very 
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well-defined) techniques of cell fractionation to isolate Golgi apparatus membranes, 
which may have contained contaminating ER.  
 
1.2.4. Ca2+ Transport at the Golgi Apparatus  
Ca2+ transport in Golgi apparatus-derived membrane vesicles from lactating rat 
mammary glands requires an activating phosphate group (e.g. the liberated phosphate 
group from hydrolysed ATP) and a Ca2+ gradient. Both sulphydryl and uncoupling 
reagents can inhibit Ca2+ transport in these vesicles, which suggests sulhydryl groups 
and H+ movement across their membranes are required for Ca2+ movement. Golgi 
apparatus-derived vesicles are also capable of accumulating enough Ca2+ to build a 
concentration gradient of 470:1, with the lowest [Ca2+] at the extravesicular side 
(West, 1981). Movement of Ca2+ through the membranes of such vesicles requires 
ATP and is dependent on the presence of Mg2+. The effect of Mn2+ has also been 
tested and its replacement of Mg2+ can result in a “deleterious” effect on Ca2+ uptake 
(West, 1981).  
Using murine mammary glands, the Km for Mg2+-ATP and Ca2+ have been 
calculated to be 2µM and 0.8µM, respectively, in Golgi apparatus-derived 
membranes. The same organ has also been used to demonstrate exogenous CaM is 
unlikely to affect ATPase activity of the Golgi apparatus, which is in contrast to its 
notable effects on PMCA (Watters, 1984). Sensitivity to quercetin (an inhibitor of 
Ca2+-stimulated ATPase activity) has been found to differ between the ATPase 
activities of Golgi apparatus membranes, erythrocyte plasma membranes and SR 
membranes. The Ki for this inhibitor is approximately 5µM for both erythrocyte 
plasma membranes and SR membranes, but has no significant inhibitory effect on 
Golgi apparatus membranes (Watters, 1984). Note that the values stated above came 
from experiments that were done with the use of non-physiological [Ca2+]. In 
contrast, Ca2+-activated ATPase activity measured from the Golgi apparatus-derived 
vesicles from rat mammary gland using assay medium [Ca2+] closer to that found 
under normal physiological conditions (2.3µM) (Virk et al., 1985) (c.f. 5µM (West, 
1981) and 0.5mM (Baumrucker and Keenan, 1975)) has shown the Km for Ca2+ at this 
organelle and associated with its ATPase activity is 0.14µM, with a Vmax of 3.1nmol 
Ca2+/min/mg protein. The stoichometry between ATP-dependent Ca2+ transport in 
these vesicles and their Ca2+-stimulated ATPase activity was also determined to be 
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within the range of 0.3-0.7, which is similar to values calculated for the more 
established “membrane-bound Ca2+-stimulated ATPases” (i.e. SERCA and PMCA).  
 
1.3. Ca2+-ATPases (An Overview) 
1.3.1. The Basic Function of a P-Type ATPase 
An ATPase is an enzyme that hydrolyses ATP in order to use both (1) the energy 
released from breaking a high-energy phosphate-phosphate bond (located between the 
β and γ phosphate groups of ATP) and (2) the negatively-charged phosphate group 
liberated from such a reaction to promote a change in its structural conformation. This 
change leads to its transportation of ions from one side of a membrane to the other in 
the case of P-type ATPases, such as the Na+-K+-ATPase and SERCA (Moller et al., 
1996). The conformational change of a P-type ATPase is promoted by the liberated γ-
phosphate group of hydrolysed ATP electrostatically binding to a catalytic aspartate 
residue, which subsequently causes a rearrangement of amino acid side chains at close 
proximity to the bound phosphate group. This results in a significant macromolecular 
change in structure of the ATPase.   
 
1.3.2. The Ca2+-ATPases - SERCA, PMCA & NCA 
The link between Ca2+ and P-type ATPases was first suggested from observations of 
Ca2+ being able to strongly activate ATPase activity found in myosin extracts from 
rabbit leg muscle (Bailey, 1942). Later on, it was hypothesised the SR can act as a 
mobilisable Ca2+ store for the purpose of muscle contraction (Ebashi, 1961). Since 
then, a 2.6Å resolution crystal structure of SERCA has been published (Toyoshima et 
al., 2000) and this revealed more about the mechanisms involved in the transport of 
Ca2+ by the ATPase that was originally identified in myosin. Two other Ca2+-ATPases 
are also known to exist, which are PMCA (Brini, 2009) and the nuclear Ca2+-ATPase 
(NCA) (Nicotera et al., 1989). However, NCA is now believed to be identical to 
SERCA (Lanini et al., 1992). 
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1.4. The Structure & Function of a Ca2+-ATPase (The SERCA Model) 
1.4.1. Ca2+-ATPases: Members of the P-type ATPase Family 
Four classes of transport ATPases are known to date, which are the P, V, F and ABC 
ATPases. SERCA and PMCA are both classed as the P-type ATPases. Both of these 
Ca2+-ATPases have the same basic structure of a membrane protein consisting of ten 
transmembrane α-helices (M1-M10), or eleven in the case of SERCA2b (Dhitavat et 
al., 2003), and four domains, the latter of which are the transmembrane (M), actuator 
(A), phosphorylation (P) and nucleotide-binding (N) domains. All discussion about 
Ca2+-ATPase structure from hereon in this section will refer to SERCA because it is 
the only Ca2+-ATPase that has had its structure thoroughly studied (Toyoshima, 
2008). The crystal structures of SERCA are shown in figure 1.4.1.1.  
 
1.4.2. M: The Transmembrane Domain 
The M (transmembrane) domain is a membrane-embedded yet still notably dynamic 
part of the protein. Amino acid residues in helices M4-M8 form the Ca2+-binding sites 
at the centre of the protein, which are known as site I and site II in SERCA. Site I is 
formed mainly by the M5 and M6 helices, while site II is formed by the M4 and M6 
helices. Amino acid residues that contribute to the Ca2+-binding sites do so by using 
their oxygen atoms to co-ordinate with their nearest Ca2+ at a distance of 2.2-2.6Å. 
The two sites can be distinguished from each other based on which oxygen atoms 
their Ca2+-coordinating amino acids use to bind Ca2+. Amino acids at site I all use 
oxygen atoms located at their side chains, whereas those at site II (with the exception 
of N796) use oxygen atoms of the carbonyl groups located at their main-chain. 
PMCA has been calculated to have a 1:1 stoichiometric ratio for the number of Ca2+ 
transported for every one ATP molecule it hydrolyses and this suggests it only has 
one functional Ca2+-binding site, which was identified to be equivalent to site I 
(Schatzma.Hj, 1973).  
 In addition to the Ca2+-binding sites, there are two other important parts of the 
M domain that contribute to the binding of Ca2+ by SERCA and its related ATPases. 
The first is the N-terminal region of the M3 helix, which has been shown to be where 
thapsigargin (a potent SERCA pump inhibitor) binds to Ca2+-ATPase close to its 
F256 residue (Yu et al., 1998, Wootton and Michelangeli, 2006). Mutagenesis 
experiments have suggested this region of the SERCA pump is involved in forming  
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Figure 1.4.1.1. Crystal Structures & Reaction Cycle of SERCA 
 
Crystal structures for the four reaction states of SERCA that form during the 
process of Ca2+ transport, along with SERCA’s reaction cycle  (middle inset), are 
shown. The letters M (transmembrane), P (phosphorylation), N (nucleotide) and A 
(actuator) next to the structures indicate the positions of the four structural 
domains of SERCA (Toyoshima, 2008). 
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the “gateway” to site I and site II (Andersen et al., 2001). The second region of 
importance at the M domain is known as the L67 loop, which is a part of the amino 
acid sequence that forms a loop connecting the M6 and M7 helices. Mutational 
studies have shown this 25 amino acid-long loop is important in maintaining the 
structural integrity of the whole protein, contributes to the susceptibility of the pump 
being phosphorylated following ATP hydrolysis and defines its affinity for Ca2+ 
(Zhang et al., 2001).  
 
1.4.3. P: The Phosphorylation Domain 
The P domain is where the catalytic aspartate residue required for the binding of a 
liberated γ-phosphate group after ATP hydrolysis is located (the ‘P’ in the name 
stands for ‘phosphorylation’). The catalytic aspartic residue of SERCA is D351 
(Carafoli, 2002) and that for PMCA is D475 (Verma et al., 1988). This domain is 
formed by two parts of the SERCA amino acid sequence, which sit in a central 
position of the folded pump whilst completely protruding into the cytoplasm. One of 
the two parts of this domain is linked to the M4 helix, while the other is linked to the 
M5 helix, and both are connected to the N domain (to be discussed of later on) at 
opposite ends. A key residue found in the P domain is K684, which uses its 
positively-charged side chain to stabilise the negative charge of the “transition state 
complex” that results from the electrostatic interaction between the catalytic aspartate 
residue and the liberated γ-phosphate group of hydrolysed ATP. It is this residue, 
along with a number of catalytically important short sequences (e.g. the DKTGT355 
sequence) and the Rossman fold of this domain, which makes SERCA a member of 
the haloacid dehalogenase superfamily of proteins (Wuytack et al., 2002).  
 
1.4.4. N: The Nucleotide-Binding Domain 
The N (nucleotide-binding) domain is where ATP binds. This takes place near the 
vicinity of amino acid residues F487, R489 and K492, which have been shown to be 
required for ATP binding in SERCA (McIntosh et al., 1996). This domain protrudes 
into the cytoplasm and is the largest of the three domains that is positioned in this 
way. It is likely that the N domain is highly mobile because SERCA’s crystal 
structure shows it is more than 25Å away from the P domain’s catalytic aspartate 
residue when both bound to Ca2+ and in the absence of ATP. Thus it would have to 
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move in order to transfer the liberated γ-phosphate group of hydrolysed ATP between 
these two domains. This mobility of the N domain is likely to be possible due to the 
flexibility of the amino acid sequence that links the N domain to the P domain, 
suggesting it can act as a hinge between these two domains (Stokes and Green, 2003).   
 
1.4.5. A: The Actuator Domain 
The A (actuator) domain is the remaining one of the three domains that has been 
found to protrude into the cytoplasmic side of the membrane in which SERCA is 
embedded. It is the smallest of all four domains of the protein and consists of the 110 
amino acids located between the M2 and M3 helices, along with 40 amino acids at the 
N-terminus of the pump. This domain’s sensitivity to protease digestion suggests it is 
highly mobile and its position relative to the N and P domains make it very likely to 
be involved in the movements of these two domains that are necessary for the transfer 
of a phosphate group between them (Toyoshima et al., 2000).  
 
1.4.6. The Reaction Cycle of Ca2+-ATPases 
The mechanism of action to be discussed here for the SERCA Ca2+-ATPase is 
believed to be the same as that for all other P-type ATPases. It is sometimes referred 
to as a Post-Albers-type reaction cycle (Apell, 2004). The Ca2+-ATPase is believed to 
exist in two main conformations, which are the E1 state (where the protein has a high 
affinity for Ca2+) and the E2 state (when the protein has a low affinity for Ca2+). There 
are three main processes involved in the cycle, which are ion/ATP binding, ATP 
hydrolysis, and conformational change (Moller et al., 2005). The existence of the 
reaction steps to be discussed was first suggested from measurements made of the 
kinetic parameters associated with Ca2+-dependent ATPase activity found in SR 
vesicles from rabbit skeletal muscle, such as Ca2+ affinity and rate of ATP hydrolysis 
(Takakuwa and Kanazawa, 1981a, Takakuwa and Kanazawa, 1981b). The regions at 
which these steps take place in the SERCA structure was not elucidated until its first 
high resolution crystal structure was made available (Toyoshima et al., 2000).  
The first step of the SERCA reaction cycle (middle inset in figure 1.4.1.1) is 
the binding of two cytosolic Ca2+ to the pump at the M domain and thus the formation 
of the E1 state (Ca2E1). The second step is the formation of a high-energy 
intermediate (Ca2E1~P) following ATP-binding at the N domain and subsequent 
phosphorylation of the catalytic aspartate residue in the P domain of the ATPase. This 
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is followed by the third step of the mechanism, which is a transition from the high-
energy intermediate state to the low-energy intermediate state (E2P), via a major 
conformational change of the ATPase, which puts the opening of its ion-binding site 
into a position that faces the other side the membrane in which the ATPase is 
embedded. This results in the release of the bound Ca2+ from the pump and into the 
lumen of the organelle or the extracellular space, with their subsequent replacement 
by two or three H+ at the ion-binding site. The forth and final step to give a complete 
cycle is the hydrolytic release of the bound phosphate group with another 
conformational change, but this time moving the opening of the ion binding site to 
face the cytoplasmic side of the membrane (i.e. its original position at the start of the 
cycle) to form the E1 state again. The bound H+ are removed when this cycle is re-
started by the binding of two new Ca2+ (Wuytack et al., 2002).  
 
1.5. The Golgi Apparatus Ca2+-ATPase: PMR1 in Yeast  
1.5.1. The Genetics of PMR1 
It was in yeast Sacchromyces cerevisiae (S.cerevisiae) where a gene that encodes a 
Golgi apparatus Ca2+-ATPase was first isolated. The gene was named pmr1 and was 
identified based on its homology to the gene known to encode a plasma membrane-
located ATPase in the same organism, named pma1 (Serrano et al., 1986). From this, 
it was suggested that pmr1 is likely to encode a Ca2+-ATPase-type ion pump 
homologous to P-type ion pumps, and which resembled SERCA and PMCA (Rudolph 
et al., 1989). At the same time, another gene, named bsd1, was found to protect yeast 
deficient in superoxide dismutase (SOD) expression from oxidative stress when 
mutated to give a recessive phenotype. Furthermore, the position of this gene was 
found to match that mapped for the pmr1 gene and thus the two were identical 
(Lapinskas et al., 1995).  
 
1.5.2. Activity & Role of PMR1 
The identification of PMR1’s “significant sequence similarity” with mammalian 
SERCA and PMCA (at their N-terminus and region between transmembrane helices 
5-6) was what first suggested PMR1 to be a Ca2+-ATPase (Rudolph et al., 1989). 
BLAST sequence analysis shows PMR1 shares 34% amino acid sequence identity 
with human SERCA (all three isoforms). It is at least partially located at the Golgi 
apparatus in yeast, but not at all in the ER or plasma membrane when endogenously 
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expressed. PMR1’s possible role in the secretory pathway was demonstrated from 
experiments where pmr1 mutant strains of yeast were monitored for their ability to 
glycosylate invertase and proteolytically process α factor. These processes require the 
activity of GDPase (an enzyme involved in Golgi apparatus-localised glycosylation) 
and KEX2 (an endoprotease), respectively. The absence of pmr1 expression was 
shown to cause defects in both processes, which however could be partially 
(glycosylation) or fully (proteolytic processing) recovered by increasing [Ca2+] in the 
external medium (Antebi and Fink, 1992). Other processes that involve the Golgi 
apparatus, such as vacuolar sorting of carboxypeptidase Y (CpY) and unfolded 
protein response (UPR) pathway (the detection and removal of misfolded proteins in 
the ER), have also been shown to be defective in mutant yeast unable express pmr1. 
Though control of UPR can be recovered following heterologous expression of 
SERCA1a (note that yeast do not express SERCA), which originally suggested 
endogenous PMR1 supplies the ER with Ca2+ as well as the Golgi apparatus in yeast 
(Durr et al., 1998).  
The initial rates of Ca2+ uptake in S.cerevisiae-derived membranes rich in 
PMR1 protein have been calculated to be within the range of 1-2 nmol/min/mg 
protein, which agrees well with rates determined from rat mammary gland Golgi 
membranes (Virk et al., 1985). PMR1 is distinct from mammalian SERCA and 
PMCA due to their difference in sensitivity to certain inhibitors. Vanadate inhibits 
SERCA and PMCA with Ki values of 50-300µM and 0.6µM, respectively, whereas 
PMR1 has a Ki value of 130µM, which would make it appear to relate more to 
SERCA. However, it has also been demonstrated that PMR1 cannot be inhibited by 
thapsigargin, at least at concentrations of up to 5µM, and Ca2+ transport activity 
measurements have shown PMR1 resembles PMCA by having only one Ca2+ binding 
site (Sorin et al., 1997).  
Recently, PMR1 expression in yeast has been shown to be able to influence 
viral recombination, using the Tomato bushy stunt virus (TBSV) (a virus that 
normally infects tomato plants). Loss of PMR1 expression increased the TBSV’s rate 
of RNA recombinant formation, which is a factor of the viral life cycle that promotes 
resistance to viral infections by increasing their genetic diversity. This effect was 
attributed to PMR1 keeping cytosolic Mn2+ concentration low, which hinders the 
process of viral RNA recombination (Jaag et al., 2010).  
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1.5.3. Important Amino Acid Residues in PMR1 
Some of the residues identified to be of significance to PMR1 function include Q783 
in the M6 helix, which has been suggested to play a role in Mn2+-selective binding. 
E329 in the M4 helix and A749 in the M5 helix are likely to play a role in Ca2+-
selective binding. Residues that have been noted to be important for correct folding 
and Golgi apparatus localisation of the PMR1 pump are N774, D778, T817 and D856, 
which are within the region between the M6-M8 helices (Wei et al., 2000). Phenotype 
screening experiments confirmed Q783 is involved in Mn2+ transport and showed 
D778 is required for cation binding. V335 and F738 have also been identified as two 
residues that are likely to contribute to PMR1’s ability to transport Mn2+, which is due 
to their likely interaction with Q783 and the location of all three residues at the 
membrane interface of the pump. The exact positions of the Q783 and V335 side 
chains have been noted to be important because swapping the position of these amino 
acids causes loss of PMR1 activity (Mandal et al., 2000). 
Mutant yeast lacking in PMR1 expression have an increased level of 
sensitivity to high [Ca2+]. Such yeast accumulate more Ca2+ than wildtype, are less 
responsive to changes in extracellular [Ca2+] and are also more sensitive to Mg2+. The 
latter suggests the transport of Ca2+ and Mg2+ competitively influenced each other. 
The wildtype phenotype can, however, be recovered in these mutants after they are 
made to express hSPCA1 (the human PMR1 homolog (to be discussed in detail later) 
(Hu et al., 2000, Sudbrak et al., 2000)), which suggested the Ca2+ transport properties 
of PMR1 and its human homolog are very similar (Szigeti et al., 2005).  
 
1.5.4. Control of PMR1 Expression 
Tcn1p (also known as Crz1p) is a transcription factor in yeast that is likely to control 
pmr1 expression in response to changes in cytosolic [Ca2+] via its regulation by 
calcineurin (a Ca2+-activated phosphatase) (Matheos et al., 1997). PMR1’s expression 
is also linked with that of another Ca2+-ATPase, named PMC1, which is localised in 
the vacuoles of yeast. Simultaneous low or no expression of both pmc1 and pmr1 
genes in yeast can cause an increase in cytosolic [Ca2+] and subsequently growth 
arrest. However, loss of PMR1 alone does not affect yeast growth significantly and 
growth arrest from loss of both PMC1 and PMR1 expression only occurs when 
calcineurin is activated (Cunningham and Fink, 1994, Cunningham and Fink, 1996).   
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1.6. The Golgi Apparatus Ca2+-ATPase: SPCA in Other Eukaryotes 
Note that any PMR1 homolog from hereon are those expressed in higher eukaryotes 
and will be referred to as a secretory pathway Ca2+-ATPase (SPCA).  
 
1.6.1. C.elegans 
Caenorhabditis elegans (C.elegans) express two mRNA transcripts that encode for 
SPCA, which differ at their 5’-untranslated sequence and can be trans-spliced to give 
additional transcripts. Their predicted amino acid sequences share around 50% 
identity with yeast PMR1 and 37% identity with rat SERCA2a. However, this 
organism does not appear to express multiple isoforms of SPCA at the protein level. 
Further sequence analysis has shown it only has one Ca2+-binding site, which makes it 
resemble PMCA as shown in studies with PMR1 (Sorin et al., 1997). However, this 
site shares high sequence similarity with the site II Ca2+-binding site found in 
SERCA, rather than site I unlike PMCA. SPCA has been directly observed to be 
localised at the Golgi apparatus in C.elegans (Van Baelen et al., 2001).        
 
1.6.2. Sea urchin 
Sea urchin sperm express SPCA and it is unusual compared to its homologs in other 
species because it is localised to the mitochondrion rather than the Golgi apparatus of 
each cell. This is one of a very few cell types that has been shown to have an atypical 
location for SPCA function (Gunaratne and Vacquier, 2006). Thapsigargin and 
cyclopiazonic acid (CPA; a mycotoxin) have very little influence on intracellular 
[Ca2+] in sea urchin sperm cells, which suggests SPCA is the main Ca2+-ATPase in 
these cells because of this protein’s insensitivity to these inhibitors of Ca2+ transport 
as suggested from previous studies (Sorin et al., 1997). Furthermore, SPCA is likely 
to be important in the acrosome reaction in sea urchin sperm because bis-phenol (an 
inhibitor of all Ca2+-ATPases (Brown et al., 1994)) can inhibit this process 
(Gunaratne and Vacquier, 2006).  
 
1.6.3. Drosophila 
Drosophila melanogaster (D.melanogaster) is another eukaryote that expresses 
SPCA, which was initially named SPoCK for this organism and comes in the form of 
three different isoforms. These isoforms are located at different organelles, which are 
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the Golgi apparatus (SPoCK-A), ER (SPoCK-B), and peroxisome (SPoCK-C). Like 
the Golgi apparatus and ER, the peroxisome is a Ca2+ store (Raychaudhury et al., 
2006). Again, like sea urchin sperm cells, D.melanogaster demonstrates an atypical 
location of SPCA function in the form of this latter organelle. The SPoCK gene 
product has a predicted 50% identity match with yeast PMR1. SPoCK-A and SPoCK-
B have been shown to contribute to Ca2+ signalling in embryonic S2 cells and adult 
renal tubule principal cells from D.melanogaster, respectively. Whereas SPoCK-C 
plays a role in bulk Ca2+transport in peroxisome-derived spherites commonly found in 
the renal anterior tubule of D.melanogaster. Thus, whereas SPoCK-C is only 
associated with Ca2+ transport and storage, the SPoCK-A and –B isoforms can 
contribute to Ca2+ homeostasis and/or Ca2+ signalling (Southall et al., 2006).    
 
1.7. The Golgi Apparatus Ca2+-ATPase: SPCA in Mammalian Cells 
1.7.1. Rat SPCA 
Mammalian SPCA was originally identified using DNA probes of the S.cerevisiae 
pmr1 gene to screen for a homolog in rat cDNA libraries derived from brain, kidney, 
testes and stomach tissue. From this, two mRNA sequences of two different lengths, 
3.9kb and 5kb, were isolated. Their predicted translated amino acid sequences 
exhibited all the conserved domains known to be associated with P-type ATPases, and 
shared a high level of sequence similarity with PMCA, SERCA and PMR1 (Gunteski-
Hamblin et al., 1992). BLAST analysis shows rat SPCA (Pubmed protein databank 
entry number NP_571982.2) shares 33% sequence identity with human SERCA (all 
three isoforms) at their amino acid sequences. The abundance of mRNA for both 
sequences is notably high in brain, lung and stomach. Though most rat tissues are able 
to express some SPCA and so it is likely to play a general housekeeping role in most 
cell types. A third mRNA transcript size, 3.7kb, is expressed in rat testes, and a forth 
transcript size, 6kb, has also been isolated. The 3.7kb and 3.9kb mRNA sequences 
only differ at their C-terminus and thus the 3.7kb transcript is likely to be an 
alternatively spliced variant of the 3.9kb transcript (Gunteski-Hamblin et al., 1992).  
 
1.7.2. Argument Against the Existence Of Mammalian SPCA 
It was once argued that Ca2+-activated ATPase activity previously measured may 
have been from newly synthesised SERCA and/or PMCA in transit through the Golgi 
apparatus rather than from one specifically located at the Golgi apparatus. Using 
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Golgi apparatus membrane fractions isolated from rats that were treated with a protein 
synthesis inhibitor, cycloheximide (to ensure the lumen of this organelle carried little 
or no proteins in transit to other organelles), Taylor et al. showed the ATPase activity 
that had been located in the Golgi apparatus previously was most likely have been a 
detection of both SERCA and PMCA (Taylor et al., 1997). Although there has been 
one recent study that supports the localisation of SPCA at the plasma membrane of 
cells in rat liver (Dmitriev et al., 2003), a greater number of others have given 
substantial evidence in support of the existence of mammalian SPCA at the Golgi 
apparatus following Taylor et al.’s work (Missiaen et al., 2001, Van Baelen et al., 
2001, Wootton et al., 2004, Sepulveda et al., 2007, Sepulveda et al., 2009), including 
a demonstration of SPCA’s localisation at the Golgi apparatus using 
immunohistochemistry (figure 1.7.2.1).  
 
1.8. The Role of SPCA in Eukaryotic Cells 
1.8.1. SPCA in Oxidative Stress 
C.elegans has previously been used to demonstrate the role of SPCA in the oxidative 
stress response pathway, which is a process also found in mammalian cells (Cho et 
al., 2005). From this, it has been observed that this organism’s sensitivity to Ca2+ and 
Mn2+ depletion is abnormal when endogenous SPCA expression is artificially 
depleted (using RNA silencing methods). Furthermore, SPCA-depletion in C.elegans 
mutants deficient in superoxide dismutase 1 (SOD1) expression (and thus are highly 
susceptible to oxidative stress) result in the mutants being less oxygen-sensitive 
compared to control cells, which resembles previous findings in yeast (Lapinskas et 
al., 1995). Resistance to oxidative stress in the double mutant has been attributed to 
SPCA’s role in Mn2+ homeostasis (rather than its Ca2+ handling function) due to the 
requirement for Mn2+ by antioxidant enzymes and the ability of this ion to act as a 
radical oxygen species (ROS) scavenger (Cho et al., 2005). 
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Figure 1.7.2.1. Immunolocalisation of Over-Expressed SPCA & SERCA in 
COS-1 Cells 
 
Over-expressed C.elegans SPCA protein (green staining in (1a) and (1c)) is shown 
to co-localise with the Golgi apparatus marker, 58K protein (red staining in 1b) 
and (1c)), in COS-1 cells. Whereas over-expressed rabbit SERCA2a protein (green 
staining in (2a) and (2c)) does not co-localise as tightly with 58K protein (red 
staining in (2b) and (2c)) and is more diffusely distributed in COS-1 cells than 
SPCA (Missiaen et al., 2001).     
(1) (2) 
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1.8.2. SPCA in Protein Synthesis & ER Stress 
SPCA’s role in protein folding and post-translational modification of newly 
synthesised proteins in the ER and Golgi apparatus was suggested from siRNA 
knockdown experiments with cell lines. Depletion of SPCA expression by this 
method in rat thyroid cells (FRT) and human embryonic kidney 293 cells (HEK 293) 
can prevent mutant cog thyroglobulin, which cannot be correctly glycosylated, from 
being removed via ER-associated degradation (ERAD). However, the same result has 
not been observed with all proteins, such as mutant insulin that also cannot be 
correctly glycosylated. From this, it has been suggested that a protein’s dependence 
on SPCA activity for its glycosylation depends on the amount of N-glycans they 
require. Loss of SPCA expression is unlikely to reduce ERAD directly because 
knockdown of SPCA expression in HEK 293 cells does not change the expression 
levels of BiP (an ER chaperone), which normally increases when the unfolded protein 
response (UPR) pathway is activated by ERAD defects. At the same time, FRT cells 
are more susceptible to tunicamycin-induced ER stress, which occurs as a result of a 
defective ERAD system, when SPCA expression is knocked down. Thus it has been 
suggested that SPCA assists ERAD by affecting its activity downstream of its 
activation, possibly by providing Ca2+ required by ER chaperones (e.g. BiP) (Ramos-
Castaneda et al., 2005).  
 
1.8.3. SPCA in Lactation 
SPCA expression has been shown to increase in mammary tissue during the 
progression of pregnancy in rats. SPCA turnover in mammary tissue can be rapid 
enough to result in mRNA expression becoming seven to eight times higher in 
lactating mammary glands than in brain. At the same time, SPCA protein levels can 
be two to three times higher in mammary glands than in brain. SPCA protein 
expressed is also 2kDa bigger in mammary glands than that expressed in rat brain and 
testes. This latter observation was attributed to either alternative splicing or post-
translational modification, but it has yet to be established which one is correct 
(Reinhardt et al., 2000). The importance of SPCA expression in the process of 
lactation has also been emphasised by a more recent study, which has shown SPCA 
protein levels are reduced by 80-95% within 24 hours of this process being stopped 
artificially, leading to the start of involution by causing mitochondrial overload and 
subsequent cell death to stop milk production (Reinhardt and Lippolis, 2009).  
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1.8.4. Influence of SPCA on Other Ca2+ Homeostasis Proteins 
The abundance of SPCA can influence the expression levels of a number of other 
proteins involved in Ca2+ homeostasis (at least when over-expressed). By over-
expressing rat SPCA in the African green monkey kidney cell line, COS-7, the 
abundance of SERCA, PMCA and calreticulin (an ER-localised Ca2+-binding protein) 
have been shown to decrease. On the other hand, expression levels of CALNUC (a 
Golgi apparatus-localised Ca2+-binding protein) increases following over-expression 
of rat SPCA in these cells (Reinhardt et al., 2004). 
 
1.8.5. SPCA in Insulin Secretion 
RNA silencing of SPCA expression in both the pancreatic islet β-cell-lines from rat, 
INS1, and mice, MIN6, results in a higher than normal influx of Ca2+ following SOC 
activation, which is reduced to control levels when cells are treated with nimodipine 
(a voltage-gated Ca2+ channel inhibitor). However, voltage-gated Ca2+ channel 
expression and activity do not differ between SPCA-depleted and control cells. 
Furthermore, glucose-stimulated insulin secretion is increased but basal insulin 
secretion remains the same as control levels in SPCA-depleted cells. Glucose-
stimulated Ca2+ oscillations have also been noted to be different in their duration and 
frequency between SPCA-depleted and control cells. Thus it has been suggested that 
SPCA’s role is not solely to store Ca2+ into the Golgi apparatus and secretory vesicles, 
but also (at least in rat pancreatic β-cells) to modulate Ca2+ signalling, which can 
affect the activity of plasma membrane-located voltage-gated Ca2+ channels (Mitchell 
et al., 2004). 
 
1.8.6. SPCA in Brain Development & Function 
SPCA1 (one of two SPCA isoforms expressed in mammalian cells) knockout mice 
have shown this Ca2+-ATPase is required for closure of the neural tube during 
embryonic development. This is in contrast to its apparent lack of contribution to 
development of the cardiovascular system, which was observed to be normal in 
homozygous null mutants that all died by gestation day 11.5. Death of these null 
mutants was attributed to higher than normal apoptotic activity and “Golgi-specific 
stress”, both of which are likely to have been due to deficient handling of Ca2+ and 
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Mn2+ by the Golgi apparatus (Okunade et al., 2007). SPCA1 expression and activity 
have also been shown to increase in the brain (specifically noted in the cortex, 
hippocampus and cerebellum) during the early stages of postnatal development in 
mice. In addition to this, intracellular localisation of SPCA1 can change over time 
with progression of development. Its associated pattern of change in localisation made 
authors suggest that this Ca2+-ATPase may play a role in neuronal migration and 
morphogenesis (Sepulveda et al., 2008). Furthermore, SPCA has also been associated 
with neuronal differentiation after experiments with a mouse neuroblastoma cell line, 
N2a, showed SPCA1 knockdown in expression hinders neurite formation and Golgi 
apparatus-localised protein trafficking (Sepulveda et al., 2009). 
Experiments that focused on SPCA1 expression in pig cerebellum has shown 
its activity can be detected in both synaptosomes and microsomes in this part of the 
brain, and have a restricted intracellular localisation pattern that corresponds to 
“major compartments” of the Golgi apparatus found in the soma of Purkinje cells and 
interneurons. Furthermore, the ability of Mn2+ to inhibit Ca2+ transport by SPCA1 in 
cerebellar neurons suggests it is involved in neurodegenerative diseases that are 
promoted by Mn2+ toxicity (Sepulveda et al., 2007). Levels of SPCA expression and 
activity have also been shown to be sensitive to oxidative stress in ischemic rat brain 
(Pavlikova et al., 2009).       
 
1.9. SPCA & Ca2+ Signalling in Mammalian Cells 
1.9.1. C.elegans SPCA in COS-1 cells 
COS-1 (an African green monkey SV40 transformed kidney cell line) cells made to 
express C.elegans SPCA by transfection can produce one of either two different 
responses to 0.1mM ATP stimulation after pre-treatment with thapsigargin, which are 
either (1) a “steady” rise and gradual fall in [Ca2+], or (2) oscillatory “baseline Ca2+ 
spiking”. Both of these responses have been observed to be near-equally common in 
transfected COS-1 cells (Missiaen et al., 2001). Such cells pre-treated with 
thapsigargin (in order to remove the effects of SERCA) and stimulated with ATP 
have also been used to demonstrate the effects of a number Ca2+ signalling effectors 
on SPCA.  
 From this, it has been shown that the ER is 55% more sensitive to IP3 
stimulation in control cells than those made to over-express C.elegans SPCA. 
Treatment with caffeine (an inhibitor of IP3Rs (Brown et al., 1992), as well as 
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activator of RyRs (Tovey et al., 1998)) can produce a latent period between 
capacitative Ca2+ entry (CCE) and subsequent ATP-stimulated Ca2+ release in 
C.elegans SPCA-over-expressing COS-1 cells, which is not observed in control and 
SERCA1-over-expressing cells. This latent period is followed by a rapid cytosolic 
[Ca2+] rise rather than a more gradual one seen in control and SERCA1-over-
expressing cells. It has been suggested that the difference in IP3R sensitivity between 
control and SPCA-over-expressing COS-1 cells, as demonstrated with caffeine, is 
responsible for the latent period observed between CCE and ATP-stimulated Ca2+ 
release in C.elegans SPCA-over-expressing cells.  
Another finding from the same experimental COS-1 cell model is that ATP 
stimulation results in Ca2+ oscillations (mostly of the steady baseline-type) in over 
50% of thapsigargin pre-treated SPCA-over-expressing cells, which was in contrast to 
the classic Ca2+ response profile of a sustained Ca2+ rise followed by a gradual fall 
back to basal levels observed in 90% of control and SERCA1-over-expressing cells.  
Furthermore, ilimaquinone (a Golgi-apparatus-disrupting agent) can have a diverse 
number of effects on the Ca2+ oscillations observed in ATP-stimulated SPCA-over-
expressing cells, ranging from the modification of their frequency or amplitude to 
their complete inhibition. From this, it has been suggested that these Ca2+ oscillations 
observed in both cell types may be influenced by protein kinase D activity because 
ilimaquinone disrupts the Golgi apparatus by activating its vesiculation via this 
enzyme. Note that the vesiculation process itself is unlikely to be responsible for 
ilimaquinone’s effects because brefeldin A (another compound that promotes Golgi 
apparatus vesiculation) has no effect on the Ca2+ oscillations observed in SPCA-over-
expressing cells (Missiaen et al., 2001).    
 
1.9.2. SPCA & Ca2+ Signalling In Other Mammalian Cell Types  
The rat aortic smooth muscle cell line, A7r5, and human bronchial epithelial cell line, 
16HBE14o, have been shown to contain thapsigargin-insensitive Ca2+ uptake activity 
that contributes to 8% and 11%, respectively, of the total activity. Treatment of these 
cells with sodium azide, oligomycin and antimycin A demonstrate these uptake 
systems are not associated with the mitochondria. Thapsigargin-insensitive Ca2+ 
stores in A7r5 cells are releasable upon IP3 stimulation (Missiaen et al., 2001), and 
such Ca2+ stores in both cell lines are not mobilisable following treatment with high 
concentrations (0.1-20mM) of inositol-1,3,4,5-tetrakisphosphate (IP4), cyclic ADP-
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ribose (cADPR), caffeine or nicotinic acid adenine dinucleotide phosphate (NAADP). 
Furthermore, thapsigargin-insensitive Ca2+ stores in A7r5 cells can contribute to cell 
signalling following hormone stimulation, which has been demonstrated using 
arginine vasopressin (AVP) (Missiaen et al., 2002).  
Other cell types, such as the human epithelial cell line, HeLa, human foreskin-
derived keratinocytes and COS-1 (the latter made to over-express C.elegans SPCA 
due to low endogenous SPCA levels), as well as 16HBE14o and A7r5 cells, were 
later used to further demonstrate the sensitivity of thapsigargin-insensitive Ca2+ stores 
to agonist stimulation. Their associated agonists were histamine (HeLa), ATP 
(keratinocytes, 16HBE14o and COS-1) and AVP (A7r5). These agonists were chosen 
because their associated signalling pathways are mediated by IP3 and thus the focus 
was on the relationship between IP3R activity and thapsigargin-insensitive Ca2+ stores. 
From the use of this range of cell types, it was shown that thapsigargin-insensitive 
Ca2+ stores are not responsible for agonist-stimulated Ca2+ release in all except SPCA-
over-expressing COS-1 cells, which suggested their endogenous SPCA does not 
contribute to Ca2+-mediated responses following IP3 stimulation and its role is to only 
supply Ca2+ to the Golgi apparatus-localised Ca2+-dependent enzymes (Vanoevelen et 
al., 2004).  
This would conflict with previous findings from A7r5 cells (Missiaen et al., 
2002) and later experiments with human neutrophil granulocytes (Baron et al., 2009). 
However, the authors of the latter suggested this discrepancy was likely to have been 
due to a difference in the thapsigargin concentration used to inhibit SERCA activity 
between the studies and noted 10µM thapsigargin, which was used on the five cell 
lines in the previous study, can inhibit SPCA activity (Dode et al., 2006). Thus a 
lower thapsigargin concentration (0.1µM) and shorter treatment time were used to 
inhibit SERCA activity more specifically (after comparison with 10µM thapsigargin 
also showed complete loss of Ca2+-mediated agonist response) in studies with human 
neutrophils, which showed thapsigargin-insensitive Ca2+ stores are releasable by 
treatment with agonists (N-formyl-methionyl-leucyl-phenylalanine (fMLP) and 
interleukin-8 (IL8)) that promote the Ca2+-dependent process of chemokinesis (Baron 
et al., 2009) (figure 1.9.2.1).    
 The trans-Golgi compartment of the Golgi apparatus is where SPCA is 
expressed in mammalian cells and contains a free luminal Ca2+ concentration of 
130µM according to a recent study with HeLa cells (Lissandron et al., 2010). The  
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Figure 1.9.2.1. Thapsigargin-
Insensitive Ca2+-Mediated Responses 
to Agonists in Various Mammalian 
Cell Lines & Thapsigargin 
Sensitivity of SPCA 
 
(i) Responses to agonist-induced 
changes in [Ca2+] at the cytosol in the 
absence (A) and presence (B) of 10µM 
thapsigargin pre-treatment from (a) 
HeLa cells, (b) keratinocytes, (c) 
16HBE14o cells, (d) normal COS-1 
cells, (e) COS-1 cells over-expressing 
C.elegans SPCA and (f) A7r5 cells 
(Vanoevelen et al., 2004).  
(ii) Sensitivity of human SPCA activity 
to thapsigargin inhibition, whereby the 
dotted line represents the same 
measurements made for SERCA1a 
(Dode et al., 2006). (iii) Studies on 
human neutrophils using 0.1µM and 
10µM thapsigargin pre-treatment in an 
attempt to detect for SPCA activity in 
agonist (e.g. fMLP) response (Baron et 
al., 2009). 
 
(i) 
(iii) 
(ii) 
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same study also showed SPCA-controlled Ca2+ stores contribute to ~30% of all 
agonist-releasable Ca2+ stores and ~60% of such stores that are not derived from the 
ER. Furthermore, it demonstrated that RyR, and not IP3R, controls the release of Ca2+ 
from SPCA-controlled stores, at least in rat cardiac ventricular myocytes.    
 
1.10. SPCA in Humans 
1.10.1. Identification of hSPCA1 & its Splice Variants 
Human SPCA1 (hSPCA1) was originally discovered in two studies that focused on 
the genetic cause of Hailey-Hailey disease (HHD) (to be discussed later) (Hu et al., 
2000, Sudbrak et al., 2000). Its gene, named ATP2C1, is located at chromosome 3 in 
humans at position 3q21 and is the loci for mutations associated with HHD (Ikeda et 
al., 1994). The ATP2C1 gene sequence matches considerably well with those that 
encode the P-type Ca2+-ATPases rat SPCA (97%) and yeast PMR1 (49%) (Sudbrak et 
al., 2000). Four open reading frames can be found between exon 26 and 28 of its gene 
sequence (Hu et al., 2000, Sudbrak et al., 2000). Only two alternatively spliced 
mRNA sequences from ATP2C1 were initially found, which were named ATP2C1a 
and ATP2C1b (Hu et al., 2000, Sudbrak et al., 2000). This was followed later on by  
the isolation of two more splice variants, which were named ATP2C1c and ATP2C1d 
(Fairclough et al., 2003). 
 So far, four hSPCA1 protein splice variants have been identified and are 
named hSPCA1 -a, -b, -c and -d. It has been possible to express all except the 
hSPCA1c splice variant in HEK 293 cells. Sequence analysis of hSPCA1c shows this 
variant does not have a part of its amino acid sequence that corresponds to a complete 
transmembrane helix M10 structure, which is found in the other three splice variants. 
Furthermore, attempts to measure Ca2+-stimulated thapsigargin-insensitive phospho-
enzyme formation and Ca2+ transport activity from this variant have been 
unsuccessful, unlike the other three variants (Dode et al., 2005). Taken together, it has 
been suggested that hSPCA1c is non-functional. 
 Kinetic parameters associated with Ca2+-ATPase activity of the remaining 
three hSPCA1 splice variants have been measured and compared to SERCA1a, 
following their over-expression in COS-1 cells. From this, hSPCA1 functional splice 
variants have been demonstrated to have lower maximum ATP-binding affinities, 
slower ATP turnover rates (attributed to their slower rates of dephosphorylation) and 
higher Ca2+-binding affinities than SERCA1a. The latter would apparently conflict 
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with rates of Ca2+ dissociation from these Ca2+-ATPases being faster than SERCA1a. 
However, this was explained by the idea that the apparent higher Ca2+-binding 
affinities of hSPCA1 -a, -b and -d are not due to stronger binding of Ca2+ but is 
instead caused by slow processing of the Ca2+-bound phosphoenzyme intermediate. 
ATP turnover rates of the three functional hSPCA1 isoforms are not affected by pH or 
K+ concentration, unlike SERCA1a (Dode et al., 2005). 
     
1.10.2. hSPCA2 
The isoform of hSPCA1, named hSPCA2, shares 64% amino acid identity with 
hSPCA1 (Xiang et al., 2005). Unlike hSPCA1, hSPCA2 has a more limited tissue 
distribution for its expression, whereby the tissue types that have been shown to 
express the most hSPCA2 are the testes and brain in one study (Xiang et al., 2005), 
and stomach and rectal tissue in another study (Vanoevelen et al., 2005a). As shown 
in figure 1.10.2.1, the latter study involved a more extensive search into the tissue 
distribution pattern of hSPCA2 by using mRNA samples from 83 different tissue 
types, compared to protein samples from 9 references in the former study, which did 
not test stomach and rectal tissue. The trans-Golgi network is where hSPCA2 has 
been observed to localise (at least in rat hippocampus-derived neuronal cells), along 
with its vesicular derivatives, with a “perinuclear” and “punctate” pattern of 
distribution. This is the same as hSPCA1 according to previous observations (Behne 
et al., 2003), but in contrast to PMR1’s localisation in the medial-Golgi apparatus 
compartment in yeast (Durr et al., 1998). Sub-cellular localisation of hSPCA2 in 
human colon tissue also showed it is located primarily at the Golgi apparatus, whilst 
having a “juxtanuclear” distribution pattern at this organelle with hSPCA1 
(Vanoevelen et al., 2005b). 
A study using a mutant yeast strain, which failed to express PMR1 but was 
transformed to express hSPCA2, showed the Mn2+ handling efficiency of hSPCA2 is 
the same as hSPCA1. However, hSPCA2 does not transport Ca2+ as efficiently as 
hSPCA1. The lower Ca2+ transport efficiency of hSPCA2 is explained by its lower 
binding affinity for Ca2+ compared to hSPCA1, which is evident from their Km values 
of 1.35µM and 0.25µM, respectively. Furthermore, the lower Ca2+ affinity of hSPCA2 
could be due to its EF hand-like motif (a motif commonly associated with  
Ca2+-binding) being less well conserved compared to hSPCA1. Yeast cells made to 
express hSPCA2 in the absence of PMR1 are less efficient in handling unfolded  
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Figure 1.10.2.1. Tissue Distribution of hSPCA1 & hSPCA2 Expression 
 
(A) Western blots showing the detection of hSPCA2 protein (~100kDa; 
molecular masses noted on the left) in only brain and testes out of 9 different 
tissue types (ii). The protein band detected in heart tissue at blot D was present 
on the control blot, thus not hSPCA2 protein (i). Lung, kidney and spleen 
tissues had produced ~100kDa hSPCA2 protein bands in other Western blots 
(Xiang et al., 2005). (B) mRNA hybridisation dot blots for hSPCA2 (i) and 
hSPCA1 (ii) at 83 different tissue types (iii) (Vanoevelen et al., 2005b).   
 
 
B 
 
(i) (ii) 
(iii) 
A 
(i) 
(ii) 
  31 
proteins compared to wildtype PMR1-expressing cells. Taken together, hSPCA2 
expression in the brain and its conserved Mn2+ transport efficiency (with loss of Ca2+ 
transport ability) have been linked to Mn2+ neurotoxicity-related disease, such as 
Parkinson’s disease, whereby hSPCA2 could contribute to the brain’s ability to deal 
with Mn2+ toxicity (Xiang et al., 2005). 
Over-expression of hSPCA2 in mammalian COS-1 cells has been shown to 
not affect their endogenous protein levels of hSPCA1 nor SERCA2b. With regards to 
ion-transporting efficiency, hSPCA2 is more efficient in Mn2+ transport than hSPCA1 
and has a Km for Mn2+ binding of 0.27µM when over-expressed in COS-1 cells. This 
Km value differs from that determined using yeast cells made to express hSPCA2, 
which may be due to differing Golgi apparatus structure and lipid composition 
(Vanoevelen et al., 2005a, Xiang et al., 2005). 
 
1.10.3. The Kinetics of hSPCA2 Activity 
One study has compared the functional kinetics of hSPCA2 with that of one of the 
four hSPCA1 splice variants, hSPCA1d (Dode et al., 2006). From this, hSPCA2 has 
been shown to have a weaker apparent affinity for Ca2+ but slower rate of Ca2+ 
dissociation than hSPCA1d. The conflict between these two findings is explained by 
the E1-P(Ca2+) to E2-P transition being faster for hSPCA2 than hSPCA1d.  Another 
difference between the two hSPCA isoforms is that hSPCA2 is more prone to 
thapsigargin inhibition, which is shown by Km values of 28µM for hSPCA1d and 
2µM for hSPCA2. This difference in sensitivity to thapsigargin has been attributed to 
a higher dephosphorylation rate and slower rate of E2 to E1 transition, producing a 
greater amount of hSPCA2 protein found in the E2 state (which thapsigargin binds to) 
at any given time compared to hSPCA1. The hSPCA2 isoform also has a higher ATP 
turnover rate than hSPCA1d, though it was still lower than that for SERCA1a. 
Furthermore, hSPCA2 has a lower affinity for phosphate binding and consequently a 
faster dephosphorylation rate compared to both hSPCA1d and SERCA1a, which may 
be the cause of a faster ATP turnover rate observed for the former Ca2+-ATPase.   
The two hSPCA isoforms resemble each other with regard to their lack of 
sensitivity to pH and K+ concentration. The lack of sensitivity to pH changes, which 
was recognised by the authors to be characteristic of the hSPCA pumps, has been 
attributed to these pumps being embedded in Golgi apparatus membranes (Dode et 
al., 2005). Such membranes have a higher content of sterols and sphingolipids than 
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ER membranes and this property of the former make them ideal for stabilising the E2 
state of a Ca2+-ATPase, which is unstable following the release of its bound Ca2+ 
because of the exposure of multiple negative charges at the Ca2+-binding site. The E2 
state of SERCA is instead stabilised by the binding of protons and filling of the Ca2+-
binding site with water molecules, which makes this Ca2+-ATPase sensitive to pH 
(Michelangeli et al., 1990). The lack of K+ sensitivity by both hSPCA isoforms has 
been suggested to be due to the absence of an acidic residue corresponding to E732 in 
SERCA, which has been found to be involved in K+-binding in the latter Ca2+-ATPase 
(Shigekawa et al., 1978). A neutral (N704 in hSPCA2) or shorter (D674 in hSPCA1d) 
residue at the equivalent position in the amino acid sequence of hSPCA is found 
instead.     
 
1.10.4. hSPCA1 & Human Spermatozoa 
An example of a cell type that uses hSPCA1 for a specialised role is human 
spermatozoa. This cell type has been shown to express hSPCA1, which is likely to 
contribute to progesterone-stimulated Ca2+ oscillations because it is a process that 
involves the mobilisation of Ca2+ from intracellular stores not controlled by SERCA 
pumps (shown by their insensitivity to both thapsigargin and CPA inhibition) (Harper 
et al., 2005). The association of hSPCA1 with such Ca2+ oscillations in human sperm 
cells make it unlikely to be involved in the acrosome reaction, which contrasts 
observations made previously in sea urchin spermatozoa (Gunaratne and Vacquier, 
2006). Like yeast, mature human spermatozoa are unlikely to express SERCA-type 
pumps, which makes hSPCA1 the main intracellular Ca2+-ATPase in this cell type. In 
human sperm, hSPCA1 is located in the region between the anterior midpiece and the 
rear of the sperm head (a region known as the redundant nuclear envelope) (Harper et 
al., 2005), unlike SPCA’s mitochondrial localisation in sea urchin sperm (Gunaratne 
and Vacquier, 2006).  
 
1.11. Hailey-Hailey Disease (HHD): The Clinical Significance of hSPCA1 
1.11.1. HHD – The Pathology 
Hailey-Hailey disease (HHD; also known as familial benign chronic pemphigus) is an 
inheritable disease of autosomal dominance, which manifests itself primarily in 
keratinocytes at the skin in the form of blisters, redness and erosions. Age of onset 
varies but is most commonly within the range of 30-40 years (Dobson-Stone et al., 
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2002). A key histological observation of HHD is loss of cell-cell adhesion between 
keratinocytes, a condition known as acantholysis, which has been described to give 
the skin’s epidermis a “dilapidated brick wall” appearance (Sudbrak et al., 2000).   
 
1.11.2. hSPCA1 Mutations in HHD 
Genetic profiles of 64 HHD patients in one study (Dobson-Stone et al., 2002) were 
used to organise their ATP2C1 mutations into three groups, which were those likely 
to cause (1) “non-sense-mediated mRNA decay”, (2) fault in mRNA splicing, and (3) 
non-conservative amino acid substitutions. Even within these three groups, no pattern 
was found between type and/or location of the mutations and the phenotype produced 
by them with regards to features such as, for example, age of onset and severity of 
lesions. Thus there is no single cause of HHD at the gene level and any one of a 
number of faults to hSPCA1, be it its absence or incorrect protein folding, can result 
in the HHD phenotype.      
 
1.11.3. hSPCA1 & Ca2+ Homeostasis in HHD Keratinocytes 
HHD is caused by deregulation of Ca2+ homeostasis. This was originally suggested 
from its similarities to Darier’s disease (DD), which is caused by mutations in the 
gene that encodes the SERCA2 pump (ATP2A2) (Sakuntabhai et al., 1999). Under 
conditions of normal and high extracellular [Ca2+], HHD keratinocytes have a higher 
resting intracellular [Ca2+] and weaker ability to respond to changes in [Ca2+] in the 
external environment when compared to normal keratinocytes. This observation, 
together with the idea that hSPCA1 is a Ca2+ pump, suggests a decrease in hSPCA1 
activity would disrupt post-translational modification of proteins involved in cell-cell 
adhesion, which takes place in the Golgi apparatus and requires Ca2+ most likely to be 
supplied by hSPCA1 (Hu et al., 2000). Another way abnormal hSPCA1 activity could 
cause HHD is by disrupting Ca2+-mediated cell signalling in keratinocytes (Sudbrak et 
al., 2000).      
 It has been confirmed that hSPCA1 (like most of its homologs) is localised to 
the Golgi apparatus in human keratinocytes, more specifically at the trans-Golgi 
membranes (Durr et al., 1998). Its protein levels are often observed to be lower than 
normal both in differentiated and undifferented keratinocytes of HHD patients. Ca2+ 
uptake is also deficient at the Golgi apparatus in HHD keratinocytes, when compared 
to normal keratinocytes, in the same two differentiation states. The severity of this 
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Ca2+ transport deficiency varies, corresponding well with the variable phenotypes of 
HHD patients. Total intracellular [Ca2+] is lower than normal in HHD differentiated 
cells but normal in undifferentiated cells, which suggests hSPCA1 plays an important 
role in Ca2+ handling in the former type of keratinocytes (Behne et al., 2003). 
 The Ca2+ handling properties of normal human keratinocytes resembles that of 
COS-1 cells made to over-express the C.elegans SPCA gene. The Golgi apparatus is 
also the major location of Ca2+ uptake in human keratinocytes, unlike other cell types 
(e.g. rat liver cells) that use the ER for most of their Ca2+ uptake. Ca2+-mediated 
responses to ATP stimulation in normal and SPCA-over-expressing COS-1 cells, as 
well as normal human keratinocytes, have been observed to differ. Whilst the 
response profile of a single rise and subsequent fall in cytosolic [Ca2+] is seen in all 
three cell types, the onset of a Ca2+ rise following ATP stimulation is immediate in 
normal COS-1 cells but is distanced from the time point of ATP addition by a long 
latency period in the other two cell types (Callewaert et al., 2003). Note that this latter 
response profile has been observed previously in the same two types of COS-1 cells 
(Missiaen et al., 2001). A long latency period between stimulation and response was 
also observed in SPCA-over-expressing COS-1 cells and human keratinocytes, but 
not in normal COS-1 cells, when CCE was induced (Callewaert et al., 2003). It has 
been suggested that this response profile, characteristic of hSPCA1, is caused by 
extracellular Ca2+ entering the Golgi apparatus and being kept away from the 
cytoplasm for a longer period of time by hSPCA1 activity compared to normal COS-1 
cells. 
 
1.11.4. hSPCA1 Splice Variants  
The Ca2+ and Mn2+ transport efficiencies of hSPCA1d has been measured in COS-1 
cells made to express the ATP2C1d-encoded splice variant only (Fairclough et al., 
2003). This splice variant was chosen for study because it has the longest predicted 
amino acid sequence and thus is more likely to manifest all the phenotypic defects 
associated with the mutations tested. From this, hSPCA1d’s Km for Ca2+ has been 
measured to be 0.2µM, which is similar to the values obtained for the hSPCA1a 
variant (0.26µM) (Ton et al., 2002) and C.elegans SPCA (0.25µM) (Van Baelen et 
al., 2001). In addition to this, hSPCA1d’s affinity for Mn2+ has been suggested to be 
very similar to that for Ca2+ because the [Mn2+] required to inhibit half of the pump’s 
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total Ca2+ transport capacity is the same as the Km value for Ca2+ affinity (Fairclough 
et al., 2003). 
 
1.12. Control of hSPCA1 Expression 
Two transcription factors, Sp1 and YY1, have been observed to interact with the 5’-
untranslated region of the ATP2C1 gene in keratinocytes. The region of 
transcriptional regulation is between the region of -347 and +76 nucleotides from the 
transcriptional start site. This region contains both the promotor binding site and cis-
enhancing elements, the latter of which are involved in altering the expression levels 
of their associated gene. Sp1, but not YY1, expression levels have been found to 
increase in normal keratinocytes when their extracellular [Ca2+] is increased, which is 
likely to also increase total hSPCA1 expression activity in these cells. This may 
explain why the skin of some HHD patients only manifests their defects in the 
presence of environmental stress (i.e. when extracellular Ca2+ levels change 
significantly). Thus some cases of HHD may be caused by mutation in a part of 
ATP2C1’s promoter region that is Sp1’s binding site, which would allow normal 
hSPCA1 expression at resting [Ca2+] but result in lack of ability to adapt to stress-
induced changes in environmental [Ca2+] (Kawada et al., 2005). In other HHD 
phenotypes, the transcription stage of ATP2C1’s gene expression is normal but 
hSPCA1’s protein levels or function is defective (Fairclough et al., 2003), which 
would make the affected keratinocytes unlikely to cope well with both resting 
conditions and stress-associated changes in external [Ca2+]. 
 
 
1.13. An Overview of Regucalcin (RGN)  
1.13.1. RGN: A Ca2+-Binding Protein 
Regucalcin (RGN) was first identified as a cytosolic Ca2+-binding protein in rat liver 
(Yamaguchi and Yamamoto, 1978). It is unusual due to the absence of an EF hand 
motif in its structure, which is a structural motif that was once seen as an essential 
feature for a protein to able to bind Ca2+. Later on, it was demonstrated that this 
protein is capable of contributing to Ca2+ signalling, just like proteins such as CaM 
and calcineurin, despite its apparent major structural deficit. To date, it has been 
shown to be involved in calcium homeostasis in various organs, most notably the liver 
and kidneys (Yamaguchi, 2000a). This protein is also sometimes referred to as the 
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senescent marker protein 30 (SMP30) because its expression levels in a number of 
tissues appear to be age-dependent (Fujita, 1999). 
 
1.13.2. The RGN Gene 
RGN consists of 299 amino acids, has a molecular weight of approximately 33kDa, 
and the gene which encodes it has been located on the X-chromosome in rats (region 
Xq11.1-12) and humans (region Xp11.3-q11.2) (Fujita et al., 1995). The RGN gene 
has been found to exist in the genomes of a number of other mammalian organisms, 
including dogs and chickens, but has notably not been found in yeast (Shimokawa et 
al., 1995). Comparisons made between gene sequences from seven different 
vertebrate species have shown the coding regions of the RGN gene have been highly 
conserved during evolution. At the protein level, the amino acid sequences 
corresponding to these genes also demonstrate a high degree of conservation, with 
69.9-91.3% similarity between all RGN proteins from the same seven different 
sources (Misawa and Yamaguchi, 2000a).  
The RGN gene is made up of seven exons and six introns. Its 5’-flanking 
region is where transcription factors bind to alter RGN expression levels in response 
to changes in the concentration of certain factors, such as oral calcium administration 
(Murata and Yamaguchi, 1998). Important sequences within the 5’-flanking region 
for basal and regulated gene expression have been elucidated (Murata and 
Yamaguchi, 1999). The promoter region of the RGN gene has been suggested to 
contain 28 transcription factor binding sites, and those that repress its expression (e.g. 
Sp1, C/EBP-β and SRY) are believed to bind within the region of -513 to -352 
nucleotides from the transcriptional start site (Rath et al., 2008). In humans, it has 
been noted that the RGN gene can be transcribed to produce two transcripts of 
different lengths. Detailed analysis showed that only their 5’-untranslated regions 
differ, which may contribute to the synthesis of different transcripts at different times 
or stresses (Misawa and Yamaguchi, 2000b). Not all factors that affect RGN gene 
transcription influence Ca2+ homeostasis. A key example of this is the effect of 
dexamethasone (a corticosteroid), which has been demonstrated to increase RGN 
mRNA levels significantly in rat kidney cortex but, at the same time, has no effect on 
the calcium content within this organ (Kurota and Yamaguchi, 1996). 
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1.13.3. Transcriptional Control of RGN Expression 
Nuclear transcription factors that are most likely to influence RGN expression levels 
include NFI-A1 and AP-1 (Yamaguchi, 2005), as well as the regucalcin gene 
promoter region-related protein (RGPR-p117) (Misawa and Yamaguchi, 2001). 
RGPR-p117 is expressed in a number of higher organisms (including humans, rats, 
dogs, cows and fish) and has a well conserved gene sequence (Misawa and 
Yamaguchi, 2002). This transcription factor, when phosphorylated, is believed to bind 
the TTGGC sequence of the nuclear factor (NF1)-like motif in the regucalcin gene 
promoter sequence, and possibly promoter regions of other genes that also have this 
motif (Yamaguchi, 2009).  
RGPR-p117 proteins in mammals consist of 1045-1060 amino acids and all 
have a conserved DNA-binding leucine zipper motif (Sawada and Yamaguchi, 2005). 
One RGPR-p117 splice variant of 625 amino acids has been found in humans and 
suggested to be involved in the formation of placental carcinomas (Yamaguchi, 
2009). Post-translational modification of RGPR-p117 is likely to be essential for its 
function as a transcription factor because recombinant RGPR-p117 protein has been 
shown to be unable to bind the RGN gene promoter (Yamaguchi et al., 2003a) and 
analysis of its amino acid sequence has suggested it contains a number of sites for 
phosphorylation, N-glycosylation and amidation (Yamaguchi, 2009) 
Unlike RGN, RGPR-p117 expression is unaffected by the aging process 
(Yamaguchi et al., 2003a), but it has been shown in rats to be sensitive to Ca2+ 
administration when expressed in the liver (Misawa and Yamaguchi, 2002). Over-
expression studies in the rat kidney epithelial cell-line, NRK52E, have suggested 
RGPR-p117 is involved in the regulation of RGN expression when the latter is 
required for inhibiting DNA and protein synthesis (Tomono et al., 2007), and also in 
preventing apoptotic cell death by altering the mRNA expression levels of caspase 
proteins (Yamaguchi et al., 2007). Related experiments have shown RGPR-p117 
over-expression alone cannot significantly alter RGN mRNA levels and that 
hormonal control is also required (Yamaguchi, 2009).  
 
1.13.4. Hormonal Regulation of RGN Expression 
Insulin treatment of food-deprived rats has been demonstrated to increase RGN 
mRNA levels in rat liver (Yamaguchi et al., 1995). Furthermore, it has also been 
shown that RGN over-expression can cause insulin resistance in the rat hepatoma cell 
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line, H4-II-E, by repressing the expression of proteins involved in insulin signalling 
(e.g. insulin receptor and phosphatidylinositol 3-kinase (PI3K)) (Nakashima and 
Yamaguchi, 2007). Parathyroid hormone (PTH) can also increase RGN mRNA 
expression levels, which has been demonstrated in the mouse osteoblastic cell line, 
MC3T3-E1 (Yamaguchi et al., 2008a). This effect of PTH on RGN could be related to 
its stimulatory effect on RGPR-p117 mRNA expression levels, which has been 
observed in NRK52E cells (Yamaguchi, 2009). As mentioned above, RGN mRNA 
levels have also been observed to be affected by dexamethasone (a glucocorticoid) in 
the kidney cortex of rats (Kurota and Yamaguchi, 1996).  
Studies on different rat tissues have suggested 17-β-estradiol (an estrogen) can 
either increase (e.g. liver) (Yamaguchi and Oishi, 1995) or decrease (e.g. mammary 
gland and prostate) RGN mRNA levels (Maia et al., 2008). Thyroid hormone (T3) can 
have varied effects that is time-dependent, whereby treatment of rats with T3 to 
induce hyperthyroidism can initially result in higher than normal RGN mRNA levels 
in liver but this effect decreases with prolonged (5.5 days) treatment before eventually 
leading to the opposite effect (Sar et al., 2007).       
 
1.13.5. RGN Distribution in Mammalian Cells 
RGN mRNA is not expressed widely among all tissues in organisms that have the 
gene, though the findings that can be found in the literature so far often conflict with 
each other as to which tissues do express RGN. In rat, RGN protein has been detected 
in samples of liver and kidney at abundant levels, both with the use of ELISA and 
Western blotting (Yamaguchi et al., 1991, Yamaguchi and Isogai, 1993, Yamaguchi 
et al., 2002b). On the other hand, there has been a conflict between data from these 
two methods of analysis, as well as from immunohistochemistry experiments, for 
samples from spleen, testis, skeletal muscle, lung, duodenum, colon and heart of rat 
(Yamaguchi et al., 1991, Yamaguchi and Isogai, 1993, Yamaguchi et al., 2002b). 
RGN expression in rat brain has in some studies been shown to not exist at the protein 
level (Yamaguchi et al., 2002b) and in other studies has been detected successfully 
(Yamaguchi et al., 1991, Yamaguchi et al., 1999). Mice have been shown to 
endogenously express detectable levels of RGN mRNA in liver, kidney, lung and 
cerebrum (Mori et al., 2004). This same study on mice also showed mice express 
RGN mRNA in testis and lung, which conflicts with the findings from Western 
blotting and immunohistochemistry experiments stated above for rats. Sex-dependent 
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differences in RGN expression have also been observed in rat stomach tissue for 
endogenous expression, as well as in a number of other tissues when transgenically 
expressed (Yamaguchi et al., 2002b). 
 RGN has been suggested to play a role in bone resorption/loss from 
experiments with transgenic mice (Yamaguchi et al., 2002a, Uchiyama and 
Yamaguchi, 2004, Yamaguchi et al., 2004b, Yamaguchi et al., 2005). Lower than 
normal RGN protein levels have been suggested to be associated with X-linked 
muscular dystrophy from experiments with mice diaphragm, and the same study has 
also demonstrated RGN expression in mice heart and limb muscle (Doran et al., 
2006). However, the expression of RGN in rat heart is questionable due to conflicting 
outcomes of attempts to detect it, whereby some have shown it cannot be detected 
(Yamaguchi et al., 1991, Yamaguchi and Isogai, 1993, Yamaguchi et al., 2002b) and 
some have shown it can be detected (Yamaguchi and Nakajima, 2002). Discrepancy 
in RGN expression in rat heart may or may not be due to differences in age of the 
animals used for study (Akhter et al., 2007, Lim et al., 2009). Mammary glands and 
prostates in rats have been identified as other tissues where RGN is expressed (Maia 
et al., 2008, Maia et al., 2009).  
 
1.13.6. The Protein Structure of RGN 
RGN from mouse has been shown to share 60-66% amino acid sequence similarity 
with yeast (residues 136-186) and bacterial (residues 142-192) RNA polymerases, but 
it shares little homology with mammalian RNA polymerase (Ishigami et al., 2003). 
Circular dichroism experiments (Yamaguchi, 1988) have shown rat liver RGN has an 
α-helical content of 34% in the absence of Ca2+, but this percentage decreases when 
Ca2+ is present in its surrounding medium and this suggests RGN binds Ca2+ by 
loosening its structure. The same study also calculated that one RGN protein is 
capable of binding up to seven Ca2+, however, a later study disputed this finding by 
suggesting RGN has no Ca2+-binding activity (Kondo et al., 2004). The isoelectric 
point of rat RGN is 5.20 (Yamaguchi, 1988, Yamaguchi, 2005). Two attempts have 
been made to obtain a crystal structure of human RGN, with the most recent one 
successfully demonstrating the ability of this protein to bind one Ca2+ (Warizaya et 
al., 2004) (Chakraborti and Bahnson, 2010). Figure 1.13.6.1 shows early predictions 
of secondary structure features within the rat RGN amino acid sequence, alongside  
the completed crystal structure of human RGN published in 2010. The main contrast  
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Figure 1.13.6.1. The Predicted & Solved Structures of RGN Protein 
 
(A) Predicted secondary structure features of the rat RGN amino acid sequence, 
which contains 299 amino acids and the numbers indicate the positions of these 
residues from the N-terminus (left) to the C-terminus (right) (Yamaguchi, 2005). 
(B) The solved crystal structure of human RGN, shown to bind to a single Ca2+ in 
the centre of its six-β-propeller barrel fold (Chakraborti and Bahnson, 2010) 
A 
B  
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between these two structures, along with data from circular dichroism experiments, is 
the crystal structure shows far less α-helical content in the RGN protein structure.      
 
1.14. RGN & Ca2+-ATPases 
1.14.1. First Observations for Regulation of Ca2+-ATPases by RGN  
RGN’s role in regulating Ca2+-ATPase activity was first suggested from experiments 
with rat liver plasma membranes (Yamaguchi et al., 1988) and microsomes 
(Yamaguchi and Mori, 1989). More detail on RGN’s ability to alter Ca2+-ATPase 
activity was obtained from studies with microsomes from rat kidney cortex (Kurota 
and Yamaguchi, 1997). Later on, brain microsomes (Yamaguchi et al., 1999), liver 
microsomes (Takahashi and Yamaguchi, 1999), liver mitochondria (Takahashi and 
Yamaguchi, 2000), liver nuclei (Tsurusaki and Yamaguchi, 2000a), and heart muscle 
microsomes (Yamaguchi and Nakajima, 2002) were all used to investigate the effect 
of RGN on their Ca2+-ATPase activities. From this, the way in which RGN influences 
Ca2+-ATPase activities has been shown to depend on where the Ca2+-ATPase in 
question is located, with regards to the cell type and organelle.  
 
1.14.2. RGN Effects on Microsomal Ca2+-ATPases 
In rats, the way and extent to which RGN modulates Ca2+-ATPase activity in 
microsomes depends on the latter’s organ of origin. The brain (Yamaguchi et al., 
1999) has been identified as an organ in which RGN reduces such activity, whereas 
the opposite action has been observed in heart (Yamaguchi and Nakajima, 2002), 
kidney cortex (Kurota and Yamaguchi, 1997) and liver (Yamaguchi and Mori, 1989). 
For example, the concentration of RGN shown to give maximal increase of Ca2+-
ATPase activity, which was determined by measuring amount of phosphate liberated 
from reactions (and thus the activity was ATPase-specific), has been calculated to be 
10-5M in kidney cortex and 10-8M in heart muscle. Furthermore, the effects of 
dibutyryl cyclic AMP (dcAMP), IP3, digitonin (a solubilizer of membrane lipids) and 
CaM on microsomal Ca2+-ATPase activity have also been demonstrated to differ, 
both in the presence and absence of RGN, between the same four organs (Yamaguchi 
and Mori, 1989, Kurota and Yamaguchi, 1997, Yamaguchi et al., 1999, Yamaguchi 
and Nakajima, 2002). 
Nevertheless, there are also similarities between microsomal membranes from 
rat brain, heart, kidney and liver with regards to the effects of RGN on their Ca2+-
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ATPase activities. These include its inability to overcome the inhibitory effect of 
vanadate, thapsigargin and N-ethylmaleimide (NEM; a thiol reactive compound), as 
well as its lack of influence on the enhancing effect of dithiothreitol (DTT; a reducing 
agent) (Yamaguchi and Mori, 1989, Kurota and Yamaguchi, 1997, Yamaguchi et al., 
1999, Yamaguchi and Nakajima, 2002). RGN also has little to no influence on Mg2+-
ATPase activity in all four organs. Observations from experiments with NEM and 
DTT suggest SH-groups in Ca2+-ATPases (most likely those in their active sites) are 
involved in the regulation of these ion pumps by RGN (Takahashi and Yamaguchi, 
1994). 
 
1.14.3. Effects of RGN on Mitochondrial & Nuclear Ca2+-ATPases 
Rat liver has been used in the past to demonstrate the effects of RGN on Ca2+-ATPase 
activities in the mitochondria (Takahashi and Yamaguchi, 2000) and nucleus 
(Tsurusaki and Yamaguchi, 2000a), whereby it has been shown to increase and 
decrease such activity, respectively. In the presence of CaM, RGN’s activatory effect 
in rat liver mitochondria was unaffected, whereas the removal of RGN’s inhibitory 
effect in rat liver nuclei can result in CaM enhancing their Ca2+-ATPase activity. It 
has been suggested that RGN can translocate from the cytosol into the nucleus 
(Omura and Yamaguchi, 1999), and RGN protein has also been detected in the 
mitochondria (Yamaguchi et al., 2008b).  
Similarities that the mitochondria and nucleus share are the same as that found 
between microsomal Ca2+-ATPase activities from liver, kidney cortex, brain and heart 
muscle, with regards to RGN’s effects in the presence of vanadate, NEM and DTT. 
Other treatments have also been tested on these two organelles to identify which types 
of Ca2+-ATPases are acted on by RGN. In the nucleus, 1µM thapsigargin has been 
shown to inhibit the same Ca2+-ATPase activity that RGN also hinders, thus 
demonstrating that RGN acts on SERCA (Tsurusaki and Yamaguchi, 2000a). The 
same effect of thapsigargin has also been shown in experiments with liver 
(Yamaguchi and Mori, 1989) and heart (Yamaguchi and Nakajima, 2002) 
microsomes. Experiments on mitochondria have shown ruthenium red and lanthanum 
chloride (Ca2+-uniporter inhibitors) can completely block the activatory effect of 
RGN on this organelle’s Ca2+-ATPase activity, which suggests RGN can also 
influence the activity of Ca2+-uniporters (Takahashi and Yamaguchi, 2000).   
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1.14.4. RGN at the Plasma Membrane Ca2+-ATPase 
RGN is likely to be able to affect the activity of PMCA as well as SERCA. Over-
expression of human RGN in the hepatic cell line, HepG2 (Fujita et al., 1998), and the 
mouse carcinoma cell line, P19 (Son et al., 2008), have both demonstrated this. In 
HepG2 cells, higher than normal RGN protein levels was linked to an increase in both 
ATP-stimulated Ca2+ efflux activity and resistance to A23187 ionophore-induced cell 
death. The latter effect was also observed in P19 cells that over-expressed RGN. 
However, such P19 cells showed no difference compared to control cells with regards 
to their Ca2+-mediated responses to thapsigargin in the absence of external Ca2+, 
which suggests RGN does not influence SERCA activity (at least when over-
expressed). Rat RGN over-expression in a rat kidney proximal tubular epithelial cell-
line, NRK52E, has also been shown to repress the expression of L-type Ca2+ channels 
and Ca2+-sensing receptor (CaR) (Nakagawa and Yamaguchi, 2006).      
 
1.15. Other Targets of RGN in Ca2+ Signalling 
1.15.1. An Overview of Other RGN Targets 
In rat liver, RGN has been suggested to affect the activities of proteins other than 
Ca2+-ATPases, such as plasma membrane-localised GTPases (Takahashi and 
Yamaguchi, 2001), glucose-6-phosphatase (Ca2+-activated, not basal, activity) 
(Yamaguchi et al., 1989), protein kinase C (Yamaguchi and Mori, 1990), as well as 
calpain and possibly other cysteinyl proteases (Yamaguchi and Nishina, 1995). In rat 
brain, the activities of Ca2+-dependent protein kinases (Hamano and Yamaguchi, 
2001) can be altered by RGN. The same has also been noted for nitric oxide synthase 
(NOS) and nuclear protein tyrosine phosphatase in the brains of RGN transgenic rats 
(Tobisawa and Yamaguchi, 2003). Superoxide dismutase (SOD) (Ichikawa and 
Yamaguchi, 2004) and protein phosphatase (Ichikawa et al., 2004) are two other 
proteins, along with NOS (Ma and Yamaguchi, 2002), that can have its activity 
affected by RGN in rat hearts. Another organ where NOS has been shown to be prone 
to RGN’s influence on its activity is the liver, as shown in transgenic rats (Yamaguchi 
et al., 2003b).  
 
1.15.2. More RGN Effects in the Nucleus  
RGN’s ability to translocate into the nucleus, which is promoted by protein kinase C 
activation according to observations made in NRK52E cells (Nakagawa and 
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Yamaguchi, 2008), has been linked to a possible role for RGN in cancer because it 
can directly bind to DNA and nuclear proteins to regulate the expression of genes 
involved in promoting tumour formation (e.g. p53 and c-src) (Tsurusaki and 
Yamaguchi, 2004). RGN has also been shown to inhibit both nuclear protein kinases 
(Katsumata and Yamaguchi, 1998) and phosphatases (Omura and Yamaguchi, 1999). 
It has been suggested that Ca2+-activated DNA fragmentation in isolated nuclei from 
rat liver can be prevented by RGN’s ability to inhibit the activity of Ca2+-activated 
endonucleases (Yamaguchi and Sakurai, 1991). Ca2+/CaM-dependent cAMP 
phosphodiesterase (Yamaguchi and Tai, 1991) is another enzyme that can have its 
activity suppressed by RGN. For both of the latter enzymes, it has been hypothesised 
that RGN inhibits their activities by binding and thus sequestering activatory Ca2+ 
away from them. On the other hand, RGN has been shown to be able to bind to CaM 
(Omura and Yamaguchi, 1998) and this interaction may explain the effect the former 
has on Ca2+/CaM-dependent cAMP phosphodiesterase, as well as other similar 
enzymes that are regulated by CaM. Other targets of RGN at the nucleus are shown in 
figure 1.15.2.1. 
 
1.16. Roles of RGN in Mammalian Cells 
1.16.1. RGN & Aging 
In terms of the role of RGN, it has been most notably linked with the process of 
aging. In rats, the abundance of RGN mRNA has been observed to increase from non-
detectable to maximal levels in the liver of an 18-day old embryo developing up to the 
stage of a 35-day old adult. Following this, the trend then reverses to give a decline in 
RGN mRNA levels as aging progressed to the onset of senescence in liver and kidney 
cells. This latter event coincides with an increase in c-fos and c-jun expression levels 
(Fujita, 1999), which are proteins that make up the AP-1 factor and have been shown 
to be able to bind onto the RGN gene in liver cells (Yamaguchi, 2005). Despite the 
RGN gene being located in the X chromosome, its role in aging is not sex-dependent, 
at least in rats (Fujita, 1999). Though RGN expression levels do differ in liver 
between the sexes in rats regardless of age, whereby male rats have been shown to 
express more RGN mRNA than female rats (Ueoka and Yamaguchi, 1998).  
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Figure 1.15.2.1. The Targets of RGN at the Nucleus 
 
The diagram shows the signalling pathways that RGN are believed to be able 
to affect the activities of by interacting with some other associated proteins. 
These targets of RGN, which are located at the nucleus, are important in rat 
liver regeneration (Yamaguchi, 2000b) 
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Later, experiments with HepG2 cells showed RGN over-expression is capable 
of preventing cell death caused by Ca2+ ionophore treatment, which was explained by 
RGN’s ability to enhance PMCA Ca2+ transport activity (Fujita et al., 1998). In 
addition to this, PMCA’s responsiveness to this modulation of its activity by RGN in 
rat brain is lost as aging progresses (Hanahisa and Yamaguchi, 2001). Smad3-
knockout mice are resistant to radiation-induced liver damage and it has been 
suggested that their higher than normal expression levels of RGN could explain their 
resistance to apoptosis (Jeong et al., 2008). This latter observation further supports the 
idea that RGN plays a protective role in liver cells.  
The expression level of RGN in brain has been shown to decrease with 
increasing age in rats (Fujita et al., 1992, Yamaguchi et al., 1999, Fujita, 1999). 
Treatment with amyloid β-peptide protein (residues 1-42; well established to be 
associated with Alzheimer’s disease) has been demonstrated to stimulate a decrease in 
RGN gene expression in primary rat cortical neuronal cells. With this, a compound 
called EUK4010 was shown to be capable of partially reversing the reduced RGN 
expression of this treatment (Sun et al., 2006).  
 
1.16.2. RGN & Liver Regeneration 
RGN mRNA levels increase in regenerating livers from start to completion of the 
process, which suggests it has a role in tissue maturation. Partial hepatectomy of a 
rat’s liver can induce an increase in its RGN mRNA abundance, which is most 
notable 24-hours after surgery and thus suggests enhancement of RGN expression 
occurs in the S-phase of the cell cycle (Yamaguchi, 2000b). Changes in RGN 
expression levels have also been shown to directly correlate with the Ca2+ content in 
liver (Yamaguchi and Kanayama, 1995). With regards to function, RGN has been 
shown to inhibit DNA (Yamaguchi and Kanayama, 1996, Misawa et al., 2001, 
Morooka and Yamaguchi, 2002) and protein (Tsurusaki and Yamaguchi, 2000b) 
synthesis (both with and without the presence of Ca2+) in regenerating liver. Thus 
RGN is likely to play a role in controlling DNA and protein synthesis levels in this 
process. Diabetes and alcohol consumption, both of which can affect liver health, can 
both decrease RGN expression levels in rats (Isogai et al., 1997). Transgenic rats, 
which were treated to exhibit a hyperlipidemic disease state, have shown RGN can 
decrease leptin mRNA levels in both liver and adipose tissue, as well as also decrease 
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adiponectin mRNA levels in liver (Yamaguchi et al., 2004a, Yamaguchi and 
Nakagawa, 2007). 
 
1.16.3. RGN the Anti-Oxidant 
RGN is capable of preventing oxidative stress damage in brain tissue by maintaining 
low levels of both reactive oxygen species (ROS) and NADPH oxidase activity (Son 
et al., 2006). This may be related to RGN being able to influence SOD activity in rat 
heart (Ichikawa and Yamaguchi, 2004). Indeed, over-expression of human RGN in 
HepG2 cells has been linked to reduced SOD protein levels (Handa et al., 2009). 
Over-expression of human RGN in P19 cells has been shown to be protective against 
oxidative stress induced by peroxy radicals (Son et al., 2008). RGN protein levels 
have been shown to increase in the hippocampus of rat brain 4 weeks after being 
treated with kainate, which induces oxidative stress, and this change in RGN 
expression is likely to be promoted by activation of the ERK signalling pathway (Son 
et al., 2009). RGN can act as a liver-specific gluconolactonase and plays an important 
role in vitamin C metabolism, which has been confirmed with the use of RGN 
knockout mice (section 1.17).  
 
1.16.4. RGN & Cancer 
Over-expression of human RGN in P19 cells has been shown to result in decreased 
cell proliferation when compared to control transfectants (Son et al., 2008). RGN 
protein levels have also been noted to be lower in H4-II-E cells when compared to 
normal rat liver cells (Inagaki and Yamaguchi, 2000). Furthermore, RGN mRNA 
levels have been shown to correlate with the progressive stages of tumour formation, 
whereby the former decreases as tumour growth and de-differentiation worsens, in 
breast and prostate cancers (Maia et al., 2009). These observations support the idea 
that a decrease in RGN expression could promote or be a consequence of 
tumorigenesis. 
 
1.17. RGN Knockout Mice 
In addition to male and female transgenic rats that have been used to demonstrate the 
effects of RGN in a number of tissues (section 1.13.5, 1.15.1 and 1.16.2), a RGN 
knockout mouse model has also been generated. Experiments with RGN knockout 
mice have shown such mice are highly susceptible to tumour necrosis factor-α-
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induced apoptosis in liver (Ishigami et al., 2002). Furthermore, the livers of RGN 
knockout mice accumulate a higher than normal amount of lipid, which would 
indicate a deregulation of lipid metabolism (Ishigami et al., 2004).  This is likely to be 
related to the ability of RGN to affect leptin and adiponectin expression levels in liver 
and adipose tissue (Yamaguchi et al., 2004a, Yamaguchi and Nakagawa, 2007). Poor 
glucose tolerance, caused by suppressed glucose-stimulated insulin secretion, has 
been observed of RGN knockout mice (Hasegawa et al., 2010).   
 The lungs of RGN knockout mice at the ages of 1,3 and 6 months are similar 
in structure to lungs from older mice, whereby they are characterised by enlarged 
peripheral airspace in the absence of alveolar destruction (Mori et al., 2004). 
Furthermore, these knockout mice are more susceptible to age- and smoking-related 
oxidative stress in their lungs. Thus it has been suggested that RGN could act in a 
protective role against diseases induced by long-term smoking, such as pulmonary 
emphysema (Sato et al., 2006). Indeed, the lungs of RGN knockout mice can manifest 
characteristics of pulmonary emphysema (Koike et al., 2010). Another organ that is in 
constant contact with atmospheric oxygen, and thus highly susceptible to oxidative 
stress, is the skin. RGN knockout mice suffer from poor skin development due to 
lower than normal ability to synthesise hydroxyproline, which is a modified amino 
acid that is essential for the maintenance of collagen strength in skin and hair, as well 
as lungs (Arai et al., 2009). 
 The most well characterised effect of RGN absence in the knockout mouse 
model is the removal of its ability to contribute to the synthesis of vitamin C, which is 
recognised as the main function of RGN that gives it its protective role against 
oxidative stress. RGN acts as a gluconolactonase and has been suggested to play a 
role in vitamin C synthesis in mice by lactonising L-gulonic acid to form L-gulono-γ-
lactone, which is the penultimate reaction step of the ascorbic acid biosynthetic 
pathway (Kondo et al., 2006). RGN knockout mice are susceptible to developing 
scurvy and their loss of ability to synthesise vitamin C has been linked to an 
observation of increased superoxide formation in the brain of these mice following 4 
and 8 weeks of vitamin C deprivation in their diet (Kondo et al., 2008). Hearing loss 
(Kashio et al., 2009) and higher than normal susceptibility to liver fibrosis (Park et al., 
2010) have also been observed in RGN knockout mice and attributed to absence of 
vitamin C production. It should be noted that humans do not synthesise vitamin C but 
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do express RGN. The function of RGN in humans with regards to its role in dealing 
with oxidative stress has yet to be fully determined.  
 
1.18. Aims of the Present Research 
 
From examining the literature above, it was clear that information behind the 
regulation of SPCA activity was missing. The role of SPCA in hormone signalling 
under physiological conditions and in the context of disease had not been explored 
fully. SPCA’s involvement in diseases other than HHD had not been of much focus in 
publications already available on this Ca2+-ATPase. A well-recognised specific 
inhibitor of SPCA activity that could leave SERCA activity unaffected had yet to be 
available for use in SPCA research. This is all in contrast to the wealth of information 
that is available for SPCA’s closely related microsomal Ca2+-ATPase, SERCA.  
 For RGN, which was even more novel than SPCA, research had been done on 
its expression pattern in a relatively small range of tissue types, as well as on its role 
as a gluconolactonase in the vitamin C biosynthesis in mice. There are certainly other 
tissues that have yet to be tested for RGN expression in order to further define roles 
for RGN that are unrelated to vitamin C production. Studies have been done on 
RGN’s ability to influence the activity of Ca2+-dependent enzymes (in cell-free 
reaction mixtures), and the regulation of RGN expression by hormones and 
transcription factors has also been explored. However, only two studies have been 
done in the past on the effects of RGN on Ca2+ homeostasis with regards to its 
influence on Ca2+ mobilisation in intact cells.  
 The research to be discussed from hereon focuses on the aspect of regulation 
on SPCA and RGN. The main two aims of the study on SPCA were (1) to examine 
whether SPCA expression and/or activity can be affected by a disease state mimicked 
in cell culture (diabetes was chosen to fulfil this) and (2) to identify an inhibitor that 
can inhibit SPCA activity without affecting that of SERCA in isolated microsomes 
and intact cells. The main three aims of study on RGN were (1) to identify a new cell 
or tissue type that expresses RGN, (2) to visualise the effects of RGN on ER Ca2+ 
storage and hormone-stimulated Ca2+ mobilisation in intact cells, and (3) to produce a 
recombinant rat RGN that could be used to produce anti-RGN antibody (to help with 
the other two aims of the RGN study) and be purified for detailed biochemical 
studies.  
  50 
 
 
 
CHAPTER 2. 
MATERIALS & METHODS 
 
 
 
 
 
 
 
 
 
  51 
CHAPTER 2. 
MATERIALS & METHODS 
 
2.1. Mammalian Cell Culture 
2.1.1. General Mammalian Cell Culture Sterile Technique 
Mammalian cell culturing was done using a vertical laminar flow hood. Cells were 
incubated at 37oC and 5% v/v CO2 using a CO2 incubator. All materials placed into 
the flow hood and incubator were sterilised using 70% v/v ethanol. Surfaces of the 
flow hood were also cleaned with 70% v/v ethanol before and after use. All solutions 
and cell-handling materials were either purchased in sterile form (e.g. culture flasks 
and pipettes) or sterilised by autoclaving (at 110-120oC and 15psi for 20 minutes) 
prior to their use in the flow hood. Waste solutions were discarded into Precept 
(Johnsons).  
 
2.1.2. A7r5 Cell Culture & Glucose Treatment 
Rattus norvegicus (Norwegian rat) embryonic thoracic aortic smooth muscle cell-line, 
A7r5 (a gift from Prof. C.W. Taylor; University of Cambridge, UK), was cultured in 
Dulbecco’s Modified Eagle Medium (DMEM; Lonza), which was supplemented with 
10% v/v foetal bovine serum (FBS; PAA), 4mM L-glutamine (PAA), 1% v/v 
penicillin-streptomycin (filter-sterilised with a 0.2µm pore filter) (PAA) and 1% v/v 
non-essential amino acids (PAA). The media also contained 25mM D-glucose for 
general culture of cells (as recommended by the American Type Culture Collection 
(ATCC)) and to obtain cells in a hyperglycaemic (HG) state. Media that contained 
5.5mM D-glucose instead was used to obtain cells in a physiologically normal 
glucose (NG)-fed state. The media was replaced with fresh media every 2 and 4 days 
after sub-culturing. Cells were used for sample collection or experiments 5 days after 
sub-culturing.  
 
2.1.3. COS-7 Cell Culture & Transfection 
Cercopithecus aethiops (African green monkey) kidney cell-line, COS-7 (a gift from 
Dr. N. Hotchin; University of Birmingham, UK), was cultured in DMEM (Lonza), 
which was supplemented with 10% v/v FBS (PAA), 2mM L-glutamine (PAA) and 
1% v/v penicillin-streptomycin (filter-sterilised) (PAA). The media also contained 
5.5mM D-glucose as the only glucose concentration used for culture of COS-7 cells. 
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Cells were transfected one day after sub-culturing using Genejuice reagent (Novagen) 
and maxiprep DNA (section 2.3.1). The manufacturer’s protocol for the use of the 
transfection reagent was followed. Cells were seeded (section 2.1.4) at a density of 
1x105 cells per well of a 12-well plate, 2x105 cells per well of a 6-well plate, or 
1.2x106 cells per 10cm diameter Petri dish. Cells were transfected 24 hours after 
seeding. 
The transfection reagent was mixed with transfection media, which was 
DMEM media (without phenol red) (PAA) containing 25mM D-glucose and only 
supplemented with 2mM L-glutamine (PAA) (i.e. no FBS and antibiotics). This first 
mixture was incubated in the culture hood for 5 minutes. Maxiprep DNA was added 
to the mixture and incubated in the culture hood for a further 15-20 minutes before 
being added to the culture media. After applying the transfection mixture, cells were 
returned to the cell culture incubator for 48 hours before experimental use.         
An optimised ratio of 3µg:9µl of plasmid DNA-to-transfection reagent was 
used per 100µl of transfection media in each well of a 6-well plate for all plasmids 
used (as advised by Dr. J. Vanoevelen; Katholieke Universiteit Leuven, Belgium). 
Manufacturer’s instructions were followed to re-scale quantities of DNA, transfection 
reagent and transfection media for plates and Petri dishes of other sizes. From this, 
1.5µg:4.5µl and 18µg:54µl ratios of DNA-to-reagent was used for each well of a 12-
well plate and each 10cm diameter Petri dish, respectively. 
 
2.1.4. Sub-culturing of Mammalian Cells 
Sub-culturing (also known as ‘passaging’) was done when cells were judged to be 
approximately 70-80% confluent (i.e. total cell population covered 70-80% of the 
culture flask surface on which cells had adhered to) by viewing them using a Nikon 
TMS light microscope at 100x magnification. Media was removed from cells in 
culture flasks, which were then washed with Dulbecco’s phosphate buffered saline 
(DPBS; Lonza). Trypsin-EDTA (Invitrogen) or trypsin-Versene (Lonza) solution was 
then applied and incubated with the cells for 2-5 minutes in the CO2 incubator. After 
this treatment (known as ‘trypsinisation’), the culture flask was agitated by gentle 
tapping to fully detach its contents of cells, fresh media was added to re-suspend the 
cells and a small volume of this suspension was transferred into a new culture flask 
containing fresh media (referred to as ‘seeding’) to start a new passage of cell culture. 
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Cells were sub-cultured every 3-4 days for general maintenance. With regards to 
volumes of solutions typically used for a 75cm2 culture flask, cells would be grown in 
10ml of media, washed with 5ml of DPBS, trypsinised with 2ml of trypsin solution, 
re-suspended after trypsinisation with 5ml of media and 1-2ml of cell suspension 
would be used to seed a new 75cm2 flask. These volumes would be re-scaled for 
culture flasks of other sizes (e.g. 25cm2 and 162cm2).  
 
2.1.5. Cryopreservation & Rejuvenation of Mammalian Cells 
Cells were frozen in liquid nitrogen, when not required for cell culture, to maintain a 
reserve of them for future use. After sub-culturing, the remaining suspension of cells 
not used to seed a new flask was centrifuged at 900g for 10 minutes at 4oC, the media 
was removed and the cell pellet was re-suspended in fresh media containing 10% v/v 
DMSO (sterile, biotechnology grade; Sigma). 5ml of media would be used for cells 
from a 75cm2 flask that was 70-80% confluent and had only been sub-cultured to 
produce one new 75cm2 flask of cells. This cell suspension was then aliquoted into 
cryovials and stored in an isopropanol jacket at -80oC for 1-5 days. After this, the 
frozen vials were moved into and stored long-term in a liquid nitrogen storage tank 
until required for cell culture.  
To use the frozen cells for cell culturing (known as ‘rejuvenation’), cryovials 
were taken out of liquid nitrogen and its contents quickly thawed by repeated 
agitation of the cryovial in a 37oC water bath. The thawed cells would then be diluted 
10-fold with fresh media and centrifuged at 900g for 10 minutes at 4oC. The media 
was then removed and cell pellet re-suspended in fresh media at the appropriate 
volume to fill a new culture flask for growth in the cell culture incubator. The media 
was changed 24 hours later. Frozen vials of Mus musculus (mouse) Sertoli cell-line, 
TM4, and Homo sapiens (human) neuroblastoma cell-line, SH-SH5Y (a gift from Dr. 
M. Grant; University of Birmingham, UK) were thawed and centrifuged in the way as 
stated above for the preparation of their total cell lysates, but were not seeded into cell 
culture flasks for growth.  
 
2.1.6. Counting Mammalian Cells using a Haemocytometer 
To quantify the population of cells in a suspension, 10µl of the cell suspension was 
applied onto the counting grid of a haemocytometer, which was sealed with its 
coverslip and viewed under the light microscope. The counting grid used was as 
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shown in figure 2.1.6.1. The volume of each of the nine large squares (referred to as 
the ‘corner’ or ‘middle’ square in figure 2.1.6.1) was 0.1µl (1mm width x 1mm length 
x 0.1mm depth). Three out of the nine large squares were selected randomly for 
counting their individual content of cells. The three numbers of cells were then 
averaged and multiplied by 10 to give the number of cells in 1µl of the original cell 
suspension from which the sample was taken. By dividing the required number of 
cells (e.g. the seeding density for wells of a 6-well plate) by the concentration of cells 
in the cell suspension, the volume of cells needed to obtain the former of these two 
was determined.  
 
2.1.7. Preparation of Acid-Etched Coverslips 
1cm diameter glass coverslips were immersed in a minimal volume of concentrated 
nitric acid and left for 1 hour in a fume cupboard. The acid was then discarded into a 
copious volume of cold tap water and a running tap of cold water was used to fully 
dilute the acid still on the coverslips for 5-10 minutes. After excess water was 
discarded, the coverslips were transferred into a glass Petri dish and rinsed with fresh 
cold tap water for 30 minutes. Following this, the water in the glass Petri dish was 
removed as much as possible and coverslips were immersed in a minimal volume of 
100% v/v methanol. The Petri dish of acid-etched coverslips was left in a fume 
cupboard for 24-48 hours to allow the methanol to evaporate off before being 
autoclaved.  
 
2.1.8. Mammalian Cell Culture on Acid-Etched Coverslips 
Each well of a 12-well plate was filled with one acid-etched coverslip, followed by 
0.5ml of autoclaved 2% w/v gelatin solution (made by dissolving porcine skin gelatin 
powder  (Sigma) in dH2O) and incubated in the cell culture incubator for 30 minutes. 
During this time, the cell suspension needed for seeding the coverslips was obtained 
by sub-culturing (section 2.1.4) and its population of cells counted (section 2.1.6) to 
determine the volume of cells required to seed each coverslip. For A7r5 cells, 1x104 
cells were used to seed each coverslip for fluorescence Ca2+ imaging (section 2.5.1), 
and 3-4.5x104 cells were used to seed each coverslip for immunofluorescence and 
lectin staining (section 2.5.2). For COS-7 cells, 1x105 cells were used to seed each 
coverslip for both fluorescence Ca2+ imaging and immunofluorescence experiments. 
For each well of the 12-well plate, the gelatin solution was removed, replaced with  
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Figure 2.1.6.1. The Counting Grid of a Haemocytometer 
(Image source: The Health Protection Agency (UK) website 
(http://www.hpacultures.org.uk/technical/ccp/cellcounting.jsp)) 
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2ml of fresh media and the cells were seeded onto the coverslips. 
 
2.2. Sample Preparation from Mammalian Cells 
2.2.1. cDNA from Cell Culture mRNA Extracts 
0.1% v/v diethylpyrocarbonate (DEPC)-treated PBS (DEPC-PBS) was made by 
adding DEPC (Sigma) to PBS (0.14M NaCl, 2.7mM KCl, 1.5mM KH2PO4 and 
8.1mM Na2HPO4; pH 7.4) and left in a fume cupboard overnight before being 
autoclaved. DEPC-dH2O was also made (by treating dH2O with DEPC in the same 
way as PBS), which was used to make 70% v/v ethanol for cleaning work surfaces 
and materials entering the flow hood. 
Cells were grown from a seeded density of 6x105 cells per 75cm2 culture 
flask. They were harvested by trypsinisation, centrifuged at 900g for 10 minutes at 
4oC, the media was removed and cell pellet re-suspended in DPBS to have its 
population counted (section 2.1.6). The latter cell suspension was then centrifuged 
again at 900g for 10 minutes at 4oC to allow removal of DPBS and re-suspension of 
the cell pellet with DEPC-PBS to give a concentration of 1x104 cells/µl. This last 
suspension of cells was used for extraction of total mRNA content from 2x104 cells 
and its conversion to cDNA copies using a CellsDirect™ cDNA synthesis kit 
(Invitrogen), along with a GeneE thermocycler (Techne), and following 
manufacturer’s instructions. Sample preparation was done in the flow hood. All 
cDNA samples were stored at -80oC. 
 
2.2.2. Total Cell Lysate from Cell Cultures & Adult Boar Sperm         
For A7r5 cells, a proportion of each cell suspension used for cDNA preparation was 
also used for preparing total cell lysates. 1-1.25x106 cells were mixed with an equal 
volume of lysis buffer (50mM Tris-HCl (pH 7.4), 150mM NaCl, 1mM EDTA, 1% v/v 
Triton X100, 1% w/v sodium deoxycholate, 0.1% w/v SDS and 1mM PMSF) and 
incubated on ice for 2 hours, before being passed through a 25-guage needle via a 
syringe 5 times to homogenise the mixture. The cell lysate was then centrifuged at 
2,400g for 5 minutes at room temperature, the supernatant was collected and the pellet 
was discarded. The protein concentration in the samples (the supernatants) was 
determined using the Bradford assay (section 2.4.3). Samples were stored at -80oC.  
The method used for preparing cell lysates from other cell-lines, as well as 
adult boar sperm, was the same as that for A7r5 cells, but were lysed whilst still 
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attached to culture plates (except for boar sperm cells, which were cleared from 
ejaculate fluid by centrifugation at 900g for 10 minutes at 4oC before lysis buffer was 
added to the cell pellet). Media was removed from the cells, which were washed with 
DPBS before lysis buffer was added to them. Cells were incubated with the lysis 
buffer for 10 minutes at room temperature (or 1 hour on ice for boar sperm) with 
gentle agitation, before the cell lysate was homogenised, centrifuged and supernatant 
collected as described for A7r5 cells.    
 
2.2.3. Microsomal Membranes from Cell Cultures  
The method was modified from that described previously (Wootton et al, 2004). A7r5 
cells were seeded and grown at equal densities on 10cm diameter Petri dishes. COS-7 
cells were transfected and grown on 10cm diameter Petri dishes (section 2.1.3). A7r5 
cells were harvested by trypsinisation, centrifuged at 900g for 10 minutes at 4oC to 
allow removal of the media, and the cell pellet was re-suspended in DPBS. COS-7 
cells were washed with DPBS after removal of media, detached from Petri dishes 
using a cell scraper and collected into fresh DPBS.  
In both cases, the cells were then centrifuged at 900g for 10 minutes at 4oC, 
the DPBS was removed and the cells were re-suspended in microsomal membrane 
preparation buffer (5mM HEPES-KOH (pH 7.2), 0.32M sucrose, 0.2mM 
benzamidine HCl, 10µM leupeptin HCl and 0.2mM PMSF). This cell suspension was 
homogenised on ice using a Polytron homogeniser (with regular pauses to prevent 
over-heating of the sample), followed by 30 strokes of a Potter homogeniser. The 
homogenate was centrifuged at 20,000g for 15 minutes at 4oC and the supernatant 
collected. The pellet was re-suspended in fresh buffer to be homogenised and 
centrifuged again. Both supernatants were combined and centrifuged at 100,000g for 
50 minutes at 4oC. The supernatant from this latter spin was discarded. The remaining 
pellet (containing the microsomal membranes) was re-suspended in fresh buffer and 
its protein concentration determined (section 2.4.3), before being aliquoted, snap 
frozen with liquid nitrogen and stored at -80oC.         
 
2.2.4. Cytosolic Fractions from Adult Male Rat Organs 
Samples were prepared from brain, kidney, liver, testis, fat pads, heart and lungs that 
had been stored at -80oC. These were thawed on ice, DPBS with 1mM PMSF was 
added to them, they were cut up into small pieces, placed into a Potter homogeniser 
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and subjected to repeated mechanical homogenisation intermittently for 5-10 minutes. 
This homogenate was then centrifuged at 100,000g for 1 hour at 4oC. The supernatant 
was collected and stored at -80oC. 
 
2.3. Preparation of Plasmid DNA for COS-7 Transfection 
2.3.1. Maxipreps 
Plasmids containing the coding sequences for human SPCA1d (hSPCA1d) (in pMT2 
vector) and human SERCA2b (hSERCA2b) (in pMT2 vector) (both gifts from Dr. J. 
Vanoevelen; Katholieke Universiteit Leuven, Belgium), along with rabbit SERCA1b-
EGFP (in pcDNA3.1(-) vector) (a gift from Dr. J. M. East, Southampton University, 
UK), human SMP30 (hSMP30) (in pcDNA3.1 vector), as well as control (i.e. no 
sequence insert present) pcDNA3.1(-) plasmid (the latter two plasmids were gifts 
from Prof. J. Lee; Pusan National University, Korea) and Prof. A Ishigami (Tokyo 
Metropolitan Institute of Gerontology, Japan), were purified using a Purelink HiPure 
Plasmid Filter Purification Maxiprep kit (Invitrogen) following manufacturer’s 
instructions. Other DNA purification kits were also sometimes used, which were 
Qiagen QIAfilter Maxiprep kit and Sigma Genelute Endotoxin-Free Midiprep kit. In 
all three cases, DNA was purified from cultures of DH5-α cells transformed with 
these plasmids (section 2.11.5).  
 
2.3.2. Quantification of Maxiprep DNA 
Maxiprep DNA was quantified by measuring its absorbance at 260nm in duplicate 
using a spectrophotometer. The blank and buffer used to dilute the DNA was the 
elution buffer used to re-suspend the final pellet of DNA. The absorbance readings 
were averaged, and this average absorbance value was multiplied by 50 (a constant 
value in the calculation) and the dilution factor (used to dilute the maxiprep DNA 
with buffer in the cuvette). This calculation gave the concentration of DNA in the 
maxiprep in units of mg/ml.  
 
2.3.3. Restriction Digest of Maxiprep DNA  
Suitability of restriction endonucleases (BIOLINE) for digestion analysis of maxiprep 
DNA were checked using the NEB Cutter V2.0 web-based program (NEB) to note the 
number of DNA fragments that would be produced after digest and ensure most or all 
of them would be visible in a 0.8% w/v agarose gel by being at least ~1kb in size. The 
  59 
expected digest DNA band sizes for hSPCA1d-pMT2, hSERCA2b-pMT2 and rabbit 
SERCA1b-pcDNA3.1(-) are shown by the restriction maps in figure 4.2.1.2. Those 
for hSMP30-pcDNA3.1(-) and control pcDNA3.1(-) are shown by the restriction map 
in figure 5.2.4.1.   
 Maxiprep DNA was diluted at a 1:5 ratio in autoclaved dH2O before adding to 
the reaction mixture. A 10µl reaction volume was made with 5µl of diluted maxiprep 
DNA, 20 units of each restriction endonuclease, 1x reaction buffer (supplied with the 
enzymes) and autoclaved dH2O. Restriction digest reactions were incubated in a 37oC 
water bath for 1 hour. The reaction mixtures were electrophoresed through a 0.8% 
w/v agarose gel afterwards (along with uncut diluted maxiprep DNA) and a 1kb DNA 
ladder, and stained (section 2.4.2).  
 
2.4. Experiments on Samples from Mammalian Cells 
2.4.1. PCR  
Each 50µl PCR reaction mixture contained 2.5 units of BIOTAQ™, 1x NH4 buffer 
(provided with the enzyme), 2mM dNTP mix, 1µl of cDNA sample prepared from 
A7r5 cells (section 2.2.1), MgCl2, forward and reverse primers, and autoclaved dH2O. 
Reaction reagents were purchased from BIOLINE and primers were made by Alta 
Bioscience (University of Birmingham, UK). Amount of primers (and references 
from which sequences were obtained), MgCl2 concentrations, annealing temperatures 
(Tm) and number of cycles for each pair of primers used are listed in table 2.4.1.1. 
Primers for SPCA1 (all splice variants) and SERCA (all isoforms) were used. Both 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (an enzyme of the glycolytic 
pathway) and β-actin (a contractility marker (Owens et al., 1986)) were also detected 
for using PCR. Ribosomal protein L19 (RPL19) PCR product levels were used to 
represent the amount of total cDNA content that was present in the samples (Al-Bader 
and Al-Sarraf, 2005). Sequences to all primers, which were all designed for rat 
mRNA, used are listed in table 2.4.1.2. The Tms used for all primers were those 
quoted in their associated references ± 1oC. A sample of PCR products for SPCA1 
was checked to ensure the correct mRNA sequences had been detected, by using their 
agarose gel extracts (section 2.10.1) and the SPCA1 PCR primers for DNA 
sequencing (section 2.10.5). 
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mRNA 
of 
Interest 
Reference Amount of 
Each 
Forward/ 
Reverse 
Primer Used 
(pmol) 
 
[MgCl2] 
(mM) 
Tm 
(oC) 
Number 
of 
Cycles 
Product 
size (bp) 
SPCA1 (Missiaen 
et al., 
2002a) 
 
20 4 52.1 35 224 
SERCA (Varadi et 
al., 1996) 
 
20 2 58.0 35 288 
GAPDH 
 
(Di Napoli 
et al., 
2007) 
 
100 2 60.0 28 400 
β-actin 
 
 
(Varadi et 
al., 1996) 
3.5 2 58.0 28 255 
RPL19 
 
(Al-Bader 
and Al-
Sarraf, 
2005) 
 
0.3 3 52.1 28 321 
 
Table 2.4.1.1. PCR Conditions for Primers Used on A7r5 cDNA Samples 
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Primer Sequences (5’ to 3’) 
 
mRNA 
of 
Interest 
 
Forward Primer 
 
Reverse Primer 
SPCA1 AAACTGGAACCCTGACGAAG TTGGCTTTCCCATCAGAGTG 
 
SERCA TGCCTGGTAGAGAAGATGAA CCCTTCACAAACATCTTGCT 
 
GAPDH ACCACAGTCCATGCCATCAC TCCACCACCCTGTTGCTGTA 
 
β-actin ATCCGTAAAGACCTCTATGC ATTTGCGGTGCACGATGGAGG 
 
RPL19 ATCGCCAATGCCAACTCT 
 
GAGAATCCGCTTGTTTTTGAA 
 
Table 2.4.1.2. Sequences of Primers Used on A7r5 cDNA Samples 
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Either a BIORAD MyCycler™ or BIOMETRA Personal Cycler thermocycler 
was used. For all primers, each cycle consisted of a melting step at 95oC for 1 minute, 
an annealing step at specific temperatures (stated in table 2.4.1.1) for 1 minute and an 
extension step at 72oC for 1 minute. An initial melting step prior to the first cycle of 
each PCR was done at 95oC for 2 minutes. A final extension step at the end of the last 
cycle of each PCR was done at 72oC for 10 minutes, and reaction mixtures were 
maintained at 4oC following this last step temporarily before being stored at -80oC.    
 
2.4.2. Agarose Gel Electrophoresis 
2% w/v agarose in TBE buffer (89.2mM Tris, 88.9mM boric acid and 2mM EDTA; 
pH 8.0), which was used for PCR products less than 1kb in size (c.f. 0.8% w/v 
agarose gels for plasmid DNA or its restriction digest fragments greater than or equal 
to 1kb in size), was heated until fully dissolved and then left to cool to approximately 
40-50oC (at which it was comfortable enough to hold the container with hand but still 
in liquid phase). The cooled solution was then poured into a mould with a well comb 
inserted and allowed to cool further to form a solid gel. The well comb was carefully 
removed (leaving well spaces into which samples could be loaded) and the gel was 
immersed into TBE buffer in an electrophoresis tank (with the wells closest to the 
cathode electrode).  
10µl of PCR product was mixed with 2µl of 6x DNA loading buffer (0.25% 
w/v bromophenol blue, 0.25% w/v xylene cyanol FF and 30% v/v glycerol) and 10µl 
of this mixture was loaded into the gel for each sample. A 100bp DNA ladder (NEB) 
was also loaded. The loaded samples and ladder were electrophoresed through the gel 
at 90 volts until the band of purple colour from the DNA loading buffer was seen to 
have moved three-quarters of the way through the gel (towards the anode electrode). 
The gel was then removed from the tank and stained with Sybr Safe DNA stain 
(Invitrogen) for 1 hour with gentle agitation. The stained gel was viewed using a UV 
transluminator and images of the DNA fragments were captured using an UVP 
ImageStore 5000 system. Some gel images were analysed for pixel intensity of 
product fragments using ImageJ software (section 2.6).         
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2.4.3. Protein Estimation: The Bradford Assay 
Protein Assay Reagent (BIO-RAD) was used to estimate the concentration of protein 
present in total cell lysates (section 2.2.2), microsomal membranes (section 2.2.3), 
nickel affinity column chromatography fractions (section 2.12.6) and 
dialysed/concentrated protein solutions (section 2.12.7-8). 1-30µl of sample was 
mixed with 170µl of working reagent and the total volume was made up to 200µl 
using dH2O for each sample in wells of a 96-well plate. Mixtures were left to incubate 
at room temperature for 10 minutes before their absorbance at 590nm was read using 
a Dynatech MRX plate reader. Readings for each sample were done in triplicate. A 
calibration curve was constructed with absorbance readings from different amounts of 
bovine serum albumin (BSA) solution within a range of 0-15µg. This was used to 
convert the average absorbance readings of each sample into their protein 
concentration values.         
 
2.4.4. SDS-PAGE 
A BIORAD mini-PROTEAN® 3 system was used and manufacturer’s instructions 
were followed to set up and use the apparatus. A 10% w/v acrylamide resolving gel 
was made from a mixture containing 3ml of resolving gel buffer (1.5M Tris and 0.4% 
w/v SDS; pH 8.8), 4ml of Ultra Pure Protogel (29.2% w/v acrylamide and 0.8% w/v 
bis-acrylamide; Geneflow), 5ml of dH2O, 40µl of 10% w/v ammonium persulphate 
solution and 20µl of tetramethylethylenediamine (TEMED; Sigma). A 4% w/v 
acrylamide stacking gel was made from a mixture containing 1.5ml of stacking gel 
buffer (0.5M Tris and 0.4% w/v SDS; pH 6.8), 0.75ml of Ultra Pure Protogel, 3.75ml 
of dH2O, 30µl of 10% w/v ammonium persulphate solution and 15µl of TEMED. A 
thin layer of saturated iso-butanol solution (made from mixing dH2O and iso-butanol 
at a 1:1 ratio) was placed on top of the resolving gel to keep the top edge of the gel 
smooth once it had polymerised. Running buffer (192mM glycine, 25mM Tris and 
0.1% w/v SDS) was used to fill the electrophoresis tank.     
Each protein sample was mixed at a 1:1 ratio with sample loading buffer, 
which was made from sample buffer (125mM Tris, 4.6% w/v SDS and 20% w/v 
glycerol) and 2-mercaptoethanol mixed at a 20:1 ratio, along with a trace amount of 
bromophenol blue. Samples were then heated at 100oC for 10 minutes before being 
loaded into the wells of a gel. Protein molecular weight markers (Sigma (10-250kDa) 
or NEB (2-212kDa, 7-175kDa)) were also loaded. Samples were electrophoresed 
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through the gel at 120 volts (~20mA) until the band of blue colour from the sample 
loading buffer had started to move out of the gel and into the running buffer. The gels 
were carefully separated from the glass plates and used either for Coomassie blue 
protein staining (section 2.4.5.) or Western blotting (section 2.4.6.).    
 
2.4.5. Coomassie Blue Protein Staining 
SDS-PAGE gels were immersed into a minimal volume of Coomassie blue protein 
stain (0.125% w/v Coomassie brilliant blue R250, 7.5% v/v glacial acetic acid and 
45% v/v methanol) and left to incubate at room temperature for 1 hour with gentle 
agitation. Following this, the stain solution was remove and replaced with de-stain 
solution (5% v/v glycerol and 7.5% v/v glacial acetic acid), which was left to incubate 
with the gel at room temperature overnight to allow removal of background staining. 
Stained gels were imaged using a Kodak Electrophoresis Documentation & Analysis 
System 120, which included a Kodak DC290 Zoom Digital Camera and Kodak 1D 
(version 3.5.2) software. 
  
2.4.6. Western blotting: Anti-SPCA1, Anti-SERCA & Anti-α-Actin  
Proteins in SDS-PAGE gels were transferred onto nitrocellulose sheets at 30 volts 
(~400mA) using an Invitrogen XCell II blot module and following manufacturer’s 
instructions. The transfer buffer used to soak the membranes and fill the tank was the 
same as the running buffer used for SDS-PAGE but with 20% v/v methanol added. 
Transfer took place for 1 hour. Once complete, nitrocellulose membranes were 
stained with Ponceau protein stain (0.1% w/v Ponceau-S, 0.1% w/v TCA and 1% v/v 
glacial acetic acid) for 5 minutes with gentle agitation. Excess stain was briefly 
washed off with dH2O. The positions of the molecular weight markers were marked 
with a pencil onto the membranes before they were immersed in 5% w/v milk 
solution, which was made from semi-skimmed milk powder dissolved in TTBS buffer 
(25mM Tris-HCl (pH 8.0), 150mM NaCl and 0.05% v/v Tween-20). The membranes 
were then left to incubate at either room temperature for 1 hour with gentle agitation 
or 4oC overnight to allow proteins in the milk solution to block non-specific binding 
sites. 
For treatment with antibodies, the milk solution was discarded and the 
membranes were washed three times briefly with TTBS. Primary antibodies (specific 
to the protein of interest) were diluted in fresh TTBS buffer and incubated with the 
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membranes for 1.5 hours. Following this, the antibodies were discarded and the 
membranes were washed three times with TTBS, with each wash lasting for 5 
minutes with gentle agitation. Fresh 5% w/v milk solution was incubated with the 
membrane for 30 minutes, discarded and the membrane washed three times briefly 
with TTBS. Horse radish peroxidase (HRP)-conjugated secondary antibodies (specific 
to the Fc region of the primary antibody) were diluted in fresh TTBS buffer at a ratio 
of 1:3000 and incubated with the membranes for 1 hour. The secondary antibodies 
were discarded afterwards and membranes were washed five times with TTBS, with 
each wash lasting for 5 minutes with gentle agitation.  
Antibody-treated membranes were incubated with Immobilon™ Western 
chemiluminescent HRP substrate (Millipore) for 10 minutes in the dark. After 
substrate incubation, membranes were kept in the dark to be dried and wrapped with 
Saran wrap. Creases in the Saran wrap were kept as minimal as possible. The 
membranes were then stored in a film case to protect from light. Viewing of 
chemiluminescent protein bands were done using a BIO-RAD Fluor-S Max 
MultiImager, which was set to capture images once every minute for 10 minutes (to 
allow monitoring of image development) and to detect for chemiluminescence 
blotting at high sensitivity. Only the last image of the 10 minutes was used. Some 
images were analysed for pixel intensities of protein bands using ImageJ (section 2.6). 
Dilution ratios for anti-SPCA1 (custom polyclonal antibody from BioCarta 
GmbH and as referenced previously (Wootton et al., 2004)), anti-SERCA 
(monoclonal Y1F4) (a gift from Dr. J.M. East; Southampton University, UK), anti-
SERCA2 (monoclonal clone ILD8) (Abcam) and anti-α-actin (monoclonal clone 
1A4) (Sigma) primary antibodies were 1:75, 1:800, 1:2500 and 1:800, respectively. 
With regards to secondary antibodies, anti-rabbit HRP was used for anti-SPCA1, and 
anti-mouse HRP was used for both anti-SERCA and anti-α-actin. The expected 
protein band sizes for SPCA1 and SERCA were both 100kDa (Wootton et al., 2004), 
α-actin was 42kDa (according to product literature from manufacturer) and SERCA-
EGFP was 127kDa.  
 
2.4.7. Ca2+-ATPase Activity: The Phosphate Liberation Assay 
The method was as described previously (Wootton and Michelangeli, 2006) with 
some modifications. Each assay consisted of a 200µl volume of reaction buffer 
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(45mM HEPES-KOH (pH 7.0), 6mM MgCl2, 2mM NaN3 (azide) and 0.25mM 
sucrose), which was supplemented with 1mM EGTA, 1µg ionophore A23187 and 
2µM sodium vanadate. 1mM CaCl2 was added for measurements of Ca2+-dependent 
activity to give a free [Ca2+] of 1µM. 1µM thapsigargin (Sigma) was added for 
measurements of thapsigargin-insensitive activity. Microsomal membranes were 
added at quantities of 20µg (A7r5) or 5-10µg (COS-7). 6mM ATP (Sigma) and 50µl 
of 6.5% w/v TCA solution were added to give negative control reactions with 
denatured membranes.  
 For experiments with bis-phenol, tetrabromobisphenol-A (TBBPA), 
trifluoroperazine (TFP), 2-aminoethoxydiphenyl-borate (2-APB) and bisphenol-A 
(BPA) (all purchased from Sigma, except bis-phenol (Pfaltz & Bauer), which were all 
prepared in DMSO, these was added to assay mixtures before initiating reactions and 
contributed to 0.1% of the total volume in each reaction mixture. The same was done 
with experiments that involved nicotinic acid adenine diphosphate (NAADP) and 
cyclic adenine diphosphate ribose (cADPR), except they were both prepared in dH2O.     
All reaction mixtures were incubated at 37oC for 10 minutes before 6mM ATP 
was added to all except the controls to initiate activity. Reactions then remained at 
37oC to proceed for 90 minutes (A7r5) or 45 minutes (COS-7). Other time points 
were also tested for A7r5 (data not shown) and COS-7 (see section 4.2.4) membranes 
during optimisation trials. 50µl of 6.5% w/v TCA solution was added to stop 
reactions (at all except the negative controls), which were then incubated on ice for 10 
minutes before they were centrifuged at 20,000g for 10 minutes at room temperature. 
For each reaction mixture, 100µl of supernatant was added to 150µl of copper acetate 
buffer (11.25% v/v glacial acetic acid, 0.25% w/v copper acetate and 0.2M sodium 
acetate; pH 4.0) in a well of a 96-well plate. To this, 25µl of 5% w/v ammonium 
molybdate was added and followed by 25µl of ELAN solution (2% w/v p-methyl-
aminophenolsulphate and 5% w/v sodium sulphite). The assay mixtures were left to 
incubate at room temperature for 10 minutes before their absorbance of 850nm was 
read using a Dynatech MRX plate reader. A calibration curve was constructed with 
absorbance readings from different amounts of phosphate using KH2PO4 solution and 
within a range of 0-150nmol. This was used to convert the absorbance readings of the 
samples into values of amounts of phosphate.  
For each reaction condition and Ca2+ concentration, each experiment consisted 
of three active assays and two negative control assays. The averaged value for the 
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control assays was subtracted from that for the active reactions to give the corrected 
amount of phosphate liberated for their associated reaction condition. The corrected 
values for the assays that contained no added CaCl2 were then subtracted from that of 
their pair-matched assays that contained 1mM CaCl2 to give the corrected amount of 
phosphate liberated that was Ca2+-dependent. Each of these final values was then 
converted into a rate of amount of phosphate liberated/min/mg protein. Activity plots 
were produced using Prism (version 5) graph plotting software.   
 
2.5. Fluorescence Microscopy with Mammalian Cells 
2.5.1. Fluo-3 & Fluo-4 AM Single Cell Ca2+ Imaging 
The method was as described previously (Ogunbayo et al., 2008) with some 
modifications. Hanks Balanced Salts Solution (HBSS; Sigma) (pH 7.2), which was 
supplemented with 4.5mM NaHCO3 and 0.81mM MgSO4, was used as the buffer for 
all steps. Supplementation with 1.26mM CaCl2 or 1.26mM EGTA was done 
depending on if experiments required the presence or absence of extracellular Ca2+, 
respectively, at both the wash and assay stage. Cells grown on coverslips (section 
2.1.8) were loaded with 6µM Fluo-3 AM or 7.5µM Fluo-4 AM in HBSS that 
contained 1.26mM CaCl2, 0.2mM sulfinpyrazone, 0.025% pluronic acid and 1% 
BSA. Incubation with dye lasted for 40 minutes, after which cells were washed with 
fresh HBSS that contained 0.2mM sulfinpyrazone for 10 minutes.  
Each coverslip was transferred into a 3.5cm diameter Petri dish containing 
HBSS buffer, which was incubated at 37oC using a heated stage at a Nikon TS-100F 
fluorescence microscope. 10x objective lens was used to view the cells. A Stellacam 
Astrovid3 was used to record videos (with an additional x10 magnification), which 
were saved onto a computer via connection with a Hauppage USB TV live video 
capture device and use of WinTV2000 software (Hauppage). The image capture rate 
for videos was one frame per second. Images were of 320x240 pixel resolution. 
Experiments started 1 minute after the start of video recording (to provide a stable 
baseline of fluorescence intensity) and total recording time for each experiment was 
either 5 or 10 minutes. A7r5 cells were treated with 10nM AVP (Bachem 
Biosciences) and COS-7 cells were treated with 10µM histamine (Sigma). 1µM 
thapsigargin was used to treat both A7r5 and COS-7 cells. A7r5 experiments also 
included those that involved their treatment with bis-phenol and 2-APB (section 
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2.4.7). All videos were analysed for their change in pixel intensity of individual cells 
over time, using ImageJ (section 2.6).    
         
2.5.2. Immunofluorescence & Lectin Staining  
Method was adapted from previous literature (Wootton et al., 2004). Cells grown on 
coverslips (section 2.1.8) were washed three times with DPBS between each 
incubation step. After discarding the media, cells were washed and fixed with 2% v/v 
formaldehyde in DPBS for 10-20 minutes at room temperature. Cells were then 
permeabilised with 0.1% v/v Triton X100 in DPBS for 5 minutes. Following this, 
anti-SPCA1, anti-SERCA (Y1F4) or custom-made anti-RGN (section 2.12.4) 
antibody was incubated with cells in DPBS at dilution ratios of 1:30-1:50, 1:50-1:100 
and 1:100, respectively. FITC-conjugated secondary antibodies (Sigma) were 
incubated with cells for 1 hour afterwards at dilution ratios of 1:50-1:100. 
Tetramethylrhodamine (TMR)-conjugated wheat germ agglutinin (WGA) 
(Invitrogen) was incubated with A7r5 cells at 10µg/ml per coverslip for 1 hour.  
 After all labelling incubations, cells were washed three times with DPBS, once 
with dH2O and excess liquid was dried off before being mounted onto glass slides 
using Hydramount (National Diagnostics). Cells were viewed and still images 
captured using the same set-up as used for single cell Ca2+ imaging (section 2.5.1), 
but at 640x480 resolution. This was the same still image capture set-up used to view 
rabbit SERCA1b-EGFP-pcDNA3.1(-)-transfected COS-7 cells. Immunofluorescence 
experiments with adult boar sperm cells (cleared of ejaculate fluid by centrifugation) 
were done as stated above but seeded onto gelatin-covered coverslips on the day of 
use.    
 
2.6. ImageJ Analysis  
Quantification of PCR product bands and chemiluminescent protein bands were done 
by analysing images of DNA-stained agarose gels (section 2.4.2) and HRP-subtrate-
treated Western blot membranes (section 2.4.6), respectively, using ImageJ software 
(version 1.41e; National Institutes of Health USA). In all cases, the average pixel 
intensity of each band was measured and the size of the area of analysis was kept the 
same for all bands in a single image. The same was done for background 
measurements, whereby the area of the image selected, which was the same size as 
that used for the PCR products or protein bands, was in the same relative position 
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(above or below) its associated band but either did not contain any DNA staining 
(PCR products) or was not part of the membrane (Western blot bands). Background 
measurements were subtracted from their corresponding PCR product or protein band. 
For PCR products, values corrected for background were also made relative to the 
corrected values for RPL19 product bands, in the case of SPCA1, SERCA, RGN, 
GAPDH and β-actin. This latter step was done to correct for any differences in total 
cDNA content in the samples, which was represented by their content of RPL19 
cDNA, and thus the corrected RPL19 product band used for calculation was from 
PCR with the same cDNA sample that was used in the PCR for the product band to be 
corrected for the total cDNA content of its corresponding sample.    
Pixel intensity measurements from fluorescence microscopy video recordings 
were also done using ImageJ. For Fluo-3 experiments with A7r5 cells discussed in 
chapter 3, each frame in a video was converted into a stack with the software and 
these were collated in order of time of recording for analysis. Fluorescent cells were 
selected and their fluorescence was measured as the average pixel intensity of the 
selected area (i.e. the area covered by the whole of each cell) per frame in recording. 
Background measurements were also taken for each selected cell per frame by using 
the same-sized area of analysis (used to measure the cells) to measure the average 
pixel intensity of an area of the video that did not contain any cells and was as close 
to its associated cell as possible. The background value was subtracted from that of its 
corresponding cell for each stack and collated to give a plot of fluorescence intensity 
change over time using Microsoft Excel, to be referred to as a Ca2+ transient 
plot/trace, for each cell. All the values in this plot were made relative to the 
fluorescence intensity value at the time point prior to treatment addition (e.g. with 
thapsigargin or AVP), which is referred to as the basal level. The trace was also 
corrected for any photo-bleaching, which was recognised as a steady decrease of 
fluorescence intensity over time, by measuring the gradient of this decrease and 
subtracting it from the background-corrected measurements of its associated cell for 
each frame after multiplying the gradient value by the time point (in seconds) 
represented by the frame being calculated for. Average plots for each experiment 
were produced by averaging all the values obtained for all selected cells in its 
associated video recording after all corrections had been calculated. These were then 
used for calculating the kinetics of the rise and decay phases of Ca2+-mediated AVP 
responses (table 3.2.4.4).   
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For all Fluo-4 experiments with COS-7 cells discussed in chapter 5 and Fluo-3 
experiments with A7r5 cells discussed in chapter 4, the method of ImageJ analysis 
was modified from the above. Video recordings were opened directly in the ImageJ 
program using the AVI reader plug-in (via the ‘Using Quicktime’ option for 
importing files). Background noise was subtracted from whole recordings using the 
‘Subtract Background’ function. Multiple cells were selected and measured for 
change in pixel intensity of the selected areas (i.e. whole cells) over time using the 
‘ROI manager’ function. These measurements were saved as Excel files. The values 
from all cells from each experiment were averaged together to produce mean pixel 
intensity change over time, and these values were normalised to basal values and 
corrected for photo-bleaching as stated above.  
 
2.7. Kinetics Measurements from Fluo-3 Fluorescence Microscopy Data 
The time taken to achieve 50% of the maximum (i.e. peak) F/Fo value shown on the 
plots of mean F/F0 over time was measured either between the start of treatment and 
peak response (i.e. half-maximal response) or between the peak response and 
beginning of the plateau at the end of the response (i.e. half-life of response decay). 
These measurements were made for each plot of mean F/Fo against time produced 
from recordings with A7r5 cells as stated in section 2.6.   
 
2.8. Statistical Analysis 
Standard errors of the means (S.E.M) were calculated for data from PCRs, Western 
blots, Ca2+-ATPase activities and kinetics measurements from Fluo-3 experiments. 
For testing statistical significance (P), two-tailed equal variance Student’s T-test 
(Microsoft Excel) was used for data from all experiments for A7r5 cells stated in 
chapter 3 except for measurements of Ca2+-ATPase activities, whereby analysis of 
variance (ANOVA) with the general liner model (Minitab) was used for this 
exception (with advice from Dr. Jeremy Pritchard; University of Birmingham, UK). 
Two-tailed unequal variance Student’s T-test was used for Fluo-3 data shown in 
chapter 4 due to differences in number of experiments for treatment with potential 
modulators (n=4) and thapsigargin/AVP (n=3).  
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2.9. PCR Experiments for Rat RGN  
2.9.1. Rat cDNA Library Screen  
The sequence of the forward primer was as referenced previously (Yamaguchi and 
Nakajima, 2002) and represents nucleotides 618-636 in the rat RGN coding sequence 
(although originally designed for the mouse RGN mRNA sequence). The sequence of 
the reverse primer was designed as follows: 
 
5’-ACCCTGCATAGGAATATGG-3’ 
 
This latter sequence represents nucleotides 906-924 in the rat RGN coding sequence. 
This sequence for the reverse primer was used instead of that from the literature 
because the former complements better with the rat RGN mRNA sequence. The 
ClustalW web-based program (EBI) was used to check these primers would 
complement the rat RGN mRNA sequence that was retrieved from the Pubmed 
nucleotides databank (entry number NM_031546) (NCBI). The size of the PCR 
product for these primers was expected to be 307bp.   
Each 50µl PCR mixture contained 2.5 units of BIOTAQ™, 1x NH4 buffer, 
2.5mM MgCl2, 2mM dNTP mix, 20pmol of each primer and autoclaved dH2O. The 
thermocyclers used were the same as those for PCR experiments with A7r5 cDNA 
samples (section 2.4.1). The initial melting step was 95oC for 2 minutes. For the 
cycles, the melting step was 95oC for 1 minute, the annealing step was 55oC for 1 
minute and extension step was 72oC for 1 minute. The PCR lasted for 30 cycles. 
Reaction mixtures were temporarily maintained at 4oC at the end of the last extension 
step, which lasted for 10 minutes at 72oC, before being stored at -20oC. PCR products 
were electrophoresed through a 2% w/v agarose gel with a 100bp DNA ladder and 
stained (section 2.4.2). Each sample in a partial rat cDNA library (prepared by Mrs. 
Rita Godfrey; University of Birmingham, UK) screened for the presence/absence of 
RGN mRNA was checked for their abundance in total cDNA using PCR with RPL19 
primers (section 2.4.1). A gel extract sample of RGN PCR product was sequenced to 
ensure it did contain mRNA coding sequence for RGN (section 2.10.1 and 2.10.5) 
   
2.9.2. Isolation of Full Length Rat RGN Coding Sequence  
Primers for the full length coding sequence of rat RGN mRNA were designed from 
analysis of the mRNA sequence from the Pubmed nucleotides databank (entry 
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number NM_031546) and made by Alta Bioscience. The NEB Cutter V2.0 web 
program was used to find restriction sites suitable for cloning the rat RGN coding 
sequence into the pET21a expression vector (Novagen). NdeI and AvaI/XhoI 
restriction sites in the vector’s multiple cloning site (MCS) was chosen because these 
sites are not present in the RGN coding sequence and so the latter would remain intact 
during restriction endonuclease treatment to obtain DNA fragments of both for 
ligation (section 2.10.3).   
 
The sequence of the forward primer was as follows: 
 
5’-CCCTTTCATATGTCTTCCATCAAGATTGAATGTG-3’ 
 
The sequence of the reverse primer was as follows: 
 
5’TAATATCTCGAG[AGTATGACCATCTAT]CCCTGCATAGGAATATGG-3’ 
  
Sequences in bold are non-coding and were included to aid digest by restriction 
endonucleases, which need non-specific sequences on either side of their preferred 
restriction site to allow them to bind strongly to the latter. Sequences underlined are 
the restriction sites, whereby the forward primer contains the NdeI restriction site and 
the reverse primer contains the AvaI/XhoI restriction site. The sequence in the square 
brackets ([]) (in the reverse primer) codes for an amino acid sequence that acts as a 
cleavage site (Ile-Asp-Gly-Arg-Thr) for Factor Xa protease. The primers were 
designed to obtain a full coding sequence from mRNA that could be cloned into a 
pET21a vector and be expressed to produce rat RGN protein that had a hexahistidine 
(Hisx6) tag at its C-terminus. The tag could then be used to purify the protein using 
nickel affinity chromatography (section 2.12.6) and the Factor Xa cleavage site would 
be used (if needed) to remove the tag after purification. The coding sequence for the 
Hisx6 tag is part of the pET21a plasmid at the 3’ end of the multi-cloning site.    
The thermocyclers used were the same as those for PCR experiments with 
A7r5 cDNA samples (section 2.4.1). The 50µl PCR mixture contained 50pmol of 
each of the above primers, 2.5 units of BIOTAQ™, 1x NH4 buffer, 2mM MgCl2, 
2mM dNTP mix and 20ng of cDNA isolated from rat liver tissue (prepared by Mrs. 
Rita Godfrey; University of Birmingham, UK). The PCR lasted for 35 cycles. The 
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initial melting step was 95oC for 2 minutes. For the cycles, the melting step was 95oC 
for 1 minute, the annealing step was 60oC for 1 minute and the extension step was 
72oC for 1 minute. Reaction mixtures were temporarily maintained at 4oC at the end 
of the last extension step, which lasted for 10 minutes at 72oC at the end of the last 
cycle, before being stored at -80oC.  
The PCR mixtures were then electrophoresed through a 0.8% w/v agarose gel 
with a 1kb DNA ladder and stained (section 2.4.2). The expected PCR product size 
for full-length rat RGN coding sequence from mRNA was 0.94kb. DNA sequencing 
was done with gel extracts (section 2.10.1 and 2.10.5) of the PCR product to confirm 
the correct sequence was obtained using the LALIGN web-based program (EMBnet, 
Swiss Institute of Bioinformatics) for sequence alignment with the mRNA sequence 
used to design the primers. PCR products were stored at -20oC. 
 
2.10. Preparation of Rat RGN Plasmids 
2.10.1. Gel Extraction & Approximation of DNA Quantities 
Extraction of PCR products (sections 2.4.1, 2.9.1 and 2.9.2) or restriction digest 
fragments of plasmid DNA (section 2.10.3) from agarose gels was done using a 
QIAquick Gel Extraction Kit (Qiagen) and following manufacturer’s instructions for 
the microcentrifuge method. Several fragments of DNA were required to obtain a 
sufficient amount of extracted DNA. The final quantity of DNA obtained was 
approximated by electrophoresising the extraction product through either 0.8% or 2% 
w/v agarose gel (depending on the size of extracted DNA) (section 2.4.2) and 
comparing the product band intensity with that of its nearest marker from the DNA 
ladder (e.g. the 1kb marker for the 0.94kb full rat RGN coding sequence), the latter of 
which had a defined quantity of DNA that was known from the volume of DNA 
ladder loaded onto the gel and information given by the manufacturer.  
For example, 0.5µg of 1kb DNA ladder contained 42ng of 1kb marker DNA. 
If a ~1kb product band (e.g. full rat RGN coding sequence) was judged by eye to be 
half the intensity of this marker, it was approximated that the amount of PCR product 
present in the band was 21ng. Dividing the amount of PCR product by its volume 
loaded into the gel for the same DNA band gave the concentration of DNA present in 
the gel extract. The same calculations were used to estimate DNA quantities for the 
purpose of DNA sequencing (section 2.10.5) and DNA ligation (section 2.10.2-3).  
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2.10.2. Ligation of Rat RGN Coding Sequence into pGEM-T Vector  
The PCR product for the full coding sequence of rat RGN (0.94kb) extracted from 
agarose gels (sections 2.9.2 and 2.10.1) was inserted into a pGEM-T vector 
(Promega) following manufacturer’s instructions for the pGEM-T Easy Vector 
System Kit. This was done to provide restriction sites at the 5’ and 3’ ends of the rat 
RGN coding sequence, which were used to insert the sequence into the pET21a vector 
later on (section 2.10.3). 25ng of pGEM-T vector was ligated with the gel-extracted 
PCR product at an 8:1 ratio, and the amount of PCR product used was calculated (as 
instructed in the manual provided with the kit) to be 61.6ng. The calculation used was 
as follows: 
 
DNA insert amount (ng) =  
((Vector amount (ng) x DNA insert size (kb)) / Vector size (kb)) x Insert:Vector ratio  
! 
 
pGEM-T empty vector and PCR product were initially mixed together and heated in a 
55oC heat block for 5 minutes (to improve ligation by melting the DNA) before 1x 
ligation buffer and 3 units of T4 DNA ligase (both provided in the kit) were added to 
complete the reaction mixture. Control reaction mixtures were also made in the same 
manner but with no insert DNA added. All reactions were incubated overnight in a 
4oC water bath. DH5-α cells were transformed (section 2.11.5) with the reaction 
mixtures afterwards and colonies on LB-agar plates from cells that had ligation 
reaction mixtures added to them were picked and grown overnight in LB cultures to 
use for minipreps (section 2.10.4). Control ligation reaction mixtures were expected 
to not produce colonies following its use for DH5-α transformation (due to absence of 
circularised plasmids).  
A restriction digest with 10 units of AvaI and 20 units of NdeI (section 2.9.2) 
for 3µl of miniprep DNA in a total reaction volume of 10µl (the rest of the volume 
was made up with 1x reaction buffer (supplied with the enzymes) and autoclaved 
dH2O) was done to check the correct plasmid was present. The reaction mixtures were 
incubated in a 37oC water bath for 1 hour, before their contents were electrophoresed 
through a 0.8% w/v agarose gel and stained (section 2.4.2). The presence of two DNA 
gel fragments, one for rat RGN (0.94kb) and one for pGEM-T vector (3.0kb), after 
restriction digest of miniprep DNA, suggested the ligation was successful and the 
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pGEM-RGN plasmid was made. DNA sequencing (section 2.10.5) was done with the 
miniprep DNA to check the rat RGN coding sequence was present using the LALIGN 
web-based program.   
 
2.10.3. Ligation of Rat RGN Coding Sequence into the pET21a Vector  
Rat RGN coding sequence was excised out of the pGEM-RGN plasmid by doing a 
restriction digest with 10 units of AvaI and 20 units of NdeI (section 2.10.2). The 
same restriction digest reaction was also done for pET21a empty vector. Reaction 
mixtures were incubated in a 37oC water bath for 1 hour, before they were 
electrophoresed through a 0.8% w/v agarose gel and stained (section 2.4.2). The DNA 
gel fragments corresponding to the RGN coding sequence (0.94kb) and pET21a 
vector (5.44kb) were extracted and the extracts were subjected to electrophoresis to 
approximate the amount of DNA they contained (section 2.10.1).  
Ligation of rat RGN coding sequence into the linearised pET21a vector was 
done at a 7:1 ratio and the amount of insert DNA required was calculated in the same 
way as done for pGEM-T vector ligation (section 2.10.2). From this, 25ng of pET21a 
vector and 30.54ng of rat RGN coding sequence was used in the reaction mixture, 
which also contained 100 units of T4 DNA ligase (NEB), 1x reaction buffer (provided 
with the enzyme) and autoclaved dH2O to make up the final reaction volume to 50µl. 
Note that the DNA and dH2O were mixed first and heated in a 60oC heat block for 10 
minutes before the T4 DNA ligase and buffer were added. The reaction mixture was 
then incubated overnight in a 16oC water bath.  
After ligation, DH5-α cells were transformed with the reaction mixture 
(section 2.11.5) and colonies were grown overnight in LB cultures to use for 
minipreps (section 2.10.4). Restriction digests of the minipreps were done with 3µl of 
miniprep DNA, using 10 units of XhoI (an endonuclease that is specific to the same 
restriction site as AvaI) and 20 units of NdeI per 10µl reaction volume. Reaction 
mixtures were incubated in a 37oC water bath for 1 hour, before their contents were 
electrophoresed through a 0.8% w/v agarose gel and stained (section 2.4.2) to check 
the correct DNA fragments were present. The pET21a-RGN plasmid was also 
sequenced (section 2.10.5) and minipreps of the plasmid were used to transform BL21 
cells (section 2.11.5) after confirming it contained the correct sequences.   
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2.10.4. Minipreps  
All minipreps of plasmid DNA for pGEM-RGN, pET21a-RGN and pET21a empty 
vector were done using a GenElute Plasmid Miniprep Kit (Sigma). Manufacturer’s 
instructions were followed. A 5ml overnight LB culture of transformed DH5-α cells 
(carrying the plasmid of interest) (section 2.11.5) was used per miniprep. Elution of 
DNA was done with 100µl autoclaved dH2O per miniprep. All minipreps were stored 
at -20oC. 
 
2.10.5. DNA Sequencing  
The nucleotide sequences of PCR products and plasmids containing the full-length rat 
RGN coding sequence (sections 2.9.2, 2.10.2 and 2.10.3) were checked using the 
Plasmid-to-Profile service provided by the Genomics Laboratory (University of 
Birmingham, UK). The primers used were either those for the full rat RGN coding 
sequence (PCR product and pGEM-RGN plasmid) (section 2.9.2) or those used to 
screen the rat cDNA library (pET21a-RGN plasmid) (section 2.9.1). SPCA1 PCR 
products from A7r5 cDNA samples (section 2.4.1) and RGN PCR products from 
cDNA copies of total mRNA from adult male rat liver and testis (section 2.9.1) were 
also sequenced using the same service.   
 
2.11. Bacterial Cell Culture 
2.11.1. Sterilisation of Solutions & Culture-Handling Materials  
All media (stored in glassware and sealed with either metal/plastic caps or foam 
bungs), some liquids (e.g. dH2O) and some culture-handling materials purchased in 
non-sterile form (e.g. micropipette tips) were autoclaved as done for mammalian cell 
culture (section 2.1.1) before use with bacterial cultures. Filter sterilisation (where 
stated) was done using a 0.2µm pore filter with syringe, and the filtrate was stored in 
sterile containers. Work surfaces were cleaned using 70% v/v ethanol. A Bunsen 
burner flame was used to sterilise necks of glass bottles and flasks, glass spreaders 
and wire loops before and after use. The flame was also used to keep nearby work 
surfaces sterile. Glass spreaders and wire loops were pre-soaked with 100% v/v 
ethanol before fully sterilised with a Bunsen burner flame.      
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2.11.2. Making LB Media & LB-Agar  
Luria-Bertani (LB) media (used for culturing DH5-α and BL21 E.coli strains, unless 
otherwise stated) was made with 10g/L tryptone (Oxoid), 5g/L yeast extract (Oxoid) 
and 5g/L NaCl, all dissolved in dH2O. LB-agar was made by adding 1.5% w/v agar 
powder (Oxoid) to LB media. LB media was supplemented with 0.1mg/ml ampicillin 
(filter-sterilised) on the day of use for all cultures.  
 
2.11.3. Setting LB-Agar Plates  
To obtain three LB-agar plates, one bottle containing 75-80ml of LB-agar was placed 
in cold tap water and heated until all LB-agar had fully dissolved. Liquefied LB-agar 
was then left at room temperature to cool to approximately 40-50oC (at which it was 
cool enough to hold the bottle in hand comfortably and while LB-agar was still in 
liquid state).  
Once cooled, ampicillin solution (filter-sterilised) was added to give a final 
concentration of 0.1mg/ml. The antibiotic-supplemented LB-agar was poured into 
three 10cm diameter Petri dishes at approximately equal volumes. The plates were 
sealed with their lids and left to cool at room temperature next to a Bunsen burner 
flame until the LB-agar had solidified. Condensation was dried off the solid LB-agar 
by opening the lids slightly whilst still keeping the plates next to a Bunsen burner 
flame. Plates were used on the same day for plating DH5-α (section 2.11.5) or BL21 
cells (section 2.12.1).      
 
2.11.4. Making Stocks of Competent DH5-α Cells  
A frozen glycerol stock (section 2.11.5) of already competent DH5-α cells (a gift 
from Dr. S. Whitehead; University of Birmingham, UK) was streaked onto a modified 
LB-agar plate using a wire loop and incubated in a 37oC oven for 14-16 hours. The 
modified LB-agar consisted of 1.2% w/v agar in growth medium (20g/L tryptone, 
5g/L yeast extract, 0.1M NaCl2 and 10mM MgSO4). The plates were set in the same 
way as normal agar plates (section 2.11.3) except that no ampicillin was added.  
One colony was picked from the plate using a sterile pipette tip and transferred 
into 5ml of growth media, which was then maintained at 37oC in a shaking incubator. 
A few of such cultures were set up for growth. Absorbance readings at 650nm were 
taken of 1ml samples from the 5ml cultures every 30 minutes until the O.D. values 
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were within the range of 0.2-0.6. 4ml of combined cultures were then used to 
inoculate 100ml of fresh 37oC pre-warmed growth media, which was then maintained 
at 37oC in the shaking incubator. Absorbance readings at 650nm were taken of 1ml 
samples from the 100ml culture until O.D. values were within the range of 0.5-0.9. 
Following this, all the remaining culture was used to inoculate 500ml of fresh growth 
media, which was maintained at 37oC in the shaking incubator and absorbance 
readings at 650nm were taken of 1ml samples from this latter culture until O.D. 
values were within the range of 0.6-0.8.  
All solutions and culture-handling materials were kept on ice from hereon. 
Note that centrifuge bottles had been rinsed with ethanol and dH2O before being 
autoclaved to sterilise thoroughly before use. The 500ml culture was placed on ice to 
be chilled for 5 minutes before being centrifuged at 6,700g for 5 minutes at 4oC. The 
media was discarded and the cell pellet was re-suspended in 100ml of TfBI solution 
(filter-sterilised) (30mM KC2H3O2, 10mM RbCl2, 50mM MnCl2 and 1.5% v/v 
glycerol; pH 5.8 using 0.2M acetic acid). The cell suspension was left on ice for 1.5 
hours before being centrifuged as before. TfBI solution was then discarded, the cell 
pellet was re-suspended in TfBII solution (filter-sterilised) (10mM MOPS, 75mM 
CaCl2, 10mM RbCl2 and 15% v/v glycerol; pH 6.5 using KOH) and left on ice for 2 
hours. The cell suspension was then aliquoted, snap frozen with liquid nitrogen and 
stored at -80oC.               
 
2.11.5. Transformation of Competent E.coli Cells & Making Glycerol Stocks  
DH5-α cells were transformed with plasmid DNA needed for minipreps (section 
2.10.4) and maxipreps (section 2.3.1). These were pGEM-RGN, pET21a-RGN, 
control pET21a and all plasmids used for over-expression in COS-7 cells (section 
2.3.1). BL21 cells (a gift from Dr. Simon Whitehead; University of Birmingham, UK) 
transformed with pET21a-RGN were used for over-expression of recombinant RGN 
protein.  
Frozen competent cells were thawed on ice and kept at ice-cold temperatures 
at all times (unless otherwise stated). Failure to do this resulted in their loss of 
competence (i.e. weakened their ability to take up plasmid DNA). 50-100µl of thawed 
competent cells was mixed by gentle pipetting with 50ng-1µg of plasmid DNA in a 
sterile tube and incubated on ice for 60 minutes. A separate sterile tube of competent 
cells with no added DNA was used as a negative control. Following this, both DNA-
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treated and control cells were heat-shocked by incubating in a 42oC water bath for 2 
minutes and then incubated on ice for a further 2 minutes. 0.5-1ml of LB media was 
added to the cells and incubated in a shaking incubator at 37oC for 90 minutes. 20-
50µl of these cultures were then plated onto ampicillin-supplemented LB-agar plates 
using a sterile glass spreader and incubated overnight in a 37oC oven. After viewing 
(and using) colonies the next day, the plates were wrapped with Parafilm and stored at 
4-6oC for up to 3 weeks for later use. Control cells were expected not to form colonies 
(due to absence of ampicillin resistance).   
Colonies were picked to inoculate either 5ml or 50ml of LB media and 
cultures were grown overnight in a shaking incubator maintained at 37oC. 5ml 
cultures were then used for minipreps. 50ml cultures were used to set up 200ml 
overnight cultures for maxipreps, whereby 10ml from the 50ml overnight culture was 
used to inoculate 200ml of fresh LB media. Glycerol stocks of transformed cells were 
made for future use by mixing at a 1:1 ratio of cell culture with 50% v/v glycerol and 
stored at -80oC. Cells were plated onto LB-agar plates from glycerol stocks by 
picking a small amount of the frozen stock with a sterile wire loop and streaking this 
onto the plate, which were then incubated in a 37oC oven overnight, or inoculating 5-
50ml of ampicillin-supplemented LB media and grown at 37oC in a shaking 
incubator.    
 
2.12. Production, Use & Purification of Recombinant RGN Protein 
2.12.1. IPTG Induction of pET21a-RGN-Transformed BL21 Cells 
Glycerol stocks of BL21 cells transformed with pET21a-RGN plasmid (section 
2.11.5) were streaked onto LB-agar plates. Colonies were picked to inoculate 50ml of 
LB media, which was maintained at 37oC overnight in a shaking incubator. 10ml of 
the overnight culture was used to inoculate 200ml of fresh LB media, which was then 
maintained at 37oC in a shaking incubator and readings of its absorbance at 600nm 
was taken every 30 minutes from 1ml samples. Once O.D. values reached 0.7-1.0, 
cells were induced to synthesise recombinant RGN by adding isopropyl β-D-1-
thiogalactopyranoside (IPTG) solution (filter-sterilised) (BIOLINE) to the culture, 
which was then incubated in a shaking incubator for a chosen period of time and 
temperature. A range of IPTG concentrations, as well as incubation times and 
temperatures were tested during optimisation (see section 5.2.10). The final 
conditions used for induction were 0.25mM IPTG, 17oC and overnight culture for 
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production of inclusion bodies. After the induction period, cultures were centrifuged 
at 11,900g for 20 minutes at 4oC, the media was discarded and the pellet was stored at 
-20oC.     
 
2.12.2. Sonication of BL21 Pellets & Solubilisation of Inclusion Bodies  
Frozen pellets of induced BL21 cells were thawed and 10ml of TED buffer (50mM 
Tris-HCl (pH 8.0), 1mM EDTA and 1mM DTT) was added to each pellet. The cells 
were re-suspended and sonicated once every minute for 15 seconds over a total period 
of 10 minutes. 10ml of fresh TED buffer, followed by 1mM PMSF, was added to the 
total cell lysate, which was then centrifuged at 20,000g for 20 minutes to separate 
inclusion bodies and soluble proteins. To solubilise the inclusion bodies prior to Ni2+ 
affinity column chromatography (section 2.12.6), the supernatant was removed and 
solubilisation buffer (0.1M NaH2PO4, 8M urea and 5mM DTT; pH 8.0) was used to 
re-suspend the pellet. The solubilised pellet was then centrifuged at 100,000g for 45 
minutes and the resulting supernatant (containing the solubilised inclusion bodies) 
was collected.  
 
2.12.3. Preparation of Dialysis Tubing 
New dialysis tubing had to be treated before use. Hot dH2O was supplemented with 
5% w/v NaHCO3 and 1mM EDTA. The solution was kept on a hot plate with constant 
stirring until it was 70oC. New dialysis tubing was then added and kept in the solution 
for 1 hour with gentle stirring. Following this, the dialysis tubing was removed and 
washed thoroughly with fresh dH2O before being stored in 20% v/v ethanol; the latter 
had to be thoroughly washed off with dH2O before using the dialysis tubing.  
    
2.12.4. Antibody Production for Anti-RGN   
Recombinant RGN protein isolated during optimisation trials of its purification was 
used to produce an antibody that recognised all RGN protein. A BL21 pellet was 
sonicated and the cell lysate centrifuged as described above (section 2.12.2). Inclusion 
bodies (within the pellet obtained from centrifugation at 20,000g) were solubilised 
with 6M urea dissolved in 50mM Tris-HCl buffer (pH 7.2) and stored overnight at -
20oC. Following this, 2ml of this protein solution was thawed on ice, transferred into 
dialysis tubing and kept in 2.5L dialysis buffer (50mM Tris-HCl (pH 7.2) with 15% 
v/v glycerol) overnight at 4-6oC with constant gentle stirring.  
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After dialysis, the protein solution was subjected to SDS-PAGE and the gels 
were stained for proteins (section 2.4.5). An abundant 33kDa protein band from the 
protein sample was excised from the gel with a scapel and used for FT-ICR mass 
spectrometry analysis (Proteomics Laboratory; The University of Birmingham, UK), 
which confirmed the identity its protein contents to be rat RGN. The same FT-ICR 
service was used to identify of the protein contents of a 66kDa Coomassie-stained gel 
band from the total cell lysate of adult boar sperm (section 5.2.6). SDS-PAGE and 
Coomassie blue staining was repeated with the same recombinant RGN sample, and 
multiple 33kDa protein bands were excised and sent to Covalab (UK) for antibody 
production.  
Two rabbits were each immunised with the 33kDa protein and boosted 14 and 
28 days after the initial immunisation. Later on, one of the two rabbits was chosen for 
a further two immunisations at 74 and 88 days after the first immunisation. Blood sera 
taken from the rabbit(s) before immunisation (the ‘pre-immune’ bleed) and on the 
days of the three or five immunisations were received for testing via Western blotting 
method (section 2.12.5).   
 
2.12.5. Western blotting with Anti-Hisx6 & Anti-RGN Antibodies 
Basic procedure for Western blotting was as described before (section 2.4.6). 
Monoclonal mouse anti-Hisx6 (clone HIS-1; Sigma) was used at a dilution ratio of 
1:1500. Custom-made anti-RGN polyclonal rabbit antibody (Covalab) was used at 
dilution ratios ranging between 1:75 and 1:750 during optimisation trials with day 88 
and final bleeds, whereas a dilution ratio of 1:50 was used with days 0 and 39 bleeds. 
All secondary antibodies were used at a dilution ratio of 1:3000. For the detection of 
RGN, either with or without Hisx6-tag, the protein band’s expected size was 33kDa 
(Yamaguchi, 2005).   
 
2.12.6. Nickel Affinity Column Chromatography 
All column chromatography was done using a BIORAD ECONO pump system. All 
column washes and runs were done at a flow rate of 0.3ml/min and for 60 minutes 
each. A fast flow rate of 15.2ml/min was used to rinse tubing only and the column 
would be detached from these during the use of this latter flow rate. Each time a new 
buffer or solution was to be used to wash the column, it would be used to rinse tubing 
at fast flow rate for 2 minutes first. HIS-Select Nickel Affinity Gel (Sigma) was 
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packed into a chromatography column to give a 2ml resin bed volume, washed first 
with dH2O and then equilibration buffer (same as solubilisation buffer (section 
2.12.2)). Excess of the latter was removed afterwards to leave approximately 0.5ml at 
the top of the resin gel.  
Solubilised inclusion bodies (section 2.12.2) were applied to the top of this 
resin gel (with care taken not to disrupt its packing), washed through the column with 
equilibration buffer, followed by wash buffer (equilibration buffer at pH 6.2) and 
elution buffer (equilibration buffer at pH 4.5). The 60 minutes of each of the latter 
three column washes (i.e. equilibration, wash and elution) consisted of the first 30 
minutes of eluant being discarded into waste and the last 30 minutes of eluant being 
collected as the sample. These three samples were then subjected to SDS-PAGE and 
the gels were stained for proteins (section 2.4.5). The fraction with both a good 
amount of 33kDa protein and minimal content of contaminating proteins was selected 
as a good sample of RGN to use for refolding (section 2.12.7).    
 
2.12.7. Protein Refolding  
The His-column fraction determined to contain the most and purest amount of RGN 
(section 2.12.6) was used for refolding experiments. For the one-step dialysis 
refolding method, the fraction was diluted to 0.1mg/ml protein concentration with the 
column buffer used to elute it off the column, 10ml of the diluted protein solution was 
transferred into dialysis tubing (section 2.12.3) and dialysed overnight at 4oC with 
gentle stirring in 5L of 50mM Tris-HCl (pH 8.0) buffer containing 1mM DTT and 
15% v/v glycerol. For the crash dilution method of refolding, the chosen column 
fraction was rapidly diluted at a 1:5 ratio by adding 50mM Tris-HCl (pH 8.0) buffer, 
which was supplemented with 5mM DTT and 10% v/v glycerol, to it whilst gently 
stirring to give a final protein concentration of 0.1mg/ml, then left for 10 minutes at 
4oC still stirring. Following this incubation, 5ml of the dilution refolded protein was 
dialysed in 5L of 50mM Tris-HCl (pH 7.2) buffer, containing 5% glycerol, overnight 
(with 5ml of sample in dialysis bag) and concentrated (section 2.12.8). Protein 
solutions from refolding attempts were snap frozen with liquid nitrogen and stored at -
80oC.  
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2.12.8. Protein Concentrating 
Vivaspin 20 centrifugal concentrators (Sartorius) were used to concentrate dialysed 
RGN protein. All centrifugation steps were 5000g for 30 minutes at 15oC. Each 
concentrator was first filled with 5ml of 50mM Tris-HCl (pH 8.0), centrifuged and all 
buffer discarded afterwards to wash the sample reservoir. This reservoir was then re-
filled with the dialysed protein solution and centrifuged again. Centrifugation of the 
protein sample was repeated until its volume was reduced by 10-fold. Following this, 
the concentrated sample was retrieved from the reservoir to have its protein 
concentration estimated (section 2.4.3), before it was aliquoted, snap frozen with 
liquid nitrogen and stored at -80oC.       
 
2.12.9. Circular Dichroism (CD) Spectroscopy 
Cl- contents of protein samples had to be reduced by dialysis in 50mM Tris buffer, 
with pH adjusted using phosphoric acid (pH 8.0), overnight at 4oC. Each sample was 
then analysed using a Jasco J715 spectropolarimeter (with Spectra Manager v.1.07.02 
program) in quartz cuvettes (0.2mm pathlength), using 190-260nm wavelength range 
and 16 repeat readings. Such measurements were also done for fresh dialysis buffer 
(used in section 2.12.7) without added protein as controls, the values of which were 
subtracted from those for protein samples to correct for effects of buffer and 
background. Absorbance spectra were measured to monitor linearity of light 
absorbance at all samples. The K2D2 web-based program (Ontario Genomics 
Innovation Centre) was used to analyse CD spectra for protein samples to predict 
contents of secondary structure. 
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CHAPTER 3. 
SPCA EXPRESSION & ACTIVITY IN A7r5 CELLS CULTURED IN 
NORMAL & HIGH GLUCOSE MEDIA  
 
3.1. Introduction 
 
Diabetes mellitus can cause cardiovascular diseases, by promoting pathological 
processes, such as the formation of atherosclerotic plaques (Rader and Daugherty, 
2008). Such diseases are characterised by the dis-regulation of calcium homeostasis in 
vascular cells (Levy, 1999), with examples such as higher than normal basal 
intracellular [Ca2+] in rat cardiomyocytes and altered hormone-induced Ca2+ 
signalling in human vascular smooth muscle cells (Fleischhacker et al., 1999). This 
has been attributed to altered expression and/or activity of Ca2+-binding proteins, 
which has been exemplified by increased enzymatic activity of calpain in endothelial 
cells (Stalker et al., 2005) and decreased expression of SERCA in heart tissue 
(Teshima et al., 2000) of diabetic rats.   
 
Vascular smooth muscle cells (VSMCs) can also exhibit diabetes-associated 
abnormalities in Ca2+ homeostasis during the progression of cardiovascular disease, 
which has been exemplified by, for example, observations of higher than normal basal 
intracellular [Ca2+] (Barbagallo et al., 1995) and increased SERCA activity (Tong et 
al., 2008) in rat-derived cells. In addition to this, VSMCs have been noted in previous 
studies to have enhanced secretory activity and produce higher than normal amounts 
of extracellular matrix proteins, such as collagen (Mazzone et al., 2008). This 
vascular cell type is specialised to assist the control of blood vessel diameter and 
structural modelling of blood vessel walls, both of which are required to adapt to 
changes in blood flow through the cardiovascular system (Rensen et al., 2007). 
VSMCs can exist in two phenotypic states, contractile and secretory (the latter also 
known as ‘synthetic’), both in healthy and diseased vascular tissue (Archer, 1996). 
However, it is characteristic of vascular diseases for proliferative secretory VSMCs to 
dominate more in its associated cell population than their more differentiated 
contractile counterparts (Thyberg et al., 1990). One of the likely consequences of this 
phenotypic switch of a VSMC population is higher than normal inflammation of 
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blood vessel walls and this is a major factor that promotes atherosclerotic plaque 
formation (Mazzone et al., 2008).    
 
One protein that is involved in both Ca2+ homeostasis and secretory function in cells 
is SPCA (Wuytack et al., 2003), which is also relatively highly expressed in 
cardiovascular tissue, such as from heart and aorta (Wootton et al., 2004). SPCA is 
important for establishing a store of Ca2+ in the Golgi apparatus, which is required by 
Ca2+-dependent enzymes that are essential for post-translational modification of 
proteins in transit through the secretory pathway. An example would be casein kinase 
(Szymanski and Farrell, 1982), which controls matrix gamma-carboxyglutamic acid 
protein trafficking via it’s phosphorylation in human VSMCs (Wajih et al., 2004). 
Ca2+ in the Golgi apparatus can also be used to promote protein-protein interactions 
required for their secretion, such as that between osteoprotegerin and von Willebrand 
factor in human vascular endothelial cells (Shahbazi et al., 2007).  
 
Despite the relationship between Golgi apparatus Ca2+ stores and protein secretion 
being relatively well established, with some links to cardiovascular disease also 
suggested, it is unknown if SPCA activity and/or expression is involved in diabetes-
related vascular pathology, like other similar Ca2+-binding proteins such as those 
mentioned above. However, one study has suggested that altered SPCA expression 
levels could contribute to the pathological effects of diabetes in pancreatic β-cells by 
affecting glucose-stimulated insulin secretion (Mitchell et al., 2004). Furthermore, 
another study has shown the Golgi apparatus can influence the proliferative state of 
VSMCs (Thyberg, 1998). Thus there is evidence to suggest SPCA and the Golgi 
apparatus could play a role in diabetes-related vascular disease.  
 
The aim of the present study was to establish if SPCA expression and/or activity can 
be altered in VSMCs maintained under a hyperglycaemic state, which resembles that 
in diabetes, compared to the normal euglycaemic state of cellular glucose availability. 
An aortic VSMC cell line, A7r5, was grown in media either supplemented with a 
normal (5.55mM; “NG”) or high (25mM; “HG”) glucose concentration to produce 
experimental models of the two states for this study. Only SPCA1 expression and 
localisation was studied because it has been shown in a previous study that aortic 
vascular cells are unlikely to express the SPCA2 isoform (Vanoevelen et al., 2005). 
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3.2. Results 
 
3.2.1. Expression Levels of SPCA1, SERCA, GAPDH & β-Actin mRNA in A7r5 
Cells Cultured in Normal & High Glucose Media 
PCR was used to measure the amount of mRNA that encoded SPCA1, SERCA, 
GAPDH and β-actin in A7r5 cells grown in media supplemented with either a normal 
(5.5mM; NG) or high (25.0mM; HG) concentration of glucose. SPCA1 (all splice 
variants) was the main subject of interest. SERCA (all isoforms and splice variants) 
mRNA levels were also measured to see if it was affected by a difference in A7r5 
media glucose concentration and how it relates to any change in SPCA1 mRNA 
levels. Amounts of RPL19 mRNA were measured as a control for the total amount of 
transcripts that was present in each sample and thus allowed correction for any 
differences in this factor. RPL19 was chosen as the control because it is a commonly 
used control for similar experiments and was unlikely to be affected by a change in 
glucose availability to A7r5 cells because it encodes for a housekeeping ribosomal 
protein (Al-Bader and Al-Sarraf, 2005).  
GAPDH and β-actin mRNA levels are two other commonly used controls for 
PCR reactions (Al-Bader and Al-Sarraf, 2005). However, their suitability as controls 
in the present study were questionable due to their associated functions. GAPDH is an 
enzyme that is part of the glycolytic pathway and it was suspected to be possible that 
any changes in basal metabolism, caused by a change in glucose availability, may 
affect its mRNA expression levels. β-actin (a cytoskeletal protein) has been 
previously used as a phenotype marker in VSMCs due to its involvement in their 
contractility (Owens et al., 1986) and so its transcript levels were not used as a control 
for the present study in case of any changes in A7r5 phenotype from culture in media 
with different glucose concentrations. However, both GAPDH and β-actin mRNA 
levels were still monitored in the present study to see if such effects to their mRNA 
abundance did occur under the experimental conditions used.   
The use of cDNA copies of mRNA extracts from A7r5 cells, rather than the 
direct use of the latter, to measure for changes in mRNA expression was implemented 
due to the greater stability of cDNA compared to mRNA. The cycle numbers deemed 
to be appropriate for observing any differences in PCR product levels between  
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Figure 3.2.1.1. Effect of PCR Cycles on Amount of PCR Product for  
SPCA1 & SERCA Primers  
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Figure 3.2.1.1. Effect of PCR Cycles on Amount of PCR Product for  
SPCA1 & SERCA Primers  
 
PCRs with SPCA1 and SERCA primers and cDNA samples from NG cells were 
done using 20, 30, 35, 50 and 60 cycles. The reaction mixtures were subjected to 
agarose gel electrophoresis. The PCR product band intensities from DNA-
stained gels were measured from two replicate PCRs (one for each cDNA 
sample preparation from A7r5 cells) for each cycle number and the mean value 
was calculated. Error bars represent the spread of data.         
  90 
 
 
 
 
 
 
 
 
Figure 3.2.1.2. Effect of PCR Cycles on Amount of PCR Product for  
RPL19 Primers  
 
PCR with RPL19 primers and cDNA samples from NG cells were done to 
test the effect of cycle numbers in the same way as represented in figure 
3.2.1.1. The cycle numbers used were 20, 25, 30, 40 and 50. The same 
measurements and calculations were also used. (Error bars for the spread of 
data are present though not visible due to their low values.)  
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samples were determined for SPCA1 and SERCA (figure 3.2.1.1) as well as RPL19 
(figure 3.2.1.2). For each of these three transcripts of interest, the cycle number for 
their PCRs was selected within the linear range of their associated plot of mean PCR 
product band intensity against cycle number, each of which was produced using 
cDNA samples from NG cells. From this, 35 cycles was used for SPCA and SERCA 
primers, while 28 cycles was used for RPL19 primers. A cycle number in this range 
on each plot avoids saturation of PCR product amount and yet still produce enough 
transcripts for measurements to be made from. The cycle number used for β-actin 
primers (i.e. 28 cycles) is comparable to that previously determined as optimal (30 
cycles) and details of the associated experiments done to select this cycle number, 
which were similar to what was done in the present study for SPCA1, SERCA and 
RPL19, are in the literature from which the sequences of the primer pairs were 
obtained (Varadi et al., 1996). The cycle number used for PCR with GAPDH primers 
was set as the same as that for RPL19 and β-actin primers, which was lower than that 
used previously as stated in the literature from which its primer sequences were 
obtained (35 cycles) (Di Napoli et al., 2007). All cycle numbers are summarised in 
table 2.4.1.1. 
For the use of β-actin and GAPDH primers, the PCR conditions were the same 
as those quoted in the literature from which their sequences were obtained, except 
with a lower PCR cycle number of 28 (i.e. same as that for RPL19 primers) in both 
cases. Both pairs of primers had been used to indicate total mRNA quantity for PCR 
reactions in the studies described in their associated literature, and thus the cycle 
numbers that had been used had been optimised (as done in the present study for 
SPCA1, SERCA and RPL19 described above) to avoid production of saturated 
amounts of PCR products. Hence to use a lower PCR cycle number than that quoted 
in both cases was unlikely to produce saturated PCR product quantities. 
PCR product band intensities determined from images of DNA-stained 
agarose gels like those at figure 3.2.1.3B were measured from three replicate PCRs 
for each primer pair, whereby one replicate represented one sample of cDNA obtained 
from one culture of cells and thus three cell cultures were used in total for each of the 
two glucose culture conditions. The mean of replicates for each primer pair used were 
calculated and those measured for samples from HG cells were made relative to 
equivalent values measured for samples from NG cells. These relative values were 
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SPCA1 SERCA β-ACTIN GAPDH 
HG    NG HG    NG HG     NG HG    NG 
B 
Figure 3.2.1.3. PCR Analysis of SPCA1, SERCA, GAPDH & β-Actin mRNA 
Expression Levels in A7r5 Cells Cultured in Normal & High Glucose Media 
β 
** 
* 
A 
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Figure 3.2.1.3. PCR Analysis of SPCA1, SERCA, GAPDH & β-Actin 
mRNA Expression Levels in A7r5 Cells Cultured in Normal & High 
Glucose Media 
 
(A) Three PCR reactions were done for each primer pair and glucose culture 
condition, using cDNA copies of mRNA extracts from three pairs of NG and 
HG A7r5 cell cultures. PCR product band intensities from images of DNA-
stained gels were measured for each PCR, corrected for background and 
made relative to equivalent measurements made for RPL19 PCR product 
bands to correct for any differences in total amount of cDNA in samples. 
Corrected values for HG cells were made relative to those from their pair-
matched NG cells. Mean values of replicate PCR reactions were calculated 
for each primer pair and glucose culture condition, and converted to the 
percentage difference values shown. Error bars indicate S.E.M. Significant 
P-values calculated from two-tailed equal variance Student’s T-test are 
indicated by * (P<0.05) and ** (P<0.01). 
 
(B) DNA-stained gels of PCR product bands, which show typical band 
intensities observed for each of the four transcripts of interest from NG and 
HG cell samples of cDNA-copied mRNA extracts. The sizes of these DNA 
bands were those stated in table 2.4.1.1 when compared to positions of 
markers from a 100bp DNA ladder.   
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Figure 3.2.1.4. Sequence Alignment Between SPCA1 PCR Products From 
HG/NG Cells & Rat SPCA1 mRNA  
→  
→  
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Figure 3.2.1.4. Sequence Alignment Between SPCA1 PCR Products 
From HG/NG Cells & Rat SPCA1 mRNA  
 
Sequences of SPCA1 PCR products for both “HG” and “NG” cells were 
aligned against that for rat SPCA1 (listed as ‘Rattus norvegicus 
ATP2C1’) from the Pubmed nucleotide databank (entry number 
NM_131907.2). Values indicated by the arrows show the percentage of 
sequence between the PCR product and databank entry that was found to 
be the same as each other. 
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converted into percentages of mean band intensity measured from HG cells samples 
compared to NG cells (HG/NG), which are shown in figure 3.2.1.3A with S.E.M 
values represented by the error bars.  
From this, it was observed that HG cells contained 60 ± 13% more SPCA1 
mRNA than NG cells. HG cells were also 19 ± 5% more abundant in their SERCA 
mRNA content than NG cells. On the other hand, GAPDH and β-actin mRNA levels 
showed minimal change, whereby increases of 7 ± 4% and 4 ± 3% were observed, 
respectively. Student’s T-test analysis determined the difference in SPCA1 (P<0.01) 
and SERCA (P<0.05) transcript levels between NG and HG levels to be significant, 
whereas those for GAPDH and β-actin (P>0.05) were not significant. The SPCA1 
PCR product for both HG and NG cells were both sequenced and confirmed to 
represent the presence of SPCA1 mRNA coding sequence (figure 3.2.1.4). 
 
3.2.2. Expression Levels of SPCA1, SERCA & α-Actin Protein in A7r5 Cells 
Cultured in Normal & High Glucose Media 
Western blots of total cell lysates from A7r5 cells were repeated twice for each 
sample. Three samples were used for the detection of each of three proteins of interest 
and for each glucose culture condition. Total protein levels of each chemiluminescent 
protein band, like those in figure 3.2.2.1B, were deemed to be the same for all bands 
on the same blot by ensuring the same amount of protein was loaded at their 
corresponding SDS-PAGE gels. The amount of α-actin protein detected would also 
serve as a loading control as well as a VSMC marker. The mean of corrected protein 
band intensity values were calculated, and those representing measurements of 
samples from HG cells were made relative to equivalent values obtained for samples 
from NG cells. Such relative values were converted into percentage values of mean 
difference in amount of protein of interest in HG cells compared to NG cells 
(HG/NG), which are shown with their S.E.M values represented by the error bars in 
figure 3.2.2.1A.     
The data presented shows a difference of 15 ± 5% more SPCA1 protein 
detected in total cell lysates from HG cells compared to those isolated from NG cells. 
Furthermore, SERCA and α-actin protein levels were found to be 9 ± 4% and 2 ± 4%, 
respectively, higher in samples from HG cells than those of NG cells. However, 
Student’s T-test analysis determined the difference observed for SPCA1 protein levels  
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Figure 3.2.2.1. Western Blot Analysis of SPCA1, SERCA & α-Actin Protein 
Expression Levels in A7r5 Cells Cultured in Normal & High Glucose Media 
 
SPCA1 SERCA α-ACTIN 
HG        NG HG        NG  HG        NG 
B 
* 
α 
A 
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Figure 3.2.2.1. Western Blot Analysis of SPCA1, SERCA & α-Actin 
Protein Expression Levels in A7r5 Cells Cultured in Normal & High 
Glucose Media 
 
(A) Two Western blots were done for each primary antibody and total cell 
lysate sample. Three pairs of NG and HG cell cultures were used for sample 
collection. Chemiluminescent protein band intensities from images of HRP 
substrate-treated blots were measured for each sample, corrected for 
background, and values from HG cells were made relative to those for their 
pair-matched NG cells. Mean values from replicate Western blots were 
calculated for each protein of interest and glucose culture condition, and 
converted to the percentage difference values shown. Error bars indicate 
S.E.M. A significant P-value calculated from two-tailed equal variance 
Student’s T-test is indicated by * (P<0.05). 
 
(B) Chemiluminescent protein bands from HRP substrate-treated Western 
blots, which show typical band intensities observed for each of the three 
proteins of interest from NG and HG total cell lysate samples. Their 
molecular mass were approximately 100kDa for both SPCA1 and SERCA, 
and 42kDa for α-actin. 
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between HG and NG cells to be significant (P<0.05), whereas those for SERCA and 
α-actin were not significant. The lack of difference in α-actin protein levels between 
NG and HG samples indicated there was no significant difference in their amounts of 
total protein that were blotted onto the analysed membranes.  
 
3.2.3. Measurements of Ca2+-Dependent ATPase Activity from Microsomal 
Membranes of A7r5 Cells Cultured in Normal & High Glucose Media 
Microsomal membranes were prepared from three cultures of A7r5 cells for each of 
the two glucose culture conditions tested. Triplicate Ca2+-dependent ATPase activity 
measurements were made for each preparation of microsomal membranes, either in 
the absence or presence of 1µM thapsigargin in reaction mixtures. All activities were 
corrected for any effects from the physical presence of membranes and reagents on 
the phosphate liberation assay used, by subtracting values from the two following 
types of control reactions: those with (1) active membranes in the absence of Ca2+, 
and (2) the presence of denatured membranes.  
In all experiments, 2mM azide was used to inhibit Ca2+-independent ATPase 
activity and Ca2+ uptake processes from any contaminating mitochondria that may 
have been present in the microsomal membrane preparations. 2µM vanadate was also 
used in all reaction mixtures to inhibit any PMCA activity that may have been present 
in the samples. Thus the Ca2+-dependent ATPase activities that were measured were 
either from a combination of SERCA and SPCA (in the absence of thapsigargin), or 
from SPCA alone (in the presence of thapsigargin). Note that the assay used did not 
discriminate between the splice variants and isoforms of both SPCA and SERCA. 
1µM thapsigargin was selected for use based on data from literature of a previous 
study, which has shown this concentration of thapsigargin inhibits all SERCA activity 
without affecting SPCA1 activity at all (Dode et al., 2006). Although 1µM 
thapsigargin can reduce SPCA2 activity by 40% as demonstrated in the same study, it 
was not considered to be problematic for the purpose of the present study because 
SPCA2 expression in aortic and other vascular cells has been shown to be non-
detectable (Vanoevelen et al., 2005). 
From the data presented in table 3.2.3.1 of all mean Ca2+-dependent ATPase 
activities calculated from measurements of phosphate liberation from Ca2+- and ATP- 
stimulated A7r5 microsomal membranes, the overall mean activities for all three  
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Mean Ca2+-Dependent ATPase Activity  
(nmol/min/mg protein) ± S.E.M 
 
 
No Thapsigargin 
 
 
1µM Thapsigargin 
 
Membrane 
Preparation 
 NG HG 
 
NG HG 
1 3.2 ± 0.5 
 
3.1 ± 0.7 0.62 ± 0.09 1.05 ± 0.17 
2 4.1 ± 1.6 
 
2.7 ± 0.4 0.38 ± 0.07 2.89 ± 1.21 
3 4.4 ± 0.5 
 
3.7 ± 0.2 1.26 ± 1.17 1.63 ± 0.48 
 
Table 3.2.3.1. Mean Ca2+-dependent ATPase Activities Associated with Three 
Preparations of Microsomal Membranes from Normal & High Glucose-Cultured 
A7r5 Cells in the Absence & Presence of Thapsigargin 
 
Three activity measurements were made for each membrane preparation and glucose 
culture condition, from which mean values were calculated and are presented with 
S.E.M values. 
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preparations of membranes from NG and HG cells were 3.9 ± 0.5 and 3.2 ± 0.4 
nmol/min/mg protein, respectively, in the absence of thapsigargin. Equivalent mean 
activities in the presence of 1µM thapsigargin for NG and HG cells were 0.75 ± 0.27 
and 1.86 ± 0.55 nmol/min/mg protein, respectively. Statistical testing using analysis 
of variance (ANOVA) showed differences between the three mean activities for each 
of NG and HG cells-derived microsomal membranes were not statistically significant 
from reactions done in the absence of thapsigargin. On the other hand, differences 
between equivalent mean activities from reactions done in the presence of 
thapsigargin were found to be significant (P<0.05), with higher thapsigargin-
insensitive activity from HG, compared to NG, membranes. This latter observation 
was consistent with an higher SPCA activity in HG, compared to NG, membranes. 
 
3.2.4. Fluo-3-Based Ca2+ Measurements in Single Cells from A7r5 Normal & 
High Glucose Cultures    
NG and HG cells loaded with Fluo-3 Ca2+-sensitive fluorescent dye were viewed 
using fluorescence microscopy and video recordings of their Ca2+-mediated responses 
to AVP in the absence and presence of thapsigargin were analysed. Changes in 
fluorescence were measured from 10 cells for each experiment and four experiments 
were done for each AVP treatment (i.e. in the absence and presence of thapsigargin) 
and glucose culture condition. Four averaged plots (one for each experiment) of 
relative changes in fluorescence over time, for each agonist treatment and glucose 
culture condition, are presented in figures 3.2.4.1-3.2.4.3. 
Analysis of Ca2+ transients produced by thapsigargin in NG and HG cells 
shown in figure 3.2.4.1 indicate there was no major difference observed between the 
cells from the two glucose culture conditions tested, since the general average 
response profile from all experiments is near the same and mean peak heights of 
change in F/F0 were 0.41 ± 0.06 for NG cells and 0.40 ± 0.05 for HG cells. Student’s 
t-test of these values confirm no statistical significance in the difference observed for 
these values between NG and HG cells from the four experiments for each glucose 
culture condition (P>0.05). The same lack of difference was also observed from NG 
and HG cells that were treated with AVP in the absence the thapsigargin, as shown in 
figure 3.2.4.2. Again, the response profiles for all experiments in the latter case were, 
on average, the same as each other and resembled typical profiles observed previously 
(Byron and Taylor, 1995). Furthermore, the mean peak heights of change in F/F0 were  
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Figure 3.2.4.1. Thapsigarigin-Stimulated Ca2+ Transients in A7r5 Cells 
Cultured in Normal & High Glucose Media 
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Figure 3.2.4.1. Thapsigarigin-Stimulated Ca2+ Transients in A7r5 Cells 
Cultured in Normal & High Glucose Media 
 
Changes in [Ca2+] within A7r5 cells grown in either normal (“NG”) or high 
(“HG”) glucose-supplemented media were detected by monitoring Fluo-3 
fluorescence levels in dye-loaded cells. Each trace represents mean values 
calculated from 10 cells. Arrows indicate the time-point at which 1µM 
thapsigargin was added.   
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Figure 3.2.4.2. AVP-Stimulated Ca2+ Transients in A7r5 Cells Cultured in 
Normal & High Glucose Media (No Thapsigargin Pre-Treatment) 
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Figure 3.2.4.2. AVP-Stimulated Ca2+ Transients in A7r5 Cells 
Cultured in Normal & High Glucose Media (No Thapsigargin Pre-
Treatment) 
 
Changes in [Ca2+] within A7r5 cells grown in either normal (“NG”) or high 
(“HG”) glucose-supplemented media were detected by monitoring Fluo-3 
fluorescence levels in dye-loaded cells. Each trace represents mean values 
calculated from 10 cells. Arrows indicate the time-point at which 10nM 
AVP was added.  
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Figure 3.2.4.3. AVP-Stimulated Ca2+ Transients in A7r5 Cells Cultured 
in Normal & High Glucose Media (Pre-Treatment with Thapsigargin) 
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Figure 3.2.4.3. AVP-Stimulated Ca2+ Transients in A7r5 Cells 
Cultured in Normal & High Glucose Media (Pre-Treatment with 
Thapsigargin) 
 
Changes in [Ca2+] within A7r5 cells grown in either normal (“NG”) or high 
(“HG”) glucose-supplemented media were detected by monitoring Fluo-3 
fluorescence levels in dye-loaded cells. Each trace represents mean values 
calculated from 10 cells. Arrows indicate the time-point at which 10nM 
AVP was added. Cells were pre-treated with 1µM thapsigargin for 5 
minutes before the addition of AVP. The thapsigargin response was 
recorded to ensure this pre-treatment was effective on the cells (but profiles 
for which are not presented here).  
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1.14 ± 0.13 for NG cells and 0.98 ± 0.20 for HG cells, which were found to not be 
statistically significant in their difference to each other according to Student’s T-test 
analysis (P>0.05). 
On the other hand, figure 3.2.4.3 does show a difference in mean Ca2+-
mediated responses to AVP after pre-treatment with thapsigargin between NG and 
HG cells, whereby their associated response profiles indicate both faster rise and fall 
phases of change in intracellular [Ca2+] were recorded following AVP stimulation in  
HG cells compared to NG cells. This difference was further analysed by measuring 
the kinetics of both phases from the response profiles shown in figure 3.2.4.3. Both 
the time taken to reach half-maximal response and half-life of decay in response to 
AVP were measured from each of the four mean response profiles and the mean 
values of these were calculated for each glucose culture condition, which are shown 
in table 3.2.4.4 with their S.E.M values. Student’s T-test analysis showed the 
difference between NG and HG cells for both kinetics measurements were statistically 
significant (P<0.05).  
The mean peak heights of change in F/F0 for these Ca2+-mediated AVP 
responses were not found to be statistically significant (P>0.05), whereby values of 
0.32 ± 0.06 and 0.39 ± 0.04 were obtained for NG and HG cells, respectively. 
However, by making the mean peak heights of change in F/F0 from thapsigargin pre-
treated cells relative to those from cells that were stimulated with AVP in the absence 
of thapsigargin, it can be shown that, on average, 28% and 40% of Ca2+-mediated 
response to this agonist is insensitive to thapsigargin treatment in NG and HG cells, 
respectively. These differences between the two AVP treatments were found to be 
statistically significant from Student’s T-test calculation for both NG (P<0.05) and 
HG (P<0.01) cells.     
Two types of control experiments were done to further investigate where the 
AVP-stimulated Ca2+ release originated from following thapsigargin treatment. Only 
HG cells were used for these. All control experiments lasted 10 minutes each and, like 
the experiments discussed above, involved thapsigargin treatment 1 minute after 
initiating their recording. One experiment involved treating the cells again with 1µM 
thapsigargin four minutes after the first treatment, instead of AVP, in the absence of 
extracellular Ca2+. This showed whether or not thapsigargin-sensitive Ca2+ release 
was still possible after one treatment of A7r5 cells with 1µM of this SERCA inhibitor.  
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Kinetics Measurements from Ca2+ Transient Profiles of AVP 
Responses in Thapsigargin Pre-treated A7r5 Cells  
 
  
NG 
 
 
HG 
 
Time taken to reach half-
maximal response (s) 
 
 
48.3 ± 5.1 
 
18.2 ± 3.2 
 
 
Half-life of decay in 
response (s) 
 
 
76.9 ± 7.4 
 
39.7 ± 5.7 
 
 
Table 3.2.4.4. Kinetics Measurements from Mean Ca2+ Transient Plots of AVP 
Stimulation in Thapsigargin Pre-Treated A7r5 Cells Cultured in Normal & High 
Glucose Media 
 
Measurements were taken from the rise and fall phases of Ca2+-mediated AVP 
response shown in the four traces of each graph at figure 3.2.4.3. Mean values were 
calculated for each of the two glucose culture conditions and are presented ± S.E.M.   
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The result of these experiments showed no further Ca2+ release (data not shown). The 
other experiment was the same as the 10-minute experiments discussed above (i.e. 
thapsigargin treatment at 1 minute and AVP treatment at 5 minutes after initiation) 
except that they were also done in the absence of extracellular Ca2+. These latter 
control experiments showed that it was indeed possible to produce AVP-stimulated 
Ca2+ release following a visible Ca2+ response to thapsigargin treatment even in the 
absence of extracellular Ca2+ (see chapter 4 for figure 4.2.6.1).   
 
3.2.5. Immunofluorescence Detection of SPCA1, SERCA & Golgi Apparatus 
Localisation in A7r5 Cells Cultured in Normal & High Glucose Media  
 
Figure 3.2.5.1 shows images taken of A7r5 cells that were fixed, permeabilised and 
treated with either antibodies or WGA for the detection of SPCA1, SERCA and the 
Golgi apparatus. WGA is a lectin that binds to glycoproteins highly abundant at the 
Golgi apparatus (Wright, 1984) and, more specifically, has been found to localise its 
binding at trans-Golgi membranes (Iida and Page, 1989). Analysis of images treated 
with antibodies against SPCA1 showed no detectable difference between NG and HG 
cells with regards to SPCA1 localisation. The same conclusion was made for the 
detection of SERCA in cells from the same two glucose culture conditions.  
Comparison of SPCA1 localisation to that for the Golgi apparatus shows 
SPCA1 is most likely to be located at this organelle because they shared very similar 
perinuclear distribution patterns of fluorescence. This was in contrast to SERCA’s 
more diffuse pattern of staining, which was observed in both NG and HG cells.    
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A) SPCA1 (NG) B) SPCA1 (HG) 
C) WGA (NG) D) SERCA (NG) 
Figure 3.2.5.1. Localisation of SPCA1, SERCA & the Golgi Apparatus 
Within A7r5 Cells Cultured in Normal & High Glucose Media Using 
Fluorescently-Tagged Antibodies & Wheat Germ Agglutinin 
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Figure 3.2.5.1. Localisation of SPCA1, SERCA and the Golgi Apparatus 
Within A7r5 Cells Cultured in Normal & High Glucose Media Using 
Fluorescently-Tagged Antibodies & Wheat Germ Agglutinin 
 
A7r5 cells cultured in normal (“NG”) and high (“HG”) glucose media were 
fixed with formaldehyde, permeabilised with Triton X100 and incubated with 
either antibodies specific for the detection of SPCA1 or SERCA, or WGA. The 
latter binds and therefore labelled glycoproteins abundant in the Golgi 
apparatus. Fluorescence was detected from either FITC-conjugated secondary 
antibodies or the TMR conjugated to WGA. Both SPCA1 detection in (A) NG 
and (B) HG cells are shown. (C) Golgi apparatus and (D) SERCA detection 
has been shown for NG cells, which showed the same distribution of 
fluorescence as observed for HG cells (latter not shown).     
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3.3. Discussion 
 
PCR and Western blotting experiments have shown SPCA1 abundance at the mRNA 
and protein levels, respectively, were significantly higher than normal in A7r5 cells 
cultured in high glucose (HG), compared to normal glucose (NG), media. Lack of 
alteration in β-actin and GAPDH mRNA levels indicate both phenotype and activities 
of glucose metabolic pathways did not differ greatly between NG and HG cells. Thus, 
the difference in SPCA1 expression levels observed between A7r5 cells cultured 
under the two glucose conditions tested were unlikely to have been due to differences 
caused by a phenotypic switch nor altered ATP utilisation of the SPCA1 Ca2+-
ATPase. Furthermore, positive detection of α-actin, a VSMC marker, in all samples 
from NG and HG cells confirm they were both representative of VSMCs. Overall, this 
suggests glucose availability itself can affect the expression levels of SPCA1 in 
VSMCs. 
 
It was notable that an approximate 60% difference in SPCA1 mRNA levels only 
reflected a difference of about 15% at the protein level. A similar discrepancy has 
been observed in a previous study that showed SPCA expression levels differ between 
brain and mammary tissues of rats, whereby the latter was found to express 7-8 times 
more of its mRNA but only 2-3 times more of its protein compared to the former 
(Reinhardt et al., 2000). The authors of this study attributed the difference in protein 
turnover rates (i.e. SPCA1 protein turnover was faster in mammary tissue compared 
to that of brain), which could also explain the discrepancy between SPCA1 mRNA 
and protein levels in the present study.  
 
Another possible explanation for the difference observed between SPCA1 mRNA and 
protein levels refers to transcriptional control of the gene that encodes SPCA1, 
whereby its transcription factors may have had more enhanced activity for the 
promotion of this gene’s expression in HG cells. This should be considered since it 
has been previously shown that both Sp1 (Han and Kudlow, 1997) and YY1 
(Hiromura et al., 2003), the transcription factors of the SPCA1 gene in humans 
(Kawada et al., 2005), are more active in VSMCs grown in high glucose, compared to 
normal glucose, media. A7r5 cells can express the Sp1 transcription factor (Teunissen 
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et al., 2003). The observations made of Sp1 and YY1 were, in both cases, attributed to 
their glycosylation states. It is well established that the hyperglycaemic state can 
promote hyper-glycosylation of proteins in vascular cells (Aronson, 2008). Thus it is 
possible that differences in SPCA1 mRNA levels would not have been directly 
proportional to its proteins levels between NG and HG cells because of over-active 
promoter activity of its gene transcription factors, caused by changes to their 
glycosylation states, if combined with a near-maximal rate of either mRNA 
translation or protein turnover.  
 
Differences in SPCA1 expression levels correlated well with levels in thapsigargin-
insensitive Ca2+-dependent ATPase activity measured from microsomal membranes. 
HG cells showed approximately 2-fold higher activity levels than NG cells. However, 
like SPCA1 mRNA levels, this relationship between protein expression and activity 
appeared to be disproportionate. One possible explanation for this discrepancy is that 
NG and HG cells expressed different amounts of different SPCA1 splice variants, 
which have been shown to exist in rats (Gunteski-Hamblin et al., 1992) and, for 
human splice variants, do differ in their kinetic properties (Dode et al., 2005). Here it 
should be emphasised that the anti-SPCA1 antibody used in Western blotting 
experiments recognised all rat SPCA1 splice variants (Wootton et al., 2004) and any 
differences in the amount of each available splice variant present in NG and HG cells 
was not identifiable in the present study. Thus the disproportional difference observed 
between SPCA protein expression and activity could have been attributed to HG cells 
expressing more of those variants with greater Ca2+-ATPase activity than NG cells.       
 
Lack of significant difference between NG and HG cells with regards to their total 
Ca2+-dependent ATPase activities, despite a difference observed for thapsigargin-
insensitive activities, suggested SERCA activity might have compensated for the 
difference in SPCA activity. This was a possibility since it has been shown previously 
that alterations to SPCA1 levels can influence that of SERCA in the opposite manner, 
which is exemplified by SPCA over-expression in COS-7 cells (Reinhardt et al., 
2004). An apparent conflict of this possibility with the lack of significant difference 
between NG and HG cells with regards to their SERCA protein levels. However, this 
could be explained by factors such as differences in lipid composition of ER and/or 
Golgi apparatus membranes between NG and HG cells. It is well established that the 
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lipid components of ER membranes can affect SERCA function (Lee, 1998) and that 
the composition of lipids in the Golgi apparatus membranes are distinctly different 
from those of ER  (Lev, 2005). It may be possible that glucose availability can affect 
lipid synthesis activity at the ER and/or Golgi apparatus, which would lead to changes 
in the structural integrity of their membranes that could, in turn, influence SERCA 
and SPCA activity without the need to change their protein abundance. 
 
The kinetics of Ca2+-mediated responses to AVP stimulation in A7r5 cells cultured 
under the two glucose conditions tested demonstrate a clear difference between NG 
and HG cells after thapsigargin pre-treatment. The faster rise and decay phases of 
AVP-stimulated Ca2+ transients in HG, compared to NG, cells was consistent with 
higher than normal SPCA expression and activity levels. For the rise phase, a faster 
than normal increase in intracellular [Ca2+] could be attributed to larger thapsigargin-
insensitive agonist-releasable stores after depletion of ER stores, following SERCA 
inhibition, which is most likely to have resided at the Golgi apparatus (Missiaen et al., 
2002, Baron et al., 2009, Lissandron et al., 2010). Note that AVP-stimulated Ca2+ 
transients are initiated by intracellular Ca2+ release and this is a pre-requisite of Ca2+ 
entry from extracellular medium that follows to form the rise phase (Byron and 
Taylor, 1995). Thus faster than normal time taken to reach half-maximal response in 
HG, compared to NG, cells could have resulted from there being more thapsigargin-
insensitive SPCA activity in HG cells and subsequently greater compensatory effect 
following the loss of SERCA-controlled agonist-releasable Ca2+ stores. Higher than 
normal SPCA activity at the Golgi apparatus Ca2+ stores in HG cells would have 
aided the recovery of resting Ca2+ levels after thapsigargin treatment better than NG 
cells. This is because HG cells would have been made more efficient at removing and 
storing the Ca2+ released from the ER by having more active Ca2+-ATPase activity 
available, which would explain the faster than normal decay phase of AVP-stimulated 
Ca2+ transients in HG cells.  
 
The physiological consequence of having the types of Ca2+ responses observed for 
AVP stimulation in A7r5 cells cultured in normal and high glucose media is evident 
when considering the role of Ca2+ in VSMC contraction. VSMCs in blood vessel 
walls contract and relax to alter their diameter in order to adjust to changes in blood 
flow. The more sustained a rise in intracellular [Ca2+] maintained in VSMCs, the 
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more prolonged their contractile response will be. Thus by having faster than normal 
rates of rise and fall in intracellular [Ca2+] following vasoactive hormone stimulation, 
like those observed in HG cells, the contraction of VSMCs is likely to be maintained 
for shorter periods of time and so thus would be less contractile. This would 
correspond well with the secretory phenotype of VSMCs in cardiovascular diseases, 
such as those induced by type II diabetes mellitus. Furthermore, enhanced SPCA1 
activity could also increase the population of cells in the secretory phenotype in 
vascular smooth muscle tissue, by promoting abnormal levels of synthesis and/or 
post-translational modification of secretory proteins due to its role in controlling the 
luminal Ca2+ store of the Golgi apparatus.      
 
With regards to lack of significant difference in Ca2+ responses produced as a result of 
AVP treatment to NG and HG cells that had not been pre-treated with thapsigargin, 
this result was consistent with there also being no difference between their total 
microsomal membrane Ca2+-dependent ATPase activities. This again leads to the 
suggestion that SERCA activity compensated for alterations of SPCA1 activity to 
make total intracellular Ca2+-ATPase activity the same between NG and HG cells, and 
thus initiated AVP-stimulated Ca2+ responses with the same degree of intensity. The 
lack of significant difference in thapsigargin-stimulated Ca2+ transients does not 
necessarily disprove of this possibility, since it only demonstrates the Ca2+ storage 
capacity of the ER, not SERCA activity in hormone-mediated signalling, is the same 
between resting NG and HG cells.  
 
The visualisation of SPCA1 localisation in NG and HG cells, along with that of the 
Golgi apparatus (using WGA) and SERCA, demonstrate alternations in SPCA1 
expression and activity did not affect its localisation in A7r5 cells, cultured under the 
two glucose conditions tested, to a visually significant extent. This would agree well 
with the low amount of change in SPCA1 protein abundance detected. Furthermore, it 
was confirmed that SPCA1 localises to the Golgi apparatus in A7r5 cells and its 
intracellular distribution patterns differ to that of SERCA, which emphasised the point 
that these two Ca2+-ATPases play roles at different organelles.  
 
Finally, two additional points should be noted from the data presented here. Firstly, it 
is widely known that some observations made with cell lines, like A7r5 cells, may not 
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necessarily occur in intact tissue, and so the experiments in the present study need to 
be repeated in the context of primary VSMCs and animal models to establish the role 
of SPCA in diabetes-associated cardiovascular diseases with greater certainty. With 
regards to the A7r5 cell-line specifically, this study has demonstrated these cells 
contain significantly detectable agonist-releasable Ca2+ stores that are not controlled 
by SERCA. Such stores in A7r5 cells had been disputed to exist due to conflicting 
observations from previous studies (Missiaen et al., 2002, Vanoevelen et al., 2004). 
However, the data presented here has confirmed their existence. 
 
To summarise, the present study has shown that A7r5 cells cultured in high, compared 
to normal, glucose media demonstrate: (1) higher SPCA1 expression, both at the 
mRNA and protein level; (2) higher thapsigargin-insensitive Ca2+-dependent ATPase 
activity at microsomal membranes; and (3) faster rates of rise and fall phases of AVP-
stimulated Ca2+ responses in intact cells following thapsigargin treatment. Together, 
these findings suggest glucose availability to VSMCs can mediate control on SPCA1 
expression and activity, which can influence the Ca2+-handling ability of the Golgi 
apparatus of these cells. The hyperglycaemic condition is likely to promote increased 
SPCA1 expression and activity in VSMCs, which could lead to increased Ca2+-
handling activity in the Golgi apparatus and decreased responsiveness to vasoactive 
hormones, at least by this organelle. SPCA may play a role in diabetes-related 
vascular pathology in VSMCs due to its responsiveness to glucose availability in 
these cells, as demonstrated with the A7r5 cell-line, which has been shown to cause 
alterations in Ca2+ homeostatic mechanisms that could potentially lead to the features 
of reduced contractility and increased secretory behaviour of these cells.  
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CHAPTER 4. 
FINDING INHIBITORS & MODULATORS OF HUMAN SPCA  
 
4.1. Introduction 
 
SPCA is a Ca2+-ATPase that is localised at the Golgi apparatus and provides this 
organelle with Ca2+ for its secretory pathway-related functions, such as the post-
translational modification of proteins (Ramos-Castaneda et al., 2005) and promoting 
the formation of Ca2+-containing secretory vesicles (Reinhardt and Horst, 1999). 
Previous studies have also shown SPCA activity can contribute to agonist-stimulated 
Ca2+-signalling in, for example, rat pancreatic β-cells (Mitchell et al., 2004) and 
human neutrophils (Baron et al., 2009). This Ca2+-ATPase exists in the form of 
different splice variants (e.g. SPCA1a-d in humans) and isoforms (SPCA1-2 in 
humans), which have different kinetic properties (Dode et al., 2005, Dode et al., 2006) 
and tissue distribution (Vanoevelen et al., 2005, Xiang et al., 2005). 
 
SPCA was first identified as PMR1, a plasma membrane related Ca2+-ATPase 
expressed in yeast and suggested to play a role in the secretory pathway due to its 
ability to affect glycosylation of proteins in transit through the Golgi apparatus 
(Rudolph et al., 1989). Since then, its expression has been detected in a number of 
other organisms, including Drosophila (Southall et al., 2006), sea urchin (Gunaratne 
and Vacquier, 2006) and pigs (Sepulveda et al., 2007). SPCA1 is regarded as a house-
keeping protein because it has been found to be widely expressed in various types of 
human-derived tissues (Vanoevelen et al., 2005). Its expression in humans has most 
notably been linked to the skin condition, Hailey-Hailey disease (HHD) (Hu et al., 
2000, Sudbrak et al., 2000). The transcription factors that control its gene expression 
in humans have been identified as Sp1 and YY1 (Kawada et al., 2005).  
 
Previous studies on SPCA activity have relied on the use of inhibitors for its related 
Ca2+-ATPases, such as SERCA with thapsigargin (Vanoevelen et al., 2004), to allow 
differentiation between their very similar activities in cells. Another method that has 
been used is artificial manipulation of its expression, either by increasing (Missiaen et 
al., 2002) or decreasing (Van Baelen et al., 2003) its levels. SPCA1 knockout mice 
have also been produced (Okunade et al., 2007). However, there are notable problems 
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with the use of some of these techniques. For example, over-expression of SPCA has 
been shown to result in some of its localisation at the ER, as well as altered 
expression levels of other Ca2+-binding proteins that include PMCA and CALNUC 
(Reinhardt et al., 2004). The use of thapsigargin has resulted in conflicting results 
with regards to the effect of agonist-stimulation on Ca2+ release from the Golgi 
apparatus, which has recently been attributed to differences in the concentration used 
of this inhibitor (Baron et al., 2009). Use of inhibitors for other Ca2+-binding proteins 
instead of those for SPCA is likely to reflect more on the effect of loss in activity of 
the former, rather than enhanced visibility of the latter’s, especially in studies 
involving intact cells. Unfortunately, a well-characterised specific SPCA inhibitor has 
yet to be found.  
 
The aim of the present study was to test the effects of seven possible SPCA1 
modulators, which were in the form of either synthetic compounds or naturally 
occurring molecules (figure 4.1.1). The experimental model chosen for use was 
microsomal membranes from COS-7 cells that over-expressed hSPCA1d (the longest 
splice variant of SPCA1 from humans (Fairclough et al., 2003)). Comparisons were 
made with microsomal membranes prepared from COS-7 cells that over-expressed 
the ubiquitous hSERCA2b (the most commonly found and longest slice variant of 
SERCA in humans (Dhitavat et al., 2003)). Any of these compounds that were able to 
inhibit hSPCA1d but not hSERCA2b activity, over a similar concentration range, may 
be considered as potentially valuable tools in future studies on SPCA. A7r5 cells, 
which express both SPCA and SERCA endogenously, were also used to observe the 
effects of these potential modulators. 
 
Five synthetic compounds were tested, which were bis(2-hydroxy-3-tert-butyl-5-
methyl-phenyl)methane (bis-phenol), tetrabromobisphenol-A (TBBPA), 
trifluoroperazine (TFP), 2-aminoethoxydiphenyl-borate (2-APB) and bisphenol-A 
(BPA). Bis-phenol has been suggested in the literature to be able to inhibit SPCA 
activity because of its ability to inhibit thapsigargin-insensitive Ca2+-ATPase activity 
in rat cerebellar microsomes (Brown et al., 1994) and inhibit Ca2+-ATPase activity in 
human spermatozoa that do not express SERCA (Harper et al., 2005). A specific 
concentration of bis-phenol that can be used to differentiate between the two Ca2+-
ATPases (i.e. inhibit SPCA but not SERCA) has yet to be firmly established. The 
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other four synthetic compounds have all been previously shown to inhibit SERCA 
activity (TBBPA (Ogunbayo and Michelangeli, 2007), TFP (Engelender and DeMeis, 
1996), 2-APB (Bilmen et al., 2002) and BPA (Hughes et al., 2000). It was of interest 
to see whether or not SERCA’s sensitivity to these four compounds differs to that of 
SPCA in order to infer any structural differences between the two Ca2+-ATPases, as 
well as finding an inhibitor that could block SPCA activity better than SERCA. 
Nicotinic acid adenine diphosphate (NAADP) and cyclic adenine diphosphate ribose 
(cADPR) are both naturally occurring molecules that are believed to be able to release 
intracellular Ca2+ stores by acting as potential second messengers (Lee and Aarhus, 
1995, Dargie et al., 1990). Ca2+ release is believed to occur at the ER and acidic 
lysosomal stores by cADPR and NAADP, respectively (Galione and Churchill, 2002, 
Gerasimenko et al., 2006). However, these findings are relatively novel, yet to be 
fully ascertained in both cases and thus there is still some scope in possibility for 
other Ca2+ stores to be affected by these two second messengers. Thus they were also 
tested on hSPCA1d activity to see if they influence Ca2+ storage at the Golgi 
apparatus by acting on this Ca2+-ATPase.              
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Bis(2-hydroxy-3-tert-butyl-
5-methyl-phenyl)methane 
(Bis-phenol) 
Tetrabromobisphenol-A 
(TBBPA) 
Trifluoroperazine 
(TFP) 
2-aminoethoxydiphenyl-borate 
(2-APB) 
Bisphenol-A  
(BPA) 
Nicotinic Acid Adenine Diphosphate 
(NAADP) 
Cyclic Adenine Diphosphate 
(cADPR) 
Figure 4.1.1. The Seven Potential SPCA Inhibitors & Modulators 
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4.2. Results 
 
4.2.1. Optimisation of hSPCA1d, hSERCA2b & Rabbit SERCA1b-EGFP Over-
Expression in COS-7 Cells 
Figure 4.2.1.1 shows successful digests for hSPCA1d-pMT2, hSERCA2b-pMT2 and 
rabbit SERCA1b-EGFP-pcDNA3.1(-) expression plasmids. Uncut plasmid DNA 
counterparts for hSPCA1d-pMT2 and rabbit SERCA1b-EGFP-pcDNA3.1(-) are also 
shown. The ‘streaky’ staining of undigested plasmid DNA, which had also been 
observed for hSERCA2b-pMT2 uncut plasmid, was due to supercoiling of circular 
DNA interfering with its movement through agarose gels and is a normal observation. 
For hSERCA2b-pMT2, only three of the six possible DNA bands produced from a 
HindIII restriction digest were visible on a 0.8% w/v agarose gel as the other three 
DNA fragments were less than 0.5kb and thus too small to be visible.  
COS-7 cells were chosen for this study because they are easy to culture and 
transfect. Furthermore, this is the same cell line that was used in a previous study on 
the effects of over-expressing rat SPCA on Ca2+ homeostasis (Reinhardt et al., 2004). 
Rabbit SERCA1b-EGFP-pcDNA3.1(-) transfection was done to allow visualisation of 
transfection efficiency in intact COS-7 cells with the Genejuice reagent, which was 
assumed would be similar for the hSPCA1d/hSERCA2b-pMT2 plasmids. Figure 
4.2.1.3A shows a Western blot of microsomal membranes prepared from COS-7 cells 
that were either transfected with rabbit SERCA1b-EGFP-pcDNA3.1(-) plasmid DNA 
or not transfected. Transfection was done using a 18µg:54µl ratio of plasmid DNA-to-
transfection reagent in 10cm diameter Petri dishes, which were filled with 10ml of 
media, as a starting point for optimisation. Microsomal membranes were prepared 48 
hours after transfection. Observation of 127kDa protein bands from microsomal 
membrane samples indicated the presence of SERCA-EGFP protein, whereby the 
molecular weights of SERCA and EGFP as separate proteins are approximately 
100kDa (Wootton et al., 2004) and 27kDa (Muller-Taubenberger and Anderson, 
2007), respectively. 127kDa bands were only detected in samples obtained from 
rabbit SERCA1b-EGFP-pcDNA3.1(-)-transfected COS-7 cells. Other protein bands 
on the Western blots that were not 127kDa in size were considered a result of non-
specific binding of antibodies, except for 100kDa bands which were assumed to be 
representing endogenous SERCA expression in COS-7 cells.  
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Figure 4.2.1.1. Restriction Digests for hSPCA1d-pMT2, hSERCA2b-pMT2 
& Rabbit SERCA1b-EGFP-pcDNA3.1(-) Plasmids 
 
Minipreps of hSPCA1d-pMT2 (“hSPCA1d”), hSERCA2b-pMT2 
(“hSERCA2b”) and rabbit SERCA1b-EGFP-pcDNA3.1(-) (“Rabbit SERCA1b-
EGFP”) plasmid DNA were digested with restriction endonucleases indicated on 
their associated restriction maps at figure 4.2.1.2. Restriction digest fragments 
(“digested”) were electrophoresed alongside undigested DNA (“undigested”). 
The position of expected DNA band sizes are indicated at each gel image. All 
samples were loaded at equal volumes in each lane. 
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Figure 4.2.1.2. Restriction Maps for hSPCA1d-pMT2, hSERCA2b-pMT2 
& Rabbit SERCA1b-EGFP-pcDNA3.1(-) Plasmids 
 
The restriction maps associated with figure 4.2.1.1. 
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Figure 4.2.1.3. Western Blots & GFP Fluorescence Microscopy Images 
for Detection of SERCA-EGFP Over-Expression in COS-7 Cells 
Transfected with Rabbit SERCA1b-EGFP-pcDNA3.1(-) Plasmid 
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Figure 4.2.1.3. Western Blots & GFP Fluorescence Microscopy Images 
for Detection of SERCA-EGFP Over-Expression in COS-7 Cells 
Transfected with Rabbit SERCA1b-EGFP-pcDNA3.1(-) Plasmid 
 
(A) A Western blot showing SERCA-EGFP was detected in microsomal 
membranes prepared from COS-7 cells transfected with rabbit SERCA1b-
EGFP-pcDNA3.1(-) plasmid (“SERCA-EGFP”), along with those isolated 
from non-transfected cells (“non-transfected”), using anti-SERCA (Y1F4). 
20µg of total protein from each sample was loaded into each lane. The 
position of the expected 127kDa protein band of rabbit SERCA1b-EGFP is 
indicated. 
 
COS-7 cells were seeded at a density of 1.2x106 cells per 10cm diameter 
plate and transfected 24 hours later with a 18µg:54µl ratio of plasmid DNA 
(µg)-to-transfection reagent (µl) per plate. Microsomal membranes were 
prepared 48 hours after transfection. 
 
 
(B) Microscopy images taken of COS-7 cells 24 and 48 hours after being 
transfected with rabbit SERCA1b-EGFP-pcDNA3.1(-) plasmid DNA. 
Detection of GFP fluorescence (“EGFP”) confirmed successful expression of 
SERCA1b-EGFP protein. Light microscopy (“Light”) images were used to 
observe for morphology and population of transfected and non-transfected 
cells. Non-transfected cells showed no GFP fluorescence under the same 
culture conditions. 
 
COS-7 cells were seeded at a density of 2x105 cells per well of a 6-well plate 
and transfected 24 hours later with a 3µg:9µl ratio of plasmid DNA-to-
transfection reagent per well. Transfected cells were viewed with a 
fluorescence microscope 24 and 48 hours after transfection. 
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Figure 4.2.1.4. Western Blots of Microsomal Membranes 
Prepared From COS-7 Cells Transfected with hSPCA1d-pMT2 
& hSERCA2b-pMT2 Plasmids 
 
Detection of SPCA1 and SERCA2 protein levels in microsomal 
membranes prepared from “hSPCA1d/hSERCA2b-pMT2” 
transfected cells and “non-transfected” cells.  Each lane was loaded 
with 20µg of total protein for each sample. SPCA1 was detected 
using anti-SPCA1 and SERCA2 was detected using anti-SERCA2.  
 
Cells were seeded at a density of 1.2x106 cells per 10cm diameter 
plate and transfected with a 18µg:54µl ratio of plasmid DNA-to-
transfection reagent ratio 24 hours later. Microsomal membranes 
were prepared 48 hours after transfection.   
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Figure 4.2.1.3B shows the use of EGFP fluorescence to detect SERCA1b-
EGFP-pcDNA3.1(-) transfection efficiency in intact COS-7 cells. Non-transfected 
cells were shown to not emit GFP fluorescence. GFP fluorescence was successfully 
detected from SERCA1b-EGFP-pcDNA3.1(-) 
transfected COS-7 cells and thus rabbit SERCA1b over-expression was confirmed to 
be possible in these cells using the transfection ratio of DNA-to-reagent tested.  
The amount of fluorescence observed from the transfected cells varied 
depending on the length of time between transfection and viewing at the microscope. 
20-30% transfection efficiency was observed from cells following 24 hours after 
transfection, whereas 60-80% efficiency was observed from cells following 48 hours 
after transfection. From this, it was decided that all experiments with transfected 
COS-7 cells would be done 48 hours after transfection. Indeed these optimised 
transfection conditions allowed for the production of microsomal membranes with 
detectable amounts of over-expressed SPCA1 and SERCA2 protein, as shown by 
Western blots in figure 4.2.1.4, from COS-7 cells transfected with hSPCA1d-pMT2 
and hSERCA2b-pMT2 plasmids, respectively.     
 
4.2.2. Ca2+-Dependent ATPase Activity Measurements with Microsomal 
Membranes Prepared from Rabbit SERCA1b-EGFP-pcDNA3.1(-)-Transfected 
COS-7 Cells 
The Ca2+-dependent ATPase activity from microsomal membranes of rabbit 
SERCA1b-EGFP over-expressing COS-7 cells was measured to ensure the 
transfection and microsomal membrane preparation methods used together could 
successfully produce microsomal membranes that contained such activity at a 
measurable level that would predominantly originate from the over-expressed Ca2+- 
ATPase. Such measurements were made using the phosphate liberation method. This 
activity was also measured with microsomal membranes from non-transfected cells.  
Mean activities for each membrane preparation and thapsigargin treatment 
condition were calculated from three assays. These mean activities are presented in 
table 4.2.2.1 with their S.E.M values. From this, differences in Ca2+-dependent 
ATPase activities, which were measured in the absence of thapsigargin, observed 
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Microsomal Membrane Ca2+-ATPase Activity ± SEM  
(nmol/min/mg protein) 
 
 
No Thapsigargin 
 
1µM Thapsigargin 
 
 
Transfected 
 
Non-
Transfected 
 
Transfected 
 
Non-
Transfected 
 
 
21.53 ± 1.86 
 
3.4 ± 0.32 
 
2.01 ± 1.05 
 
1.06 ± 0.87 
 
 
 
Table 4.2.2.1. Ca2+-ATPase Activity Measurements from Microsomal 
Membranes of SERCA1b-EGFP-pcDNA3.1(-)-Transfected & Non-Transfected 
COS-7 Cells  
 
Activity measurements were made in either the presence or absence of 1µM 
thapsigargin in reaction mixtures. Each mean activity was calculated from nine assays 
with one microsomal membrane preparation. S.E.M values are shown.   
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between non-transfected and SERCA1b-EGFP-pcDNA3.1(-)-transfected COS-7 cells 
were found to be statistically significant according to Student’s T-test (P<0.01). On 
the other hand, differences observed from activities measured in the presence of 1µM 
thapsigargin (a concentration of thapsigargin that has been shown in inhibit SERCA 
activity as stated in section 3.2.3) were not statistically significant between 
microsomal membranes from non-transfected and rabbit SERCA1b-EGFP-
pcDNA3.1(-)-transfected cells (P>0.05). This indicated that SERCA1b-EGFP over-
expression was successful and the same transfection conditions were subsequently 
used for hSPCA1d/hSERCA2b-pMT2 plasmids. 
 
4.2.3. Ca2+-Dependent ATPase Activity Measurements with Microsomal 
Membranes Prepared from COS-7 Cells Over-Expressing hSPCA1d & 
hSERCA2b 
For both hSPCA1d and hSERCA2b, Ca2+-dependent ATPase activities in the 
presence and absence of 1µM thapsigargin were measured from three preparations of 
microsomal membranes. Such activities from microsomal membranes prepared from 
non-transfected cells were also measured and these values were subtracted from those 
of their counterpart membranes that had the over-expressed human Ca2+-ATPase, so 
that only activity from the latter would be presented. Western blotting was used on 
samples of all membrane preparations to confirm over-expression was successful at 
protein level. The mean activity values, each calculated from six assays, are shown in 
table 4.2.3.1 along with their S.E.M values for both hSPCA1d and hSERCA2b. 
Student’s T-test confirmed no difference between the two conditions of thapsigargin 
treatment for all three hSPCA1d microsomal membrane preparations (P>0.05). This 
indicated no measurable inhibition of Ca2+-dependent ATPase activity from 
microsomal membranes of hSPCA1d-pMT2-transfected cells and such thapsigargin-
insensitive activity was interpreted as that from over-expressed hSPCA1d protein. On 
the other hand, the presence of 1µM thapsigargin in reaction mixtures with 
microsomal membranes from hSERCA2b-over-expressing cells inhibited virtually all 
Ca2+-dependent ATPase activity for all three preparations, which demonstrated that 
such activity originated from thapsigargin-sensitive over-expressed hSERCA2b 
protein. 
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Microsomal Membrane Ca2+-ATPase Activity ± S.E.M. (nmol/min/mg protein) 
 
 
hSPCA1d 
 
hSERCA2b 
 
 
 
 
Membrane 
Preparation 
 
No 
Thapsigargin 
1µM 
Thapsigargin 
No 
Thapsigargin 
1µM 
Thapsigargin 
 
1 
 
26.16 ± 2.95 
 
16.40 ± 2.07 
 
15.55 ± 0.79 
 
1.08 ± 0.50 
 
2 22.03 ± 2.43 25.18 ± 1.94 15.56 ± 1.90 0 
 
3 22.63 ± 1.05 25.17 ± 1.82 12.60 ± 1.56 0.98 ± 0.80 
 
 
Table 4.2.3.1. Ca2+-ATPase Activity Measurements from Three Preparations of 
Microsomal Membranes from hSPCA1d- & hSERCA2b- Over-Expressing COS-
7 Cells 
 
Activity measurements were made in either the presence or absence of 1µM 
thapsigargin in reaction mixtures. Each mean activity was calculated from six assays 
for each microsomal membrane preparation. S.E.M values are shown. 
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Figure 4.2.4.1. Time-Dependence of Mean Ca2+-ATPase Activities From 
hSPCA1d & hSERCA2b in Microsomal Membranes 
 
 
hSPCA1d 
hSERCA2b 
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Figure 4.2.4.1. Time-Dependence of Mean Ca2+-ATPase Activities From 
hSPCA1d & hSERCA2b in Microsomal Membranes 
 
Ca2+-stimulated ATPase activities were measured from microsomal 
membranes after 15, 30, 45, 60 and 75 minutes of ATP addition. Mean 
activities were taken from six replicate assays and one microsomal membrane 
preparation for each time point and error bars indicate S.E.M values. 1µM 
thapsigargin was added to reaction mixtures that contained “hSPCA1d” 
membranes, whereas no thapsigargin was added to those with “hSERCA2b” 
membranes.    
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4.2.4. Optimisation of Assay Time Length for Ca2+-Dependent ATPase Activity 
Measurements of Microsomal Membranes from hSPCA1d- & hSERCA2b-Over-
Expressing COS-7 Cells 
Figure 4.2.4.1 shows the plot obtained from hSPCA1d membranes, which were 
treated with thapsigargin and thus values represent Ca2+-dependent ATPase activity 
specific to this thapsigargin-insensitive protein. Figure 4.2.4.1 also shows the plot 
obtained from hSERCA2b membranes without the presence of thapsigargin in their 
reaction mixtures. Both plots represent mean Ca2+-dependent ATPase activities 
measured from reactions that lasted for different durations of time. These were 
required to determine the optimal length of reaction time to use for the assay in order 
to measure any differences in activity when experimental conditions were altered, 
such as with the presence of potential inhibitors. From this, 45 minutes was selected 
as a suitable length of reaction time because it is within the linear range of values 
obtained for both hSPCA1d and hSERCA2b, which meant 45 minutes was enough 
time to both produce sufficiently measurable amounts of activity and not reach 
plateau due to substrate utilisation or product inhibition. 
 
4.2.5. The Effects of Bis-phenol, TBBPA, TFP, 2-APB, BPA, cADPR & NAADP 
on Ca2+-Dependent ATPase Activities of Microsomal Membranes from 
hSPCA1d- & hSERCA2b- Over-Expressing COS-7 Cells 
Plots of mean thapsigargin-insensitive Ca2+-dependent ATPase activities against 
different concentrations of bis-phenol (figure 4.2.5.1), TBBPA (figure 4.2.5.2), TFP 
(figure 4.2.5.3), 2-APB (figure 4.2.5.4), BPA (figure 4.2.5.5), cADPR (figure 4.2.5.6) 
and NAADP (figure 4.2.5.7) present in the reaction mixtures with hSPCA1d 
membranes are shown. Plots of mean Ca2+-dependant ATPase activities (without 
thapsigargin treatment) against different concentrations of bis-phenol (figure 4.2.5.1), 
TBBPA (figure 4.2.5.2) and TFP (figure 4.2.5.3) measured from the present study are 
also shown for hSERCA2b membranes alongside their hSPCA1d counterparts. The 
data for 2-APB inhibition of hSERCA2b membranes was obtained from a previous 
study (Wootton and Michelangeli, 2006) (figure 4.2.5.4).  
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Figure 4.2.5.1. Effect of Different Bis-phenol Concentrations on Mean 
Ca2+-ATPase Activities From Microsomal Membranes of hSPCA1d- & 
hSERCA2b- Over-Expressing COS-7 Cells 
 
Percentage activity was calculated from making activity measurements in the 
presence of bis-phenol relative to those of vehicle (DMSO) control. DMSO 
content in all assays was 0.1% of their total volume. Mean activities were 
measured from three replicate assays for each bis-phenol concentration 
tested. Error bars indicate S.E.M values. Assay mixtures for “hSPCA1d” 
membranes contained 1µM thapsigargin and those for “hSERCA2b” 
membranes did not contain thapsigargin.  
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Figure 4.2.5.2. Effect of Different TBBPA Concentrations on Mean 
Ca2+-ATPase Activities From Microsomal Membranes of hSPCA1d- 
& hSERCA2b- Over-Expressing COS-7 Cells 
 
Percentage Ca2+-dependent ATPase activities measured from hSPCA1d 
and hSERCA2b membranes in reaction mixtures that contained TBBPA 
at different concentrations. Mean activities were measured from three 
replicate assays for each TBBPA concentration tested and percentage 
activities calculated in the same way as stated for figure 4.2.5.1. Error 
bars indicate S.E.M values. Assay mixtures for hSPCA1d membranes 
contained 1µM thapsigargin and those for hSERCA2b membranes did 
not contain thapsigargin.  
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Figure 4.2.5.3. Effect of Different TFP Concentrations on Mean 
Ca2+-ATPase Activities From Microsomal Membranes of hSPCA1d- 
& hSERCA2b- Over-Expressing COS-7 Cells 
 
Percentage Ca2+-dependent ATPase activities measured from hSPCA1d 
and hSERCA2b membranes in reaction mixtures that contained TFP at 
different concentrations. Mean activities were measured from three 
replicate assays for each TFP concentration tested and percentage 
activities calculated in same way as stated for figure 4.2.5.1. Error bars 
indicate S.E.M values. Assay mixtures for hSPCA1d membranes 
contained 1µM thapsigargin and those for hSERCA2b membranes did 
not contain thapsigargin.  
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Figure 4.2.5.4. Effect of Different 2-APB Concentrations on Mean 
Ca2+-ATPase Activities From Microsomal Membranes of hSPCA1d- 
& hSERCA2b- Over-Expressing COS-7 Cells 
 
Percentage Ca2+-dependent ATPase activities measured from hSPCA1d 
and hSERCA2b membranes in reaction mixtures that contained 2-APB at 
different concentrations. Mean activities were measured from three 
replicate assays for each 2-APB concentration tested and percentage 
activities calculated in same way as stated for figure 4.2.5.1. Error bars 
indicate S.E.M values. Assay mixtures for hSPCA1d membranes 
contained 1µM thapsigargin and those for hSERCA2b membranes did 
not contain thapsigargin. The data for hSERCA2b membranes was 
obtained from a previous study (Wootton and Michelangeli, 2006) 
(emphasised by the dotted line). 
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Figure 4.2.5.5. Effect of Different BPA Concentrations on Mean 
Ca2+-ATPase Activities From Microsomal Membranes of hSPCA1d- 
Over-Expressing COS-7 Cells 
 
Percentage activity was calculated from making activity measurements in 
the presence of BPA relative to those of vehicle (DMSO) control in the 
same way as stated for figure 4.2.5.1. Mean activities were measured 
from three replicate assays for each BPA concentration tested. Error bars 
indicate S.E.M values. 1µM thapsigargin was added to reaction mixtures.  
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Figure 4.2.5.6. Effect of Different cADPR Concentrations on Mean 
Ca2+-ATPase Activities From Microsomal Membranes of hSPCA1d- 
& hSERCA2b- Over-Expressing COS-7 Cells 
 
Percentage Ca2+-dependent ATPase activities measured from hSPCA1d 
and hSERCA2b membranes in reaction mixtures that contained cADPR 
at different concentrations. Mean activities were measured from three 
replicate assays for each cADPR concentration tested and made relative 
to those of vehicle (dH20) controls to calculate percentage activities. 
Error bars indicate S.E.M values. Assay mixtures for hSPCA1d 
membranes contained 1µM thapsigargin and those for hSERCA2b 
membranes did not contain thapsigargin.  
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Figure 4.2.5.7. Effect of Different NAADP Concentrations on Mean 
Ca2+-ATPase Activities From Microsomal Membranes of hSPCA1d- 
Over-Expressing COS-7 Cells 
 
Percentage activities were calculated in the same way as stated for figure 
4.2.5.6. Mean activities were measured from three replicate assays for each 
NAADP concentration tested. Error bars indicate S.E.M values. 1µM 
thapsigargin was added to reaction mixtures.   
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IC50 Values of hSPCA1d & SERCA Inhibitors  
(± S.E.M) 
 
 
INHIBITOR 
 
hSPCA1d  
(M) 
 
hSERCA2b 
(M) 
 
Fold difference  
! 
IC50 hSERCA2b
IC50 hSPCA1d 
" 
# 
$ 
% 
& 
'  
Bis-phenol 1.3 x 10-7  
(± 9.0 x10-9) 
8.1 x 10-6 
(± 3.8 x 10-7) 
62 
TBBPA 5.4 x 10-7 
(± 8.3 x 10-8) 
7.1 x 10-7 
(± 7.0 x 10-8) 
1.3 
TFP 2.0 x 10-5 
(± 9.0 x 10-7) 
1.1 x 10-5 
(± 3.1 x 10-6) 
0.6 
2-APB 1.8 x 10-4 
(± 5.0 x 10-6) 
1.5 x 10-3 
(± 2.0 x 10-4) 
7.2 
BPA 1.3 x 10-4 
(± 5.5 x 10-6) 
*2.3 x 10-4  
(± 3.0 x 10-5) 
 
*1.8 
 
Table 4.2.5.8. IC50 Values of Inhibitors for hSPCA1d & SERCA 
IC50 values ± S.E.M for all except BPA’s value for SERCA were calculated using 
Prism graph plotting software, which was used to produce the plots shown in figures 
4.5.5.1-7. The IC50 value for BPA’s inhibitory effect on hSERCA2b was not available 
and so that for *rabbit SERCA1a, taken from a previous publication (Kirk et al., 
2003), is shown in the above table instead.  
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Activities had been measured from control microsomal membranes in all cases, which 
were isolated from non-transfected cells, in the same manner as those that contained 
over-expressed protein. Any activity found in these control membranes was 
subtracted from the equivalent activities measured from their pair-matched 
hSPCA1d/hSERCA2b membranes. IC50 values calculated from the plots shown in 
figures 4.2.5.1-5 are given in table 4.2.5.8. 
 
Bis-phenol (figure 4.2.5.1) was shown to be the most potent inhibitor out of the seven 
compounds tested and also gave the largest difference in its IC50 values between 
hSPCA1d and hSERCA2b, which showed this compound was 62 times more potent 
on hSPCA1d than hSERCA2b membranes. Using data from a previous study on the 
inhibitory effect of 2-APB on hSERCA2b (also when over-expressed in COS-7 cells) 
(Wootton and Michelangeli, 2006), the present study has also shown inhibition by 2-
APB (figure 4.2.5.4) is 7.2 times more potent on hSPCA1d than hSERCA2b 
membranes.  
 On the other hand, less substantial differences in inhibitory potency between 
hSPCA1d and hSERCA2b was observed for both TBBPA (figure 4.2.5.2) and TFP 
(figure 4.5.2.3), and thus these two compounds are unlikely to be able to discriminate 
between the activities of these two Ca2+-ATPases. For BPA (figure 4.2.5.5), its IC50 
value for hSERCA2b has not been determined in both past and present study. To date, 
the nearest match that can be obtained for comparison is the IC50 value for SERCA1a, 
which has been measured using rabbit skeletal muscle SR (Kirk et al., 2003), and this 
value shows no substantial difference to that for hSPCA1d. Thus, like TBBPA and 
TFP, it is unlikely that BPA can be used as an inhibitor specific to hSPCA1d.  
 Ca2+-ATPase activities measured from hSPCA1d membranes incubated with 
0-30µM cADPR (figure 4.2.5.6) or 0-1µM NAADP (figure 4.2.5.7) did not appear to 
notably deviate from the control activity levels. Ca2+-ATPase activity measurements 
were also made from hSERCA2b membranes in the presence of 5, 10 and 20µM 
cADPR, which showed this second messenger made no significant difference to such 
activity at these concentrations when compared to control activities. Thus both 
cADPR and NAADP demonstrated no influence on hSPCA1d activity and the present 
study preliminarily also suggests cADPR does not act on hSERCA2b activity.  
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4.2.6. The Effects of Bis-phenol & 2-APB on Intracellular Ca2+ Mobilisation in 
A7r5 Cells Detected by Fluo-3 Fluorescence Microscopy 
A7r5 cells were used to investigate the effects of bis-phenol and 2-APB on 
mobilisation of internal Ca2+ stores in intact cells because this cell-line has been found 
to express both SERCA and SPCA endogenously (see section 3.2.1-2). All 
experiments were done in the absence of extracellular Ca2+ so that its effects would 
not obscure those from intracellular Ca2+ stores. Three types of responses were 
assessed, which were (i) response to 1µM thapsigargin after 10-minute pre-treatment 
with potential inhibitor, (ii) response to potential inhibitor after 10-minute pre-
treatment with 1µM thapsigargin, and (iii) response to potential inhibitor without any 
pre-treatment. The concentration used for each of the five compounds was that which 
gave 100% inhibition of hSPCA1d at isolated microsomal membranes, as indicated 
from phosphate liberation assay data presented above (section 4.2.5).  
 For 1.5µM bis-phenol, Ca2+ mobilisation in A7r5 cells was only observable as 
response type (i) (figure 4.2.6.2). The mean peak height of response calculated for 
1µM thapsigargin, after 10-minute pre-treatment with 1.5µM bis-phenol, was 0.58 ± 
0.03, which was found to not be significantly different via Student’s T-test (P>0.05) 
to that obtained from cells that were treated with 1µM thapsigargin with no pre-
treatment (0.70 ± 0.04) (figure 4.2.6.1). The shape, timing and duration of these 
response profiles were also qualitatively almost identical. This altogether suggested 
1.5µM bis-phenol treatment of intact A7r5 cells was unable to inhibit SPCA activity, 
at least at the time period monitored (5 minutes). It is possible that bis-phenol-
stimulated Ca2+ mobilisation would have been observed if the duration of experiments 
was extended.    
 500µM 2-APB (figure 4.2.6.3) was able to produce Ca2+-mediated responses 
of all three types that were observed for. The mean peak heights in Fluo-3 
fluorescence intensity change in response to 1µM thapsigargin after pre-treatment 
with 2-APB was 63% lower (0.26 ± 0.04) (figure 4.2.6.3 (i)) than that shown from 
control thapsigargin experiments (0.70 ± 0.04) (figure 4.2.6.1), suggesting a 
proportion of thapsigargin-releasable Ca2+ stores had been emptied during the 10-
minute pre-treatment period by 2-APB inhibition of SERCA. Furthermore, the 
cytosolic Ca2+ concentration of 2-APB pre-treated cells returned closer to basal levels 
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Figure 4.2.6.1. Ca2+-Mediated Responses to 1µM Thapsigargin & 
Thapsigargin-Insensitive 10nM AVP Response by A7r5 Cells in the 
Absence of Extracellular Ca2+ 
 
 
TG 
AVP 
↑  
↑  
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Figure 4.2.6.1. Ca2+-Mediated Responses to 1µM Thapsigargin & 
Thapsigargin-Insensitive 10nM AVP Response by A7r5 Cells in the 
Absence of Extracellular Ca2+ 
 
1µM thapsigargin response with no prior treatment (“TG”), and 10nM 
AVP response following response to 1µM thapsigargin (“AVP”). Each 
trace represents mean data measured from 25 cells. Arrows indicate time-
point at which treatment was added. Mean peak heights ± S.E.M were 1.03 
± 0.07 and 0.92 ± 0.08 for “TG” and “AVP” responses, respectively. 
 
  148 
 
(i) 
(ii) 
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Figure 4.2.6.2. Bis-phenol Effects on Intracellular Ca2+ Mobilisation in A7r5 Cells 
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Figure 4.2.6.2. Bis-phenol Effects on Intracellular Ca2+ Mobilisation in 
A7r5 Cells 
 
The plots show (i) 1µM thapsigargin response after 1.5µM bis-phenol pre-
treatment, (ii) 1.5µM bis-phenol response after 1µM thapsigargin pre-
treatment, and (iii) 1.5µM bis-phenol response with no pre-treatment. Each 
trace represents mean data measured from 25 cells. Positions of arrows 
indicate time point at which treatment was added to cells. Mean peak height ± 
S.E.M for response type (i) was 0.58 ± 0.03, while no response was detected 
for types (ii) and (iii). 
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Figure 4.2.6.3. 2-APB Effects on Intracellular Ca2+ Mobilisation in A7r5 Cells 
 
(i) 
(ii) 
(iii) 
↑  
↑  
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Figure 4.2.6.3. 2-APB Effects on Intracellular Ca2+ Mobilisation in 
A7r5 Cells 
 
The plots show (i) 1µM thapsigargin response after 500µM 2-APB pre-
treatment, (ii) 500µM 2-APB response after 1µM thapsigargin pre-
treatment, and (iii) 500µM 2-APB response with no pre-treatment. Each 
trace represents mean data measured from 25 cells. Positions of arrows 
indicate time point at which treatment was added to cells. Mean peak 
heights ± S.E.M were (i) 0.26 ± 0.04, (ii) 0.45 ± 0.04 and (iii) 1.23 ± 0.13. 
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after thapsigargin response than cells that had not been pre-treated. Student’s T-test 
showed a significant difference in mean peak height values from these two conditions 
of thapsigargin response (P<0.05) in A7r5 cells. 2-APB response after 10-minute pre-
treatment with 1µM thapsigargin produced a mean peak height value of 0.45 ± 0.04 
(figure 4.2.6.3 (ii)), which was found to be border-line statistically not significant in 
its difference (P>0.05, where P=0.06) to the mean peak height value of 0.62 ± 0.05 
obtained from A7r5 control responses to 10nM AVP (figure 4.2.6.1). However, the 
thapsigargin-insensitive response profile for 2-APB was notably different to that for 
the control AVP response, whereby the former showed no decline phase in cytosolic 
Ca2+ levels after the rise phase, unlike AVP. The mean height of response to 2-APB 
without pre-treatment was 1.23 ± 0.13 (figure 4.2.6.3 (iii)), which was 1.7 times 
larger than the mean peak heights of response (i) and (ii) combined together, as well 
as being almost twice as large as the mean peak height for thapsigargin-insensitive 
Ca2+ mobilisation by 10nM AVP stimulation in the absence of extracellular Ca2+. 
Thus it was likely that 500µM 2-APB did not just empty Ca2+ stores that were 
controlled by SPCA in the absence of pre-treatment.    
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4.3. Discussion 
 
Successful over-expression of active hSPCA1d and hSERCA2b protein, along with 
their isolation and detection in the microsomal membranes of transfected COS-7 cells, 
has allowed for the testing of seven potential modulators of human microsomal Ca2+-
ATPases in the present study. From this, it was found that neither of the two putative 
second messengers tested (cADPR and NAADP) were able to alter hSPCA1d activity 
at the concentrations tested. On the other hand, all five synthetic compounds that were 
tested (i.e. bis-phenol, TBBPA, TFP, 2-APB and BPA) did inhibit hSPCA1d activity, 
although to different extents.  
 
Bis-phenol and 2-APB stood out from the other three inhibitors because the 
differences in their potency in inhibiting hSPCA1d and hSERCA2b activity were 
substantially larger than those of the other three compounds. Bis-phenol and 2-APB 
inhibited hSPCA1d activity by 62- and 7.2-fold, respectively, better than hSERCA2b 
activity. 1.5µM bis-phenol was able to inhibit 100% of hSPCA1d activity of isolated 
membranes (whilst having no effect of hSERCA2b activity) but was unable to release 
Ca2+ stores from A7r5 cells at this concentration. In contrast, 500µM 2-APB, was able 
to inhibit hSPCA1d without affecting the hSERCA2b activity, as well as mobilise 
thapsigargin-insensitive Ca2+ stores in A7r5 cells. However, pre-treatment with 
500µM 2-APB did decrease the amount of intracellular Ca2+ that was releasable by 
thapsigargin treatment of A7r5 cells.  
 
The discrepancy between studies on isolated membranes and intact A7r5 cells (the 
latter of which has been demonstrated to express SPCA endogenously (see chapter 3)) 
with regards to bis-phenol inhibition of SPCA may have been caused by its highly 
hydrophobic nature, which would have made it difficult for bis-phenol to reach SPCA 
at the Golgi apparatus inside intact cells, in contrast to being more able to be in direct 
contact with SPCA at isolated membranes. Thus further optimisation is likely to be 
required in order to identify a concentration of bis-phenol (above 1.5µM) that is 
effective at inhibiting SPCA in intact cells. Though higher concentrations of bis-
phenol could also influence the activities of other proteins involved in Ca2+ 
homeostasis and future studies will have to take this into consideration. In addition to 
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this, it should be noted that a previous study on HL60 cells showed bis-phenol can 
cause Ca2+ mobilisation in these cells, but such an event was often observed to occur 
after a substantial time delay between time point of applying bis-phenol to cells and 
response onset (Brown et al., 1994). Thus it may be well advised to repeat 
experiments with 1.5µM bis-phenol on A7r5 cells, but extend the duration of 
experiments beyond 5 minutes.    
 
The ability of A7r5 cells to respond to 1µM thapsigargin after pre-treatment with 
500µM 2-APB demonstrated this compound can affect intracellular Ca2+ stores at this 
concentration (which can inhibit 100% hSPCA1d activity at isolated membranes) and 
cannot empty SERCA-controlled Ca2+ stores completely in intact cells. However, the 
63% reduction in thapsigargin-releasable Ca2+ stores after pre-treatment of A7r5 cells 
with 500µM 2-APB conflicted with data obtained from isolated membranes, whereby 
the use of the latter demonstrated this concentration is three times lower than its IC50 
value for hSERCA2b. Two explanations for this discrepancy could be made from 
taking into account 2-APB’s effects on other proteins involved in Ca2+ homeostasis. 
100µM 2-APB is able to inhibit IP3R and 30µM 2-APB can inhibit store-operated 
Ca2+ entry, both cases in permeabilised mouse pancreatic acinar cells (Choi et al., 
2010a). These other effects potentially make 500µM 2-APB (or even lower 
concentrations of this compound) unsuitable for use as an inhibitor specific to SPCA 
in intact cells. This is certainly a highly likely possibility when taking into 
consideration the substantial amount of Ca2+ that was released in A7r5 cells following 
stimulation with 500µM 2-APB in the absence of any pre-treatment, which showed a 
visibly significant difference to the thapsigargin-insensitive response these cells had 
to this compound, and thus likely to have been caused by 2-APB emptying Ca2+ stores 
that are unlikely to be associated with SPCA in intact A7r5 cells.      
 
Another peculiar observation made from 2-APB’s Ca2+-mediated responses in intact 
A7r5 cells was the difference in amount of decline of cytosolic Ca2+ levels after 
reaching peak response to 1µM thapsigargin (after 2-APB pre-treatment) and 500µM 
2-APB (after thapsigargin pre-treatment). The response to thapsigargin involved a 
visible decline back to basal levels by the end of the experiments, but the response to 
2-APB did not decline significantly after reaching peak levels before the end of 
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experiments. Ca2+ transporters that could aid recovery of cytosolic Ca2+ back to basal 
levels and also be active in the absence of SPCA and SERCA activity would be 
PMCA and the mitochondrial Ca2+ uniporter. It would appear that neither of these 
alternative Ca2+ transporters were inhibited when A7r5 cells responded to 
thapsigargin following pre-treatment with 2-APB. However, the same could not be 
said for the thapsigargin-insensitive 2-APB responses observed in A7r5 cells and it is 
unlikely the reason could be due to activation of mitochondrial Ca2+ release (in the 
event of Ca2+ overload) because the peak amount of Ca2+ released by 2-APB was not 
significantly different to that released by AVP following thapsigargin pre-treatment. It 
has been noted in the past that 100µM 2-APB can decrease the rate of mitochondrial 
Ca2+ uptake (Peppiatt et al., 2003). This would again suggest 500µM 2-APB does not 
act specifically on SPCA in intact A7r5 cells and further experiments will be required 
to understand why the shape of these Ca2+ response profiles were notably different in 
the ways that were observed.     
 
The difference in susceptibility to bis-phenol inhibition between hSPCA1d and 
hSERCA2b are likely to be related to the differences they have in the kinetic 
properties of their Ca2+-ATPase activities. A past study on bis-phenol inhibition of 
SERCA in isolated rat skeletal muscle SR suggested bis-phenol hinders SERCA’s 
activity by binding to its E2 state, where its affinity for Ca2+ is at its lowest (Sokolove 
et al., 1986, Brown et al., 1994). Factors such as a decrease in pH and increasing 
membrane fluidity by adding Triton-X100 to the rat SR were also noted to decrease 
the potency of bis-phenol inhibition at SERCA in this study. It has been shown in 
another study that hSPCA1d has a faster rate of Ca2+ dissociation than rabbit 
SERCA1a, and thus favours the E2 state more than SERCA1a (Dode et al., 2005). In 
addition to this, hSPCA1d activity was also shown to be relatively insensitive to pH 
changes in this latter study, which was attributed to the greater stability its Ca2+-
binding site has when not bound with Ca2+. These past findings can be taken together 
to suggest that bis-phenol can inhibit hSPCA1d with 62-fold greater potency than 
hSERCA2b because the probability of finding hSPCA1d in the E2 state is greater than 
it is for hSERCA2b. Another difference that has been noted between the kinetic 
properties of hSPCA1d and rabbit SERCA1a, which may also be applicable to 
hSERCA2b, is that hSPCA1d has a slower rate of dephosphorylation than rabbit 
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SERCA1a (Dode et al., 2005), which is a step that is required to promote the 
conformational change of both Ca2+-ATPases from the E2 state back to the E1 state, 
and is another factor that would keep hSPCA1d in the E2 state longer than it would 
for rabbit SERCA1a.      
 
With regards to the effect of Triton-X100 that was noted in the study on rat SR 
(Sokolove et al., 1986), this could be taken into account with hSPCA1d’s lack of pH 
sensitivity because the latter has been attributed to the membranes of the Golgi 
apparatus having a higher content of sterols and sphingolipids than those of the ER, 
which would make the former membranes more rigid and thus more capable of 
stabilising and maintaining hSPCA1d in the E2 state for a longer period of time. 
Again, this would support the idea that bis-phenol inhibits hSPCA1d better (when 
compared to hSERCA2b) because both hSPCA1d and bis-phenol favour the E2 state. 
A more rigid membrane at the Golgi apparatus may also mean a slower rate of 
transition from the E2 state back to the E1 state for hSPCA1d than hSERCA2b, 
because such a transition requires the Ca2+-ATPase to make a major conformational 
change to move its Ca2+-binding sites from the luminal side to the cytosolic side of 
the membrane it is embedded in. By making the membrane of rat SR more fluid with 
Triton-X100 (as done in the aforementioned study) it is likely to make it easier for 
SERCA to convert between the E1 and E2 states, which could reduce the probability 
the E2 state being available for interaction with bis-phenol, especially if it is the case 
that the E2 state is far less stable for SERCA than it is for SPCA.   
 
The lesser but still significant ability of 2-APB to inhibit hSPCA1d 7.2-fold better 
than hSERCA2b may also be associated with differences in the kinetic properties of 
these two Ca2+-ATPases. A previous study has suggested 2-APB inhibits SERCA in 
rabbit skeletal muscle SR by hindering its formation of a phospho-enzyme 
intermediate, which was attributed to 2-APB decreasing its rate of phosphoryl group 
transfer (Bilmen et al., 2002). Another study has shown hSPCA1d has a slower ATP 
turnover rate than hSERCA2b, which was attributed to a higher apparent Ca2+ affinity 
that slows down the rate of hSPCA1d dephosphorylation (Dode et al., 2005). Taken 
together, it could be interpreted that 2-APB binds these two Ca2+-ATPases when they 
are in conformations that do not promote the process of phosphoryl group transfer, 
and its preference to do so when still phosphorylated and/or Ca2+-bound (i.e. in the 
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E1-P(Ca2+) state) may be the reason why 2-APB is 7.2-fold more potent at inhibiting 
hSPCA1d than hSERCA2b. It has been suggested that 2-APB binds near the L67 loop 
of SERCA (Wootton and Michelangeli, 2006), which can influence both SERCA 
phosphorylation and its Ca2+ affinity (Zhang et al., 2001). This may also be the case 
for SPCA, though further studies would be required to ascertain this and would be of 
interest to do in order to further define any structural differences between SERCA and 
SPCA that result in their kinetic properties being different.  
 
The present study has demonstrated 1-40µM cADPR does not affect hSPCA1d 
activity, which has not been shown before. In addition to this, data from preliminary 
experiments with hSERCA2b suggested cADPR also does not have an effect on this 
Ca2+-ATPase in isolated membranes too. This would conflict with at least two past 
studies that have suggested cADPR can increase SERCA activity in intact xenopus 
oocytes (Yamasaki-Mann et al., 2009) and in isolated dog heart SR (Lukyanenko et 
al., 2001). This contrast between the present and past studies may be explained by 
differences in (i) the organisms used for their experiments, (ii) SERCA isoforms 
involved (SERCA1 in SR vs. SERCA2 in microsomes), (iii) the type of sample used 
(intact cells (Xenopus oocytes) vs. isolated membranes), and/or (iv) the form of 
cADPR used (non-metabolisable 3-Deaza-cADPR (microinjected into xenopus 
ooctyes) vs. standard cADPR (added to cell-free reaction mixtures containing 
microsomal membranes)). On the other hand, a third past study has shown that 
cADPR does not bind directly to isolated microsomes from both dogs and rabbits, and 
thus suggested this second messenger does not act directly on SR to cause Ca2+ 
release (Copello et al., 2001). Ideally, more hSERCA2b activity measurements in the 
presence of a wider range of cADPR concentrations is needed to give a more 
ascertained answer to the question of whether or not this second messenger can 
change SERCA activity according to the experimental model tested in the present 
study.   
 
The lack of effect on hSPCA1d activity by 0.01-1µM NAADP in the present study 
has not been demonstrated before. Most past studies on NAADP have focused on its 
ability to mobilise Ca2+ from either the ER or lysosomes (Singaravelu and Deitmer, 
2006, Macgregor et al., 2007, Steen et al., 2007, Zhang and Li, 2007), and it has been 
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debated which of these organelles is the source of intracellular Ca2+ that gets released 
in the presence of NAADP. There has been one study that has suggested NAADP-
illicted Ca2+ release is unlikely to involve the Golgi apparatus because it showed 
brefeldin A (a compound that disrupts Golgi apparatus integrity by promoting its 
vesiculation) does not affect the ability of NAADP to release intracellular Ca2+ stores 
in permeabilised mouse pancreatic acinar cells (Gerasimenko et al., 2006). However, 
the use of brefeldin A may not have been ideal because an earlier study showed this 
compound is unable to alter ATP-stimulated Ca2+ oscillations in thapsigargin-pre-
treated COS-1 cells that were made to over-express C.elegans SPCA (Missiaen et al., 
2001). In both cases, it also has to be taken into consideration whether or not NAADP 
could act on other proteins involved in Ca2+ homeostasis to indirectly influence Ca2+ 
release from SPCA-controlled stores, due to the use of whole cells. In the present 
study, it has been shown that NAADP does not affect hSPCA1d activity of isolated 
microsomes and thus unlikely to act on hSPCA1d directly.  
 
In conclusion, it appears to be highly promising that bis-phenol can be used as a 
SPCA-specific inhibitor, at least at a concentration of 1.5µM at isolated microsomal 
membranes. Further optimisation of its concentration will be required to find one 
suitable for use on intact cells, which is most likely to be above 1.5µM. 2-APB has 
also been identified as a compound that can inhibit hSPCA1d without affecting 
hSERCA2b activity (over the same concentration range) in isolated membranes. 
However, as a result of the present study, it is not recommended for use as a SPCA 
inhibitor in intact cells due to the influence it is likely to have on non-SPCA-
controlled Ca2+ stores. An inhibitor that can specifically inhibit SPCA is needed to 
assist further research on this Ca2+-ATPase, especially when experiments will involve 
observing the effects of its activity in the presence of other proteins that can influence 
Ca2+ homeostasis (e.g. SERCA, PMCA). A SPCA-specific inhibitor could also be 
potentially used as a template for drug design to aid treatment of medical conditions 
that have been associated with increased expression and/or activity of SPCA, such as 
diabetes and neurological diseases.  
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CHAPTER 5.  
THE ROLE OF RGN (SMP30) IN MAMMALIAN Ca2+ HOMEOSTASIS:  
OVER-EXPRESSION & RECOMBINANT STUDIES 
 
5.1. Introduction 
 
Regucalcin (RGN; also known as senescence marker protein 30 (SMP30)) is a protein 
that is believed to contribute to Ca2+ homeostasis by interacting with other Ca2+-
dependent proteins, such as SERCA (Yamaguchi and Nakajima, 2002) and nuclear 
protein tyrosine phosphatase (Tobisawa and Yamaguchi, 2003b). It has been noted 
that RGN is expressed in a number of tissues, such as brain (Fujita, 1999), liver 
(Yamaguchi, 2000b) and prostate (Maia et al., 2008). Furthermore, RGN is believed 
to be able to localize in the nucleus (Omura and Yamaguchi, 1999) and mitochondria 
(Yamaguchi et al., 2008b), as well as being primarily a cytosolic protein (Yamaguchi 
and Yamamoto, 1978). Links to various medical conditions, ranging from 
Alzheimer’s disease (Sun et al., 2006) to breast cancer (Maia et al., 2009), have been 
made and with association to changes in RGN expression levels. The crystal structure 
of human RGN was recently published (Chakraborti and Bahnson, 2010) and 
dispelled the argument against its ability to bind Ca2+ (Kondo et al., 2004, 
Yamaguchi, 2000a).   
 
A multitude of studies have focused on the effects of RGN’s presence on cellular 
events, such as Ca2+ transport into the ER (Yamaguchi, 2000a) and Ca2+-mediated 
gene transcription (Yamaguchi, 2000b), but virtually none have shown how RGN 
interacts with other proteins to produce these observations. It is unknown how it 
influences the activities of Ca2+-dependent transporters and enzymes. RGN could 
possibly play a part in agonist-induced Ca2+-mediated signaling pathways, by being 
involved in protein-protein interactions, or simply act by binding and sequestering 
Ca2+. Most of the focus has been on RGN expression levels, specifically its changes 
during aging (Ishigami, 2010, Maruyama et al., 2010) and in diseases (Doran et al., 
2006, Maia et al., 2009, Park et al., 2010), rather than the study of its molecular 
features. Furthermore, RGN has been shown to function as a gluconolactonase 
(Kondo et al., 2008, Arai et al., 2009, Kashio et al., 2009, Koike et al., 2010). Recent 
research has also mainly focused on the mouse model, which was first used to 
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demonstrate RGN’s role in vitamin C synthesis (Ishigami et al., 2002). The problem 
this produces is that it removes focus on the role of RGN in humans because the 
human body does not possess the ability to synthesise vitamin C. This may change 
now that the Ca2+-bound RGN crystal structure has been made available, along with 
results from biochemical studies that suggest RGN’s ability to bind Ca2+ is unlikely to 
be related to its role as a gluconolactonase because its Kd for Ca2+-binding has been 
determined to be far above those found under physiological resting conditions in the 
cell cytosol (0.57 ± 0.25mM) (Chakraborti and Bahnson, 2010).  
 
Most biochemical experiments have involved the use of cell-free based assays. 
Although efforts had been made in these studies to make the conditions used 
physiologically relevant, whole cell studies would still be more favourable if the true 
biological role of RGN in tissues are to be examined. Only two studies have involved 
the use of intact cells to investigate the effect of RGN’s function in vivo in relation to 
calcium movement, and in both cases it was suggested that RGN over-expression 
increases PMCA activity (Fujita et al., 1998, Son et al., 2008). One of these studies 
also suggested RGN over-expression has no effect on thapsigargin response in a 
mouse carcinoma cell line, P19, though the experiments used to demonstrate this only 
monitored the first 60 seconds of thapsigargin response (Son et al., 2008). Finally, 
although RGN expression has been detected in 10 out of 14 different types of tissues 
(Fujita et al., 1996, Ichikawa and Yamaguchi, 2004, Tobisawa and Yamaguchi, 
2003a, Yamaguchi et al., 2005, Doran et al., 2006, Maia et al., 2009), additional types 
of tissues/cells need to be tested to get a better profile of its distribution.   
 
The present study aimed to address some of the gaps in RGN research that have been 
highlighted above, with specific focus on finding out whether RGN can contribute to 
the formation and/or delivery of Ca2+ signaling cascades, and/or control of 
intracellular Ca2+ stores. An attempt was also made to identify other tissues that 
express RGN endogenously at the mRNA and/or protein level(s). The production of 
recombinant rat RGN and an anti-RGN antibody, along with the use of an intact cell 
model that over-expresses human RGN, were involved in the work to be discussed 
here.  
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5.2. Results 
 
5.2.1. Distribution & Abundance of RGN mRNA Expression Levels in Different 
Rat Tissues 
RGN mRNA expression levels were measured from cDNA copies of total mRNA 
from 14 different cell/tissue samples to examine its pattern of distribution across 
different types of organs. Figure 5.2.1.1 shows PCR product bands that represent the 
detection of either RGN or RPL19 mRNA sequences in a number of cDNA samples 
from different rat tissues, whereby the cDNA samples were copies of total mRNA 
extracts from these tissues. From this, it was observed that transcripts of RGN mRNA 
were detected in adult tissue samples from aorta, testes, skeletal muscle, brain, 
cerebellum, kidney and liver. RGN mRNA transcripts were also detected in tissue 
samples of juvenile rats; from heart, Sertoli cells, testes, germ-line cells 
(spermatogonia) and myeloid cells. RGN PCR was also done with cDNA copies of 
total mRNA from lungs and heart of adult rats, but the RGN mRNA transcript was 
not detected despite reasonable levels of RPL19 PCR product shown both in figure 
5.2.1.1 and in repeat experiments. It was curious to see that RGN transcript could be 
detected in the adult rat aorta cDNA sample but not in that of heart. Amount of 
RPL19 PCR product at adult heart was only slightly lower than at adult aorta and thus 
difference in amount of total mRNA in samples was unlikely to have contributed to 
the difference in RGN levels.   
Tissues that had not previously been shown to express RGN mRNA in rats 
(underlined at figure 5.2.1.1) included samples from the male reproductive system of 
both adult and juvenile rats. Adult testes showed a striking amount of RGN mRNA 
detection and this was the case for four different cDNA samples from this tissue type 
(prepared on different days from different adult rats) that were tested. Furthermore, 
juvenile testes were shown to express RGN mRNA, along with germ cells and 
myeloid cells.  As control experiments, the sequence of RGN PCR products from both 
adult rat testes and liver (the latter as a positive control) were checked and confirmed 
they did indeed represent the mRNA sequence for RGN (figure 5.2.1.2A). A control 
PCR was also done with the same two samples of cDNA, which involved the use of 
primers that would produce the full-length RGN mRNA coding sequence as its PCR 
product if it were present. Indeed, this full-length RGN transcript was detected in both 
adult rat testes and liver samples (figure 5.2.1.2B). It should be noted that although it  
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Figure 5.2.1.1. RGN mRNA Expression in Different Rat Tissues 
 
For each type of tissue represented, PCR products for RGN and RPL19 
mRNA were produced using cDNA copies of total mRNA from either male 
rat adults (“A”) or juveniles (“J”). Tissue types with their names underlined 
indicate those that had not been screened in previously published studies.  
 
The PCR product bands were of their predicted sizes, which were 307bp for 
RGN and 321bp for RPL19. All samples were loaded at equal volumes in 
each lane. 
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Figure 5.2.1.2. Control PCR & DNA Sequencing with RGN 
mRNA Transcript Copies from Adult Rat Liver & Testes 
 
(A) The DNA sequences of 307bp RGN PCR products for both 
adult rat testes and liver (presented in figure 5.2.1.1) (as labelled) 
were aligned with the rat RGN mRNA sequence from the Pubmed 
nucleotide databank (entry number NM_031546). The percentage 
alignment match for the region that the PCR products encode 
between these sequences is circled in both cases. 
 
  (B) PCR products of full-length RGN mRNA coding sequence 
(0.94kb) for adult rat testes and liver (as labelled), which were 
obtained from the same cDNA copies of total mRNA used for 
PCR of the shorter 307bp RGN product given in figure 5.2.1.1. 
The lane of 1kb DNA ladder is as labelled and the position of the 
1kb marker is indicated.  
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has been previously shown RGN is expressed in adult rat brain (Yamaguchi et al., 
1999), specific areas of RGN mRNA expression within this organ, such as the 
cerebellum examined in the present study, had not been previously shown. 
 
5.2.2. Extraction of Full-Length Rat Liver RGN Coding Sequence & Insertion 
into E.coli Expression Vector for Recombinant Protein Production 
Western blot detection for RGN protein levels in a number of different rat tissue 
samples was intended to be done after the PCR experiments presented above (section 
5.2.1). For this, an anti-RGN antibody was required. It was decided that such an 
antibody would be custom-made, with the use of recombinant rat RGN as the antigen, 
after commercially available anti-RGN antibodies were tried and proved to be poor at 
detecting RGN in cytosolic fraction samples from rat liver, which is an organ that 
expresses this protein at abundant levels (Yamaguchi and Isogai, 1993). Both would 
be produced as part of the present study.  Production of recombinant rat RGN firstly 
required the construction of a bacterial expression plasmid that contained the full-
length mRNA coding sequence for rat RGN.  
Full-length RGN coding sequence was isolated from cDNA copies of total 
mRNA extracts from adult rat liver using PCR. The use of transcripts from mRNA 
extracts ensured the sequence obtained did not contain any non-coding regions, and 
thus allowed it to be expressed using an E.coli expression vector because post-
transcriptional mRNA processing is not possible in an E.coli expression system for 
the production of recombinant proteins. The optimal Tm for producing transcripts of 
the sequence was determined to be 60oC, with the use of 2mM MgCl2 and 35 cycles. 
0.94kb PCR products made using the optimised PCR conditions were purified 
by gel extraction and the resulting gel extracts were analysed by DNA sequencing, 
which confirmed the correct coding sequence for rat RGN had been isolated in full. 
Sequence alignment of the PCR product with rat RGN mRNA coding sequence 
obtained from the Pubmed nucleotide databank (entry number NM_031546) showed 
100% match between these two sequences. Subsequently, the PCR product obtained 
was used for ligation into the pGEM-T vector, which allowed it to be moved into the 
pET21a expression vector later on, by providing restriction sites to produce sticky 5’ 
and 3’ ends outside of the RGN coding sequence for ligation into the latter. 
Figure 5.2.2.1A shows the gel extract of full-length RGN coding sequence that 
was inserted into the pGEM-T vector, along with successful AvaI and NdeI double 
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Figure 5.2.2.1. Extraction of Full-Length Rat RGN Coding 
Sequence & Insertion into pGEM-T & pET21a Vectors 
 
(A) Gel extract of full-length RGN coding sequence (left) produced 
by PCR with cDNA copies of total mRNA from adult rat liver, 
which was ligated with the pGEM-T vector to produce pGEM-
RGN. Restriction digest with AvaI and NdeI of pGEM-RGN 
(middle) produced sticky ends on either side of the RGN coding 
sequence to allow its insertion into the pET21a vector to produce 
pET21a-RGN, which was digested with the same restriction 
enzymes (right).  Two lanes are shown at each image, whereby the 
lane of the left shows 1kb DNA ladder and the lane of the right 
shows digested DNA. 1kb, 3kb and 5kb DNA marker positions are 
indicated on the left of the figure and are applicable to all three 
images.  
 
(B) Restriction maps for pGEM-T (Promega) and pET21a (Novagen) 
vectors. 
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restriction digest of the resulting pGEM-RGN plasmid. This double digest was 
required to produce complementary sticky ends that allowed insertion of the RGN 
coding sequence into a pET21a bacterial expression vector. The final expression 
plasmid, pET21a-RGN, was produced and its successful AvaI and NdeI double 
restriction digest is also shown. Note that the recombinant rat RGN coding sequence 
was engineered to include a hexahistidine (Hisx6) tag at the protein’s C-terminus, 
which was done by inserting the RGN coding sequence into the pET21a vector at the 
latter’s multi-cloning site without a termination sequence, so that the vector’s intrinsic 
Hisx6 tag coding sequence would be attached to the inserted RGN coding sequence at 
the latter’s 3’ end. This modification to the rat RGN sequence was made to aid 
identification and subsequent purification of the recombinant protein.   
 Sequences of DNA from minipreps of both pGEM-RGN and pET21a-RGN 
were checked by alignment with the same rat RGN coding sequence from the Pubmed 
nucleotide databank used for alignment with the original full-length rat RGN PCR 
product that was inserted into these plasmids. Detailed analysis showed that the two 
sequences shared 100% identity with that from the Pubmed nucleotide databank. The 
pET21a-RGN plasmid was subsequently used to transform a BL21 strain of E.coli, 
which is commonly used for recombinant protein expression, to produce bacteria that 
can express recombinant Hisx6-tagged rat RGN following IPTG induction.      
        
5.2.3. Anti-RGN Antibody Production from Recombinant Rat RGN Protein  
The RGN antigen, in the form of recombinant rat RGN, required to generate an anti-
RGN antibody, was produced from pET21a-RGN-transformed BL21 cells by adding 
0.25mM IPTG to their culture media and growing them overnight at 17oC. Following 
this, the cells were isolated from their culture media by centrifugation at 6000g, 
sonicated and their cell lysates centrifuged at 20,000g to separate soluble proteins 
(supernatant) from cell debris and inclusion bodies (pellet). SDS-PAGE and Western 
blot analysis (latter with the use of a anti-Hisx6 antibody) of these fractions (figure 
5.2.3.1) showed the recombinant RGN was located in the 20,000g spin pellet, which 
indicated it was expressed in the form of inclusion bodies (i.e. mis-folded protein). In 
order to separate the recombinant RGN from cell debris in this pellet, it was 
solubilised using 6M urea (a denaturing agent) and centrifuged at 100,000g to 
produce supernatant that contained the solubilised inclusion bodies. The 6M urea 
content in the supernatant was removed from the recombinant RGN by dialysis and 
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the latter’s presence in the form of a relatively pure over-expressed 33kDa protein 
was confirmed by SDS-PAGE, the identity of which was also ascertained to be rat 
RGN by FT-ICR analysis (figure 5.2.3.2). The 33kDa SDS-PAGE protein gel band 
shown in figure 5.2.3.2 was subsequently excised and sent to a commercial 
laboratory, Covalab, for antibody production.   
 
5.2.4. Testing Anti-RGN Antibody Using Original Recombinant RGN Antigen & 
Human RGN Over-Expressing COS-7 Cells 
In order to test the efficiency of antigen recognition by the custom-made anti-RGN 
antibody, and to provide a system for studying the role of RGN in mammalian cells 
later on, COS-7 cells were made to express human RGN by transfecting them with 
hSMP30-pcDNA3.1(-) plasmid DNA with the same transfection method that had 
previously been used to successfully transfect COS-7 cells with 
hSPCA1d/hSERCA2b-pMT2 plasmid DNA (chapter 4). Figure 5.2.4.1 shows the 
DNA fragments obtained from a NdeI and XhoI double restriction digest of minipreps 
for both hSMP30-pcDNA3.1(-) and control pcDNA3.1(-) plasmids, along with the 
restriction digest map for hSMP30-pcDNA3.1(-) indicating the expected sizes of 
DNA fragments from such a restriction digest reaction. From this, it was observed 
that restriction digests of the two plasmids were successful, based on the correctly-
sized 4.79kb DNA fragment being present for both plasmids (representing the 
pcDNA3.1(-) vector alone), as well as an additional 1.5kb fragment for hSMP30-
pcDNA3.1(-) representing the full mRNA coding sequence (including non-coding 
regions) for human RGN.  
 Figure 5.2.4.2 shows anti-RGN in a bleed taken from a rabbit 88 days after its 
first immunisation with recombinant rat RGN was able to allow detection of over-
expressed RGN in transfected COS-7 cells, as well as strong detection of its 
recombinant RGN antigen at a dilution ratio as low was 1:750, thus making it very 
sensitive. This bleed was also able to detect an abundant 33kDa protein present in the 
cytosolic fraction of adult male rat liver, which is likely to indeed be RGN because 
this tissue has already proven to express abundant levels of this protein (section 5.2.1-
2). RGN was not detected in total cell lysate samples collected from COS-7 cells that 
were transfected with control pcDNA3.1(-) plasmid DNA. 
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Figure 5.2.3.1. SDS-PAGE & Western Blot Analysis of 20,000g 
Centrifugation Spin Pellets & Supernatants for Over-Expressed 
33kDa Hisx6-Tagged RGN Protein 
 
Coomassie-stained SDS-PAGE gel (left) of 20,000g centrifugation spin 
supernatants (“SN”) and pellets (“PL”) of total cell lysates from 
sonicated pET21a-RGN-transformed BL21 cells, which were induced 
with 0.25mM IPTG and grown overnight at 17oC. These samples were 
also subjected to Western blotting (right) with polyclonal anti-Hisx6 
antibody. The expected position of 33kDa protein is indicated on the 
left and applies to both images. All protein samples were loaded at 
equal volumes at each lane. 
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Scan(s) Peptide MH+ 
gi|408807|dbj|BAA07490.1| regucalcin [Rattus norvegicus]  
697 -.LDPETGKR.- 915.48944 
716 -.LDPETGK.- 759.38831 
797 K.TTSCCFGGK.D 1017.41290 
844 R.FNDGKVDPAGR.Y 1175.58032 
845 R.FNDGKVDPAGR.Y 1175.58032 
961 R.FN@DGKVDPAGR.Y 1176.56438 
968 R.FN@DGKVDPAGR.Y 1176.56438 
1028 R.WDSISNR.V 877.41626 
1215 R.QSGGYVATIGTK.F 1181.61609 
1241 K.IECVLR.E 789.42877 
Figure 5.2.3.2. SDS-PAGE & FT-ICR Identification of 33kDa 
Over-Expressed Recombinant Protein from Solubilised Inclusion 
Bodies of pET21a-RGN-Transformed BL21 Cells 
 
Coomassie blue-stained SDS-PAGE gel (left) of 6M urea-solubilised 
inclusion bodies dialysed into 50mM Tris-HCl (pH 7.2) buffer with 
15% glycerol. The inclusion bodies were isolated from cultures of 
pET21a-RGN-transformed BL21 cells induced with 0.25mM IPTG and 
grown overnight at 17oC. The expected position of 33kDa protein is 
indicated. 
 
A sample of FT-ICR mass spectroscopy data (right), which showed the 
first 10 most common peptide fragments identified in the 33kDa 
protein band (left). Rat RGN was predicted as the most abundant 
protein in the 33kDa protein band by having the most detected peptides 
associated with it. 
 
 
33kDa 
→ 
  174 
  
 
Figure 5.2.4.1. NdeI & XhoI Double Restriction Digest  
of human SMP30-pcDNA3.1(-) 
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Figure 5.2.4.1. NdeI & XhoI Double Restriction Digest  
of Human SMP30-pcDNA3.1(-) 
 
(A) Agarose gel electrophoresis of DNA fragments in reaction mixtures from 
restriction digest (“cut”) of human SMP30-pcDNA3.1 (“RGN”) and empty 
pcDNA3.1(-) vector (“CONTROL”) with NdeI and XhoI, alongside their 
undigested DNA (“uncut”). The expected DNA fragment sizes were 1.5kb (full 
RGN mRNA sequence) and 4.79kb (pcDNA3.1(-) vector). The positions of 
1.5kb and 5kb DNA markers are indicated. All samples were loaded at equal 
volumes in each lane.  
 
(B) The restriction digest map for NdeI and XhoI double digest of human 
SMP30-pcDNA3.1. 
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Figure 5.2.4.2. Western Blots for Identification of RGN in Recombinant 
Rat RGN, COS-7 Total Cell Lysates & Rat Liver Cytosolic Fraction 
with Final Anti-RGN Bleed  
 
Detection of RGN in samples of recombinant rat RGN protein, total cell 
lysates from COS-7 cells transfected with hSMP30-pcDNA3.1(-) and control 
pcDNA3.1(-) plasmids, and cytosolic fraction from adult male rat liver. Total 
protein amounts loaded of each sample were 25µg of recombinant rat RGN 
and rat liver cytosolic fraction, and 20µg of COS-7 total cell lysates. The 
expected position of 33kDa protein on the blots is indicated at each image. 
 
The seeding density used for transfection of COS-7 cells was 1x105 cells per 
well in a 6-well plate and a 9:3 ratio of reagent(µl)-to-DNA(µg) was used 24 
hours after seeding the cells. Total cell lysate samples were collected 48 
hours after start of transfection. Dilution ratios of anti-RGN used were 1:50 
for COS-7 total cell lysates, and 1:750 for recombinant RGN and rat liver 
cytosolic fraction. 
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5.2.5. Detection of RGN at the Protein Level: Cytosolic Fractions of Rat Organs, 
Total Cell Lysate of Boar Sperm & Total Cell Lysate of Established Cell Lines  
The cytosolic fractions of seven different types of rat organs were probed by Western 
blotting for the presence of RGN protein using the custom-made anti-RGN antibody. 
These organs were liver, kidney, brain, testes, lung, heart and fat pads. All had 
originally been isolated from male adult rats that were over 5 weeks old. Figure 
5.2.5.1 shows detection of RGN was visible in samples from liver, kidney and brain, 
which were expected because these are organs that have already been demonstrated to 
express RGN protein according to previous publications (Fujita et al., 1996, Tobisawa 
and Yamaguchi, 2003a). The absence of RGN protein in the cytosolic fractions of 
adult male rat heart and lungs was also expected because the same finding was 
concluded from results from another previous study (Yamaguchi et al., 2002).  
 However, it was unexpected that the cytosolic fraction isolated from rat adult 
testes did not produce a detectable 33kDa protein band in this and repeat Western 
blots. This latter observation conflicts with that made from the results of PCR 
experiments presented above (section 5.2.1). Instead, a 66kDa protein band was 
detected in this sample, which was not the case for the other six samples tested. 
Control Western blots were done to show that the 66kDa protein band did not 
originate from any substance that was present in the PBS that was used for the 
isolation of all samples of cytosolic fractions (data not shown).  
 Another sample that was tested by Western blotting for the presence of RGN 
protein was adult boar sperm. This was chosen in an attempt to build on the 
interesting finding that RGN mRNA sequence could be detected from tissues of the 
male reproductive organs according to results collected from the PCR experiments of 
the present study (section 5.2.1). The result, also presented in figure 5.2.5.1, was the 
same as that obtained from Western blotting with samples from adult rat testes. 
Control Western blots with the PBS and lysis buffer used to prepare total cell lysate 
samples of boar sperm showed the 66kDa protein did not originate from these 
solutions alone. An attempt to identify the localisation of this 66kDa protein in fresh 
intact boar sperm was made via immunofluorescence (figure 5.2.5.2), with control 
experiments using antibodies that recognised SPCA1 and SERCA Ca2+-ATPases also  
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Figure 5.2.5.1. Western blots for RGN Detection in Cytosolic Fractions 
of Different Adult Male Rat Tissues & Adult Boar Sperm Total Cell 
Lysate 
 
Lanes on the blot are labelled with the name of the tissue type from which 
the cytosolic fraction samples they contain were isolated. This included adult 
male rat liver cytosolic fraction samples (“[Liver]”), which was added as a 
positive control for the detection of RGN by custom-made anti-RGN 
antibody. Positions of 33kDa and 66kDa proteins on the blot are indicated on 
the left and apply to both images. All samples except liver (10µg) and brain 
(20µg) were loaded at 30µg of total protein per well. Anti-RGN was used at 
a dilution ratio of 1:100. 
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Figure 5.2.5.2. Localisation of Anti-RGN, Anti-SPCA1 & Anti-SERCA 
(Y1F4) Antibodies in Adult Boar Sperm  
 
Fresh adult boar sperm cells were isolated from semen by centrifugation, 
fixed with formaldehye and permeabilised with Triton X100 before 
incubation with anti-RGN, anti-SPCA1 or anti-SERCA (Y1F4) antibody. 
The locations at which of these antibodies bound within the cells, and thus 
presumably the localisation of each antibodies intended target antigen 
(“RGN”, “SPCA1”, “SERCA”) were visualised using FITC-conjugated 
secondary antibodies and fluorescence microscopy (green labelled images). 
Matching light microscopy images were also taken (grey images). 
Antibody dilutions used were 1: 50 (anti-SPCA1, anti-SERCA Y1F4) and 
1:100 (anti-RGN, anti-rabbit/mouse FITC conjugates). Images were taken 
at x200 magnification.   
 
SERCA 
SPCA1 
RGN 
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undertaken at the same time to ensure the method used was effective on this sample. 
Indeed the result obtained with these control experiments matched those of a previous 
study (Harper et al., 2005). This suggested the method used was suitably implemented 
and the identification of anti-RGN localisation at the acrosomal region of boar sperm 
was not due to non-specific antibody binding. Control experiments with FITC-
conjugated secondary antibodies alone showed there were virtually no non-specific 
background fluorescence (data not shown).  
 It has already been shown that RGN cannot be detected from total cell lysates 
of COS-7 cells as a notable 33kDa protein band on Western blots unless they are 
made to over-express this protein via transfection methods (figure 5.2.4.2). The total 
cell lysates of three other types of established cell lines were also probed by Western 
blotting for the presence of any RGN protein they may express endogenously. These 
three cell lines were A7r5, TM4 and SH-SY5Y, which are representative of aortic, 
testicular and neuronal cells, respectively. Samples from A7r5 cells were collected 
from cultures, whereas those from SH-SY5Y and TM4 cells was collected from cells 
that had been thawed from frozen stocks (in the same way as done for rejuvenating 
cells), but isolated by centrifugation after thawing and not grown in flasks afterwards.  
 In all three cases, 33kDa protein bands representative of RGN could not be 
detected. Instead, all total cell lysate samples from established cell lines, including 
those of pcDNA3.1(-)-transfected and hSMP30-pcDNA3.1(-)-transfected COS-7 
cells, produced strongly detectable 66kDa protein bands on Western blots. Control 
experiments with samples of their culture media and BSA also gave such a band 
detected by anti-RGN (figure 5.2.5.3). This suggested the 66kDa bands detected on 
the Western blots of total cell lysates from cultures of COS-7, A7r5, TM4 and 
SHSY5Y cells were most likely to originate from the recognition of BSA in traces of 
media in these samples. The ability of polyclonal antibodies to bind to BSA protein is 
a common finding due to its use in the formulation of immunogenic solutions in the 
process of antibody production. Other bands detected on the blots in figure 5.2.5.3 
and not around 33kDa in molecular mass were dismissed as also non-specific bands 
recognised anti-RGN. 
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Figure 5.2.5.3. Detection of 66kDa Protein in Total Lysates of A7r5, 
TM4 & SH-SY5Y Cells, with Media & BSA Controls  
 
Sample contents of each Western blot lane image are as labelled below them, 
with “A7r5”, “TM4” and “SH-SY5Y” being the three different established 
cell-lines tested for their ability to express RGN endogenously. The media 
sample presented was that for SH-SY5Y cells and represents the same 
observation seen from Western blots with media for A7r5, TM4 and COS-7 
cells. The expected position of 66kDa protein bands is as indicated on the left 
and applies to all five images. Amounts of total protein loaded in each lane 
were 20µg (A7r5, SH-SY5Y), 15µg (TM4), 1µg (media) and 2.5µg (BSA).  
The band at the 66kDa position for the BSA sample is white rather than 
black due to over-exposure. 
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5.2.6. Further Analysis of Anti-RGN Immunoreactive 66kDa Band in Adult Rat 
Testes Cytosolic Fractions & Adult Boar Sperm Total Cell Lysates  
It was of interest to find out what protein(s) were present in the unexpected 66kDa 
band recognised by anti-RGN via Western blotting with samples from adult rat testes 
and adult boar sperm. The anti-RGN-recognised 66kDa bands from these two samples 
were unlikely to be explained as products of non-specific immunoreactivity  
by the antibody recognising albumin in the same way as done for the total cell lysates 
from cultures of the four established cell lines tested. This is because of a difference 
in the methods of sample preparation for these two sets of samples, whereby intact rat 
testes and boar sperm were not surrounded in media supplemented with FBS, which 
contains a high content of BSA, when collected for homogenisation/lysis. Rat testes 
were only contaminated with traces of blood, in the same way as the other six rat 
organs used in the present study and yet, unlike testes, those other organs did not 
produce 66kDa anti-RGN immunoreactive bands on their Western blots. Boar sperm 
cells were collected from unmodified whole ejaculate. 
 FT-ICR was used to identity the contents of the anti-RGN immunoreactive 
66kDa protein band. Figure 5.2.6.1 shows a Coomassie-stained gel of all protein 
present in adult rat testes and adult boar sperm samples. These bands were expected to 
contain both anti-RGN immuno-reactive and non-immunoreactive proteins. The 
intensity of their 66kDa Coomassie-stained bands were compared to the 66kDa 
chemiluminescent bands on their Western blots (figure 5.2.5.1). The boar sperm 
sample was subsequently chosen for FT-ICR analysis because these two bands for 
this sample were more similar in their intensities. Whereas the Coomassie-stained 
band for the rat testes sample was more intense than its chemiluminescent equivalent, 
which suggested its FT-ICR analysis was likely to identify more proteins that were 
not even recognised by the anti-RGN antibody compared to the boar sperm sample. 
 The FT-ICR data for the 66kDa protein band from total cell lysate of adult 
boar sperm (figure 5.2.6.1) did not show the presence of RGN at all, which means the 
protein band recognised by anti-RGN in this sample was unlikely to have been a RGN 
isoform or splice variant, and neither was it RGN protein that had somehow 
aggregated even after SDS-PAGE treatment. BLAST analysis of RGN’s amino acid 
sequence did not result in a list of sequence-similar proteins that included any of the  
 
  183 
 
 
Accession # 
# 
Peptides 
MW 
[Da] 
Description 
gi178056512 127 70300 heat shock 70kDa protein 1-like 
[Sus scrofa] 
gi47522774 79 84722 90-kDa heat shock protein [Sus 
scrofa] 
gi112980819 41 54812 mitochondrial succinate 
dehydrogenase complex subunit A 
[Sus scrofa] 
gi89574201 36 59032 succinate dehydrogenase complex 
subunit A [Sus scrofa] 
gi194039391 45 83201 PREDICTED: heat shock 90kD 
protein 1, beta [Sus scrofa] 
gi194042324 33 99816 PREDICTED: similar to hexokinase 
1, partial [Sus scrofa] 
gi194043853 23 0 PREDICTED: galactosidase, beta 
1-like [Sus scrofa] 
gi194033595 20 73768 PREDICTED: heat shock 70kDa 
protein 5, partial [Sus scrofa] 
gi51592133 21 68406 ATPase, H+ transporting, 
lysosomal V1 subunit A [Sus 
scrofa] 
gi833798 23 69366 albumin [Sus scrofa] 
Figure 5.2.6.1. SDS-PAGE & FT-ICR Identification of 66kDa 
Protein Band: Adult Rat Testes Cytosolic Fraction & Adult Boar 
Sperm Total Cell Lysate 
 
In the Coomassie-stained SDS-PAGE gel (left), 25µg and 30µg of total 
protein were loaded into each lane for the rat testes cytosolic fraction and 
boar sperm total cell lysate, respectively. The expected position of 66kDa 
protein bands is indicated. The 66kDa band for boar sperm total cell 
lysate was used for FT-ICR analysis (right) of its protein contents in an 
attempt to determine the antigen of anti-RGN in this region of a Western 
blot. The top ten proteins with the most protein fragments detected of 
them are shown (in order of descending abundance from top to bottom of 
the list). Note that this list does not indicate which protein was 
recognised by anti-RGN antibody and the most abundant was not 
necessarily the antigen. 
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proteins identified by FT-ICR analysis. Boar albumin was however detected by FT-
ICR as the tenth most abundant protein in the 66kDa protein band from adult boar 
sperm total cell lysate. This would be the most likely antigen for anti-RGN in this 
sample if taking into consideration the data that has been discussed in section 5.2.5, 
where it appeared anti-RGN had recognised 66kDa bands that most likely had 
belonged to BSA in the media of A7r5, TM4 and SH-SY5Y cells (figure 5.2.5.3). 
 Even though cytosolic fraction samples from adult rat testes were deemed 
unsuitable for FT-ICR analysis, they were still subject to further additional 
experiments in an attempt to find out whether or not its 66kDa protein band 
recognised by anti-RGN did contain RGN in some unusual form. One possibility 
considered was that the 66kDa band detected in Western blots of this sample 
contained RGN that had disulphide-bonded together to form dimers, and hence 
produced chemiluminescent bands that were double the expected molecular mass. 
This would seem unlikely due to the presence of 2-β-mercaptoethanol in SDS-PAGE 
sample buffer that is meant to break all disulphide bonds in proteins. Though it could 
have been possible that the amount of 2-β-mercaptoethanol used to prepare the total 
cell lysate of rat testes for SDS-PAGE was insufficient to break some of the 
disulphide bonds present in the RGN proteins of this particular sample.  
 Thus Western blots were done with rat testes samples that contained different 
amounts of 2-β-mercaptoethanol, within the range of 5% (i.e. normal content in SDS-
PAGE sample buffer) to 50%. Such Western blots, however, failed to show any 
difference in outcome for this cytosolic fraction sample (data not shown). Thus it was 
concluded that anti-RGN had recognised a non-specific 66kDa protein in adult rat 
testes and RGN protein had not been detected in this sample.  
 
5.2.7. Fluo-4-Based Ca2+ Measurements in Single COS-7 Cells Transfected with 
hSMP30-pcDNA3.1(-) & Control pcDNA3.1(-) Plasmids 
COS-7 cells transfected with the hSMP30-pcDNA3.1(-) plasmid to over-express 
human RGN, which were utilised to test anti-RGN’s ability to detect RGN (section 
5.2.4), were used to study the effects of RGN on Ca2+ mobilisation in intact single 
cells using Ca2+-sensitive, cell-permeable fluorescent dye, Fluo-4 AM. COS-7 cells 
transfected with pcDNA3.1(-) plasmid DNA without the RGN mRNA coding 
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Figure 5.2.7.1. Thapsigargin-Stimulated Ca2+ Transients in COS-7 
Cells Transfected with hSMP30-pcDNA3.1(-) & Control pcDNA3.1(-) 
Plasmids  
Each trace represents mean data calculated from 25 cells. Data from both 
hSMP30-pcDNA3.1(-) (“RGN”) and control pcDNA3.1(-) (“CONTROL”) 
COS-7 transfects are shown. Cells were stimulated with 1µM thapsigargin 
at the 60-second time point, in either the presence (“+ Ca2+”) (n=4) or 
absence (“- Ca2+”) (n=5) of extracellular Ca2+.   
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Figure 5.2.7.2. Histamine-Stimulated Ca2+ Transients in COS-7 Cells 
Transfected with hSMP30-pcDNA3.1(-) & Control pcDNA3.1(-) 
Plasmids  
Each trace represents mean data calculated from 25 cells. Data from both 
hSMP30-pcDNA3.1(-) (“RGN”) and control pcDNA3.1(-) (“CONTROL”) 
COS-7 transfects are shown. Cells were stimulated with 10µM histamine at 
the 60-second time point, in either the presence (“+ Ca2+”) (n=4) or absence 
(“- Ca2+”) (n=5) of extracellular Ca2+.  
+ Ca2+ + Ca2+ 
- Ca2+ - Ca2+ 
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Figure 5.2.7.3. Mean Heights of Peak Ca2+ Response to Thapsigargin & 
Histamine in hSMP30-pcDNA3.1(-) & Control pcDNA3.1(-) COS-7 
Transfects 
 
  188 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2.7.3. Mean Heights of Peak Ca2+ Response to Thapsigargin & 
Histamine in hSMP30-pcDNA3.1(-) & Control pcDNA3.1(-) COS-7 
Transfects 
Each bar represents mean data calculated from experiments in either the 
presence (“+ Ca2+”) or absence (“- Ca2+”) of extracellular Ca2+ for responses 
to 1µM thapsigargin (top) or 10µM histamine (bottom). Values from both 
hSMP30-pcDNA3.1(-) (“RGN”) and control pcDNA3.1(-) (“CONTROL”) 
COS-7 transfects are shown. Error bars represent S.E.M and * indicates 
where P<0.05 compared to control pcDNA3.1(-) transfects, according to 
two-sample equal variance Student’s T-test. Peak heights were measured 
from basal F/F0 to maximum peak F/F0 at traces of Ca2+ transients (figure 
5.2.7.1 and 5.2.7.2). 
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sequence were used as controls. 
 Figure 5.2.7.1 shows the mean Ca2+ transients that were measured from 
hSMP30-pcDNA3.1(-) and control pcDNA3.1(-) COS-7 transfects in response to 
1µM thapsigargin, in both the presence and absence of extracellular Ca2+, and thus 
show the potential effect of RGN on SERCA-specific Ca2+ mobilisation. Equivalent 
data is given in figure 5.2.7.2 for COS-7 cell responses to 10µM histamine, which 
reflect the effect of RGN on hormone-induced Ca2+ movement via an in vivo 
signalling cascade. In all cases, Western blotting with anti-RGN was used to ensure 
all hSMP30-pcDNA3.1(-)-transfected cells used for Fluo-4 microscopy experiments 
did indeed over-express RGN and all control pcDNA3.1(-)-transfected cells did not 
(data not shown). 
Analysis of the data presented here appear to show very little or no difference 
between RGN-over-expressing and control COS-7 cells with regards to their response 
timing, profile shape and duration to both thapsigargin and histamine, and both in the 
absence and presence of extracellular Ca2+. However, there did seem to be some 
difference between the peak heights of response relative to basal Ca2+ levels, 
especially with both thapsigargin and histamine responses that occurred in the 
absence of extracellular Ca2+. This observation was looked into further by measuring 
the mean peak heights of responses from all sets of eight graphs presented in figures 
5.2.7.1 and 5.2.7.2, the values of which are given in figure 5.2.7.3 along with their 
S.E.Ms.  
Student’s T-test analysis of these mean peak heights was done to test the 
significance of any difference in these values between RGN-over-expressing and 
control COS-7 cells for all four experimental conditions tested. From this, it was 
found that differences in mean peak height values measured from 1µM thapsigargin 
and 10µM histamine response did show significant difference in the absence, but not 
in the presence, of extracellular Ca2+. In the absence of extracellular Ca2+, mean peak 
heights of response to 1µM thapsigargin were 0.7 ± 0.05 for RGN-over-expressing 
cells and 0.5 ± 0.04 for control transfects, thus RGN over-expression increased 
maximal amount of thapsigargin-induced Ca2+ release by, on average, 40%. Whereas 
mean peak heights of response to 10µM histamine, again in the absence of 
extracellular Ca2+, were 0.8 ± 0.05 for RGN-over-expressing cells and 1.1 ± 0.05 for 
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control cells, thus RGN over-expression decreased maximal amount of histamine-
induced Ca2+ release by, on average, 27%.  
 
5.2.8. Immuno-detection of RGN in hSMP30-pcDNA3.1(-) & Control 
pcDNA3.1(-) COS-7 Transfects 
Anti-RGN was used with anti-rabbit FITC-conjugated antibody to identify the 
localisation of over-expressed RGN in hSMP30-pcDNA3.1(-)-transfected COS-7 
cells, with pcDNA3.1(-)-transfected cells as controls, using fluorescence microscopy. 
The images obtained (figure 5.2.8.1) showed fluorescence levels were visually higher 
overall for hSMP30-pcDNA3.1(-)-transfected cells than control cells, which further 
supported the finding from Western blots (figure 5.2.4.2) that the transfection method 
used gave successful RGN over-expression in COS-7 cells. The distribution pattern of 
fluorescence within hSMP30-pcDNA3.1(-)-transfected COS-7 cells suggested over-
expressed RGN within these cells appears to concentrate in and around the nucleus, 
with some diffuse cytosolic localisation too, which agrees with data from previous 
publications (Yamaguchi et al., 1991, Fujita, 1999, Maia et al., 2009, Nakagawa and 
Yamaguchi, 2006). Fluorescence detected at control cells, which showed to not 
express RGN on Western blots, was interpreted as background labelling. This 
observation in control transfects was possible due to the detection of 66kDa non-
specific protein in samples from the same cells (as discussed in section 5.2.5).  
 
5.2.9. SERCA Expression Levels in COS-7 Cells Over-Expressing Human RGN 
Endogenous SERCA protein levels in COS-7 cells, which were either transfected with 
hSMP30-pcDNA3.1- or control pcDNA3.1- plasmid, were examined using Western 
blotting (figure 5.2.9.1) with three samples from three pairs of human RGN-over-
expressing and control cells. Analysis of their SERCA Western blot protein bands 
showed cells that over-expressed human RGN expressed, on average, 20.8 ± 7.3% 
more SERCA than control cells. Student’s t-test showed this was significant with the 
use of three pairs of samples (P<0.05). 
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Figure 5.2.8.1. Localisation of Anti-RGN in COS-7 Cells Transfected with 
hSMP30-pcDNA3.1(-) & Control pcDNA3.1(-) Plasmids 
 
COS-7 cells transfected with hSMP30-pcDNA3.1(-) (“RGN”) and control 
pcDNA3.1(-) (“CONTROL”) plasmid DNA were fixed with formaldehyde, 
permeabilised with Triton X100 and incubated with antibodies at dilution 
ratios of 1:50 (anti-RGN) and 1:200 (anti-rabbit FITC conjugate). Anti-RGN 
localisation was identified by detection of FITC fluorescence in treated cells 
using a fluorescence microscope. Images were captured at x200 magnification. 
Whiter brightness represents larger amount of localisation of antibodies.   
 
COS-7 cells were seeded and transfected in the same manner as the cells that 
were used for Fluo-4 microscopy experiments. Cells were seeded at density of 
1x105 cells per coverslip, transfected 24 hours later using a 1.5µg:4.5µl ratio of 
plasmid DNA-to-transfection reagent. Coverslips were used 48 hours after 
transfection. 
RGN CONTROL 
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Figure 5.2.9.1. Endogenous SERCA Expression Levels in COS-7 Cells 
Transfected with hSMP30-pcDNA3.1(-) & Control pcDNA3.1(-) 
Plasmids 
 
Total cell lysates from COS-7 cells transfected with either hSMP30-
pcDNA3.1(-) (“RGN”) or control pcDNA3.1(-) (“Control”) plasmids were 
probed with anti-SERCA Y1F4 (left; “SERCA”) and anti-RGN (right; 
“RGN”) antibodies. The two images shown represent Western blot protein 
bands detected from the same pair of samples. In both cases, 20µg of total 
protein were loaded at each lane. Molecular masses of protein bands were 
approximately 100kDa and 33kDa, as expected for SERCA and RGN, 
respectively. 
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5.2.10. Optimisation of Rat RGN Expression: Attempt to Express Soluble 
Recombinant Protein in BL21 Cells 
After noting the effects of human RGN in COS-7 cells on the intensity of their Ca2+-
mediated responses to 1µM thapsigargin and 10µM histamine, an attempt was 
initiated to produce correctly folded recombinant rat RGN protein using the BL21 
expression system that was used to produce the custom-made anti-RGN’s antigen 
(section 5.2.2). It was intended that purified and correctly folded recombinant rat 
RGN could be used in further studies to examine the details behind its role in Ca2+ 
signalling, as a follow up to the results obtained with human RGN-over-expressing 
COS-7 cells.  
IPTG stimulates recombinant protein expression in BL21 cells transformed 
with pET21a plasmids, containing coding sequences inserted into their multi-cloning 
sites, by inducing expression of bacterial T7 RNA polymerase, which binds to the T7 
promoter sequence adjacent to the inserted coding sequence, and subsequently 
promotes the expression of the latter (Scharff et al., 2001). An increase in IPTG 
concentration results in an increase in recombinant protein expression. However, too 
much over-expression of recombinant protein in the transformed BL21 cells can lead 
to the formation of inclusion bodies, which are aggregates of mis-folded protein. Thus 
different IPTG concentrations were tested for induction of rat RGN expression in an 
attempt to optimise this factor to produce soluble protein within pET21a-RGN-
transformed BL21 cells.  
 BL21 cells induced with 0.1mM IPTG were sonicated and centrifuged at 
20,000g for 20 minutes to separate inclusion bodies and cell debris from soluble 
proteins, which were analysed by SDS-PAGE and the resulting gels are shown in 
figure 5.2.10.1. Inclusion bodies were expected to be localised to the 20,000g 
centrifugation spin pellet and soluble proteins were found in the corresponding 
supernatant fraction. It was observed that over-expressed protein, which was 
represented by the most densely stained band in Coomassie blue stained gels, was 
33kDa in molecular mass and thus likely to have been rat RGN (Yamaguchi, 2005). 
This identity of the heavily expressed 33kDa protein was confirmed later on using 
anti-Hisx6 antibody to successfully detect Hisx6-tagged RGN by Western blotting 
(figure 5.2.3.1). Other IPTG concentrations for induction of pET21a-RGN-
transformed BL21 cells grown at 37oC, within the range of 0.01-0.5mM, were tested 
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Figure 5.2.10.1. Production of Recombinant Rat RGN from 
pET21a-RGN-Transformed BL21 Cells After IPTG Induction 
 
Samples shown here were collected from a culture of pET21a-RGN-
transformed BL21 cells induced with 0.1mM IPTG at 0, 1, 2 and 4 
hours after induction started. The culture was grown at 37oC. For each 
sample, total cell lysates of sonicated cells (isolated from culture media 
by centrifugation) were centrifuged at 20,000g, and the resulting 
supernatant (“SN”) and pellet (“PL”) were subjected to SDS-PAGE. 
 
A lane of protein molecular weight markers is shown on the left. Lanes 
containing samples of pellets and supernatants with their associated 
incubation times are labelled. The expected position of 33kDa protein 
bands is indicated. All samples were loaded at equal volumes in each 
lane.     
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to try and make the cells produce recombinant rat RGN that would be correctly folded 
and thus not form inclusion bodies. However, even at the lowest concentration of 
IPTG tested (0.01mM), over-expression of the 33kDa protein appeared to start 
approximately 1 hour after induction and most of it was detected in the 20,000g spin 
pellets of BL21 cell lysates, while none appeared in their counterpart supernatant 
(data not shown). 
 A lower culture temperature of 17oC following IPTG addition to their media 
was also tried in an attempt to slow down recombinant protein production to 
encourage their correct folding within BL21 cells. This has been shown in the past to 
improve yields of soluble recombinant protein expression (Sheng et al., 2007). 
Although the rate of recombinant RGN expression was indeed slower at 17oC 
compared to 37oC, the protein was still being expressed in the form of inclusion 
bodies regardless of duration of culture time after IPTG addition and IPTG 
concentration used for induction, according to SDS-PAGE analysis (data not shown). 
Temperature shock treatments prior to the addition of IPTG to BL21 cultures were 
also tried, which involved heating cultures to 42oC or cooling them to ice-cold 
temperatures to induce the expression of endogenous chaperones in the BL21 cells. 
This has been shown in previous studies to be possible and the chaperones can aid 
correct folding of recombinant proteins (Wick and Egli, 2004). However, the 
inclusion bodies persisted to still be produced even after these methods were tried. 
Thus none of the conditions tested in the process of optimising the expression of 
soluble recombinant protein within pET21a-RGN-transformed BL21 cells were able 
to promote correct folding of Hisx6-tagged rat RGN in these cells. 
 
5.2.11. Ni2+ Affinity Column Chromatography with Solubilised Inclusion Bodies 
of Recombinant Rat RGN Protein 
The purification and solubilisation of inclusion bodies, along with attempts to refold 
them in vitro, were tried after unsuccessful attempts to promote production of 
recombinant RGN protein in soluble form within BL21 cells. Figure 5.2.11.1 shows a 
SDS-PAGE gel of samples collected in the process of isolating inclusion bodies from 
IPTG-induced BL21 cells and the use of Ni2+ resin, which has a high binding affinity 
for Hisx6-tags, to purify Hisx6-tagged recombinant RGN. The inclusion bodies were  
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Figure 5.2.11.1. Binding of Solubilised RGN Inclusion Bodies to Ni2+ Resin 
 
Binding of rat RGN solubilised inclusion bodies to Ni2+ resin was tested using 
column chromatography. The inclusion bodies were isolated from cultures of 
pET21a-RGN-transformed BL21 cells that were induced with 0.25mM IPTG 
and grown overnight at 17oC.   
 
 Fractions from Ni2+ affinity column chromatography with 8M urea-solubilised 
inclusion bodies are shown, whereby the samples are labelled with the pH of 
buffer used to elute them off the column (two lanes are shown for each 
sample). A lane of protein molecular weight markers is shown on the left. The 
expected position of 33kDa protein bands is indicated. All samples were 
loaded at equal volumes in each lane. 
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isolated by treating 20,000g spin pellets (from centrifugation of sonicated IPTG 
induced BL21 cells for 20 minutes) with 8M urea, followed by centrifugation at 
100,000g for 45 minutes, to solubilise and separate them from most of the 
contaminating proteins and cell debris also present in the 20,000g spin pellet.  
 Furthermore, incubation of these solubilised inclusion bodies with Ni2+ resin, 
using column chromatography, demonstrated the ability of its abundant 33kDa protein 
content to bind to such resin, as well as appear in the pH 6.2 and, to a smaller extent, 
pH 4.5 column eluants but not that of pH 8.0. This confirmed the inclusion bodies 
consisted of Hisx6-tagged RGN protein and demonstrated the use of Ni2+-affinity 
column chromatography could be used to concentrate and further purify this protein 
after solubilisation of its mis-folded form among cell debris. Even though more 
recombinant RGN was expected to be found in the pH 4.5 elution fraction rather than 
the pH 6.2 wash fraction, the latter of which elutes weakly bound protein, the pH 6.2 
wash fraction contained only 33kDa protein according to SDS-PAGE analysis and so 
was still used for refolding experiments due to the visible absence of contaminants.  
 
5.2.12. Refolding of Purified Rat RGN: Use of Dialysis & Dilution to Refold 
Solubilised Inclusion Bodies 
Following successful purification of Hisx6-tagged RGN by solubilisation of inclusion 
bodies and use of Ni2+ affinity column chromatography to remove contaminating 
proteins, the next step that had to be optimised was the refolding of the urea-
solubilised Hisx6-tagged protein. Two methods of refolding were tested, which were 
one-step dialysis and crash dilution (Tsumoto et al., 2003). Both worked by dilution 
of urea away from the protein, thus removing the denaturing effect of the former and 
allowing the latter to spontaneously fold. Dialysis allows a slower process of 
refolding than dilution. Both methods were tried because it was unknown which 
method would suit Hisx6-tagged rat RGN protein best.  
Use of the wrong conditions for protein folding led to the formation of 
precipitated protein, which was indicated by visible white precipitant or cloudiness of 
the protein solution. Precipitation of mis-folded protein was often observed following 
dialysis of samples that were high in protein concentration, which would have 
resulted in crowding and interaction between different peptides during the process of 
refolding. Thus Ni2+ affinity chromatography column fractions that were used for 
dialysis refolding of purified Hisx6-tagged protein were diluted to a concentration of 
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0.2mg/ml before being dialysed. Refolding by dilution method involved rapidly 
diluting the pH 6.2 column fraction (abundant in 33kDa protein) by adding refolding 
buffer to it to give a final protein concentration of 0.1mg/ml, before being dialysed to 
remove glycerol and DTT in the dilution buffer to further aid refolding.  
Glycerol and DTT were added to refolding buffers for both dialysis and 
dilution methods. The use of glycerol was included to reduce the chance of protein 
aggregation. DTT was included because analysis of recombinant rat RGN amino acid 
sequence showed it contains ten cysteine residues and thus it is possible the structure 
of this protein requires the formation of disulphide bridges. The presence of DTT was 
expected to prevent disulphide bridges from forming while the protein refolded into 
its correct tertiary structure before DTT was diluted away to allow the correct 
disulphide bridges to form only when the protein was in the correct tertiary structure. 
DTT concentrations used were 0.5mM for dialysis refolding and 5mM for crash 
dilution refolding. After all refolding attempts, the protein contents of samples were 
concentrated with the use of Vivaspin centrifugal concentrators to allow for them to 
be used in further analysis, such as circular dichroism spectroscopy.  
 
5.2.13. Circular Dichroism Analysis of Refolding Success for Recombinant Rat 
RGN 
Two samples of recombinant rat RGN protein solutions, one for each of the refolding 
methods used as discussed above (section 5.2.12), were subjected to circular 
dichroism (CD) spectroscopy in order to give an indication of whether or not they had 
correctly folded. Both samples consisted of a pH 6.2 fraction from Ni2+ column 
chromatography treatment of 8M urea solubilised inclusion bodies from pET21a-
RGN-transformed BL21 cells, which had been induced with 0.25mM IPTG and 
cultured overnight at 17oC. SDS-PAGE was used to ensure the pH 6.2 fractions did 
indeed contain only 33kDa protein (data not shown).  
 CD spectroscopy was used to identity the protein secondary structures present 
in the two protein samples and indicate how ordered those protein structures were 
overall. The CD spectra that were obtained from analysis of both samples (figure 
5.2.13.1-2) are given. Control CD spectra from fresh dialysis buffer (in which the 
protein solutions were dialysed to remove Cl- in their preparation for CD 
spectroscopy) without protein was also collected after experiments with each protein  
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Figure 5.2.13.1. CD & Light Absorbance Spectra From CD Experiments 
with One-Step Dialysis-Refolded Recombinant Rat RGN 
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Figure 5.2.13.1. CD & Light Absorbance Spectra From CD 
Experiments with One-Step Dialysis-Refolded Recombinant Rat RGN 
 
(A) CD spectrum collected for the protein sample was corrected by 
subtracting values from spectrum (B), which was the control CD collected 
from buffer alone, and all values were normalised to the baseline value at 
260nm. (C) Absorbance spectrum for the protein sample, which resembles 
that for buffer control and values for both were all at or below 600V 
throughout the 260-190nm wavelength range of polarised light used.  
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Figure 5.2.13.2. CD & Light Absorbance Spectra From CD Experiments 
with Crash Dilution-Refolded Recombinant Rat RGN 
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Figure 5.2.13.2. CD & Light Absorbance Spectra From CD 
Experiments with Crash Dilution-Refolded Recombinant Rat RGN 
 
(A) CD spectrum collected for the protein sample was corrected by 
subtracting values from spectrum (B), which was the control CD 
collected from buffer alone, and all values were normalised to the 
baseline value at 260nm. (C) Absorbance spectrum for the protein 
sample, which resembles that for buffer control and values for both were 
all below 600V throughout the 260-190nm wavelength range of polarised 
light used.   
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solution and used to correct the spectra values of the latter to subtract any effects from 
the buffer solution alone. Light absorbance spectra were also recorded for each and all 
experiments to monitor the linearity of polarised light absorbance by the samples, 
whereby CD data collected at any point when absorbance values were greater than 
600V was deemed unreliable due to loss of linearity in the effects of polarised light on 
the protein sample detected. The 600V threshold is a standard value used for all CD 
experiments (as advised by Dr. T. Dafforn, The University of Birmingham).  
 Taking into consideration the standard guidelines of how to read CD spectra 
based on the values and intensities of minimum/maximum peak values (Fasman, 
1996), spectra for both samples can be interpreted to show the protein structures in 
these samples contained a mixture of β-sheets and α-helices due to the broadness of 
the single minimum negative peak value around 210nm in both cases. The CD 
spectral region between 190-200nm needed to show a maximum positive peak value 
that was at least the same intensity as that of the minimum negative value to suggest it 
was well folded. This was almost the case for dialysis-refolded protein but far less so 
for dilution-refolded protein. The negative maximum peak value for the latter sample 
suggests it contained partially unfolded protein. From qualitative analysis of the 
spectra, dialysis-refolded protein was likely to have contained less mis-folded protein 
and thus appears to be the better method of refolding. 
Note that both CD spectra showed some resemblance to that first collected by 
Yamaguchi (Yamaguchi, 1988). However, the CD spectroscopy method that was used 
in this early study is questionable due to the use of 50mM Tris-HCl buffer, which was 
likely to have interfered with light absorbance by the sample and thus the CD spectra 
presented may contain invalid data. Furthermore, these early spectra of RGN that had 
been isolated from rat liver tissue shows maximum negative peak values, indicating 
the protein samples contained mis-folded protein. Thus comparisons between the 
spectra from the present study and that of the earliest study on RGN’s structure with 
the use CD have to be kept to a minimum. With regards to the human RGN crystal 
structure (Chakraborti and Bahnson, 2010), the CD spectra of recombinant Hisx6-
tagged rat RGN from the present study appears to not fit the six-β-propeller barrel 
fold presented by the former. Such a highly ordered fold of predominantly β-sheets 
would have given a CD spectrum for protein with a single minimum negative peak 
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value between 210-225nm and one maximum positive peak value, of at least equal 
intensity to the minimum peak, between 190-200nm (Fasman, 1996).  
 Analysis of human RGN’s PDB file (reference number 3G4E) showed it 
contains 64% β-sheet, 1.3% α-helix and 34.7% random fold. Prediction of secondary 
structure proportions from the CD spectra obtained in the present study using an 
online analysis program, K2D2, suggested the dialysis-refolded protein contained 
30.8% β-sheet, 16.0% α-helix and 53.2% random fold. Whereas K2D2 predicted the 
dilution-refolded protein contained 44.5% β-sheet, 3.7% α-helix and 51.8% random 
fold. Although the dilution-refolded protein appeared to have more predicted β-sheet 
than dialysis-refolded protein, the predicted fit of the CD spectra was not as good for 
the former as it was for the latter (figure 5.2.13.3) and thus the dialysis-refolded 
protein still remained the better-folded sample. Though neither protein samples had 
secondary structure predictions that matched the values given by the human RGN 
crystal structure, which again strongly suggests the recombinant rat RGN produced in 
the present study had not been folded correctly. Note that the crystal structure shows 
RGN bound to Ca2+, whereas the recombinant rat RGN produced and refolded in the 
present study was in the absence of Ca2+. It is possible that in the absence of Ca2+, 
RGN’s structure is less well ordered than when bound to Ca2+.  
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Figure 5.2.13.3. K2D2 Prediction of Secondary Structure in 
Samples of One-Step Dialysis & Crash Dilution Refolded 
Recombinant Rat RGN  
 
Fitting of CD spectra for both one-step dialysis (“DIALYSIS”) and 
crash dilution (“DILUTION”) refolded protein samples was done by 
the K2D2 program to predict their contents of secondary structure, 
which were as stated in section 5.2.13. Data for the actual CD spectra 
(“+”) that was entered into the K2D2 program to be analysed, along 
with the ‘predicted’ spectra (“x”) that K2D2 generated to give the 
closest fit to the former in order to predict contents of secondary 
structure are shown.  
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5.3. Discussion 
 
Distribution of RGN expression has proven to not be widespread across different 
types of tissues and cells, both in previous and present research, at the mRNA and 
protein level. In agreement with previous studies, RGN was detected in samples 
derived from liver, kidney and brain from adult rat (Yamaguchi et al., 1991), whereby 
the former was notably observed as the tissue with the highest RGN abundance at 
both mRNA and protein levels out of all the samples that were tested. For lung, heart 
and skeletal muscle from adult rat, there was both agreement and disagreement with 
findings from past publications. Lung tissue has been shown to not express RGN in 
rat in both present and past (Yamaguchi et al., 2002) studies, but has been suggested 
to express RGN in mice (Mori et al., 2004). Heart has been shown to express RGN in 
some studies with rats and mice (Yamaguchi and Nakajima, 2002, Doran et al., 2006), 
whilst none have been detected in rats in other studies (Yamaguchi et al., 1991, 
Yamaguchi and Isogai, 1993, Yamaguchi et al., 2002). Though it has recently been 
suggested that RGN expression levels can vary with age in the heart (Akhter et al., 
2007, Lim et al., 2009), which is supported by the present study because RGN mRNA 
was detected in a sample from juvenile, and not adult, rat heart. Skeletal muscle was 
shown to not express RGN in the present study, which conflicts with a previous study 
that did detect RGN protein in samples of mice limb muscle (Doran et al., 2006) but 
does agree with another study that could not detect RGN protein in rat muscle 
samples (Yamaguchi et al., 2002). In the case of lungs and skeletal muscle, this 
altogether suggests a possible difference in distribution of RGN in rats and mice, 
which are expected to use RGN differently because only mice is likely to use RGN 
for vitamin C biosynthesis (whereas rats cannot synthesise their own vitamin C). 
 
Fat pads from adult rat have not been screened in past studies, though rat adipose 
tissue has been shown to be able to express RGN mRNA (Yamaguchi and Nakagawa, 
2007). In the present study, it has been shown that rat fat pads do not express RGN at 
the protein level. Although both rat brain (Yamaguchi et al., 1999) and heart 
(Yamaguchi and Nakajima, 2002) have been demonstrated in past studies to express 
RGN, distribution of abundant RGN levels at specific regions within these two organs 
of rat has not been demonstrated before. For brain tissue, samples from mice have 
been previously used to show RGN expression can be detected specifically in the 
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cerebrum (Mori et al., 2004). While the cerebral cortex and hippocampus of rat brain 
has been tested in the past and found to express virtually no RGN protein (Yamaguchi 
and Isogai, 1993). In the present study, it was shown that RGN mRNA is detectable in 
the cerebellum of adult rat brain and aorta of adult rat heart.  
 
After screening for RGN mRNA expression levels in a range of samples from various 
rat tissues, the focus of interest with regards to RGN distribution in tissues became the 
male reproductive organs. At the mRNA level, strong levels of RGN expression were 
detected in multiple samples from rat testes. However, RGN was not detected at the 
protein level in the present study with rat tissue samples. The amount of RGN 
expressed in testis has yet to be made clear due to differences in the data presented in 
past studies. Immunofluorescence experiments have shown RGN is not expressed in 
rat testis (Yamaguchi et al., 1991), ELISA experiments have shown RGN can be 
detected but at levels 2000-fold lower than that found in rat liver and at ng/mg of 
tissue concentrations (Yamaguchi and Isogai, 1993), and PCR experiments have 
shown RGN mRNA is detectable in mice testis at the mRNA level (Mori et al., 2004).  
 
With regards to the discrepancy between RGN detection at the mRNA and protein 
levels with samples from adult rat testis in the present study only, a possible 
explanation could be made from the age dependence of RGN expression that has 
already been demonstrated for other tissues, such as the liver and kidney (Fujita et al., 
1996). In the present study, RGN mRNA was detected in both juvenile and adult 
testis samples, which originated from rats that were 5 days and 5 weeks old, 
respectively. However, tissues samples (used for RGN detection at the protein level in 
the present study) were prepared from intact testis that had been obtained from adult 
rats much older than 5 weeks old. Thus the conflict between RGN detection at mRNA 
and protein levels observed in the present study could be a demonstration of RGN’s 
age dependence in its expression in rat testis, whereby the RGN abundance decreases 
with increasing age. The possibility of RGN expression levels being affected by age 
in the testis of male rats, which could potentially also be the case for humans, has not 
been suggested in the past. On the other hand, another possible explanation could be 
that there is a difference in expression rate or turnover of RGN between the mRNA 
and protein levels. Thus RGN expression may be more stable at the mRNA level than 
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protein level, which would make detection of the former more successful than the 
latter, as demonstrated in the present study. 
 
In addition to RGN expression levels found in rat testis, RGN mRNA had also been 
detected in the present study within samples from germ cells, myeloid cells and 
Sertoli cells, all of which are specialised cell types found in the male reproductive 
system. The expression of RGN in these specific cell types has never been noted in 
past publications. One specialised tissue type of the male reproductive system of rats 
that has been noted to express RGN in a past study is the prostate (Maia et al., 2009).  
It was the detection of RGN mRNA in the cell types tested in the present study, along 
with testis, of both adult and juvenile male rats that led to experiments with adult boar 
sperm, with the intention of seeing whether RGN is also expressed in sperm. In the 
end, it was concluded that RGN could not be detected in adult boar sperm, but again 
the factor of age dependence of RGN expression could have also applied in this case.  
 
With regards to normal established cell-lines, RGN protein could not be detected in 
those representative of embryonic rat aorta-derived cells (A7r5), adult mice Sertoli 
cells (TM4), human brain neuroblastoma cells (SH-SY5Y) and monkey kidney cells 
(COS-7). Thus although RGN expression was successfully detected in their associated 
organs at the mRNA level (and at the protein level for brain and kidney) using 
samples from tissues that had been extracted from rats (and had not been established 
in cell culture), the same could not be said for the established cell-line equivalents, 
which is an observation that connects well with the age-dependence feature of RGN 
expression that gave this protein its alternative name, ‘senescence’ marker protein 30 
(SMP30) (Fujita, 1999). This overall finding suggests de-differentiation (a feature of 
aging and formation of established cell-lines) causes loss of RGN expression, which 
would agree with a previous study that showed RGN expression decreased in breast 
and prostate tissue as they progressively de-differentiated in the process of 
tumorigenesis (Maia et al., 2009). However, other established cell-lines have been 
noted to be able to express RGN in normal cell culture, such as the human hepatoma 
cell-line, HepG2 (Murata et al., 1997), rat hepatoma cell-line, H4-II-E (Nakajima et 
al., 1999)  and mouse osteoblastic cell-line, MC3T3-E1 (Yamaguchi et al., 2008a). 
This conflict between past and present studies may be attributed to a difference in 
control of RGN expression in established cell-lines from different tissue types, 
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whereby cell-types from certain tissues are better at retaining the ability to express 
RGN than others when de-differentiated.       
 
The absence of endogenous RGN expression and their ease of use in transfections 
made COS-7 cells an ideal model to study the effect of human RGN expression on 
Ca2+ mobilisation in intact cells. From their use, the present study demonstrated over-
expression of human RGN in COS-7 cells can influence the intensity in changes to 
their cytosolic Ca2+ levels in response to hormone stimulation and SERCA inhibition, 
which were noted to be especially visible in the absence of extracellular Ca2+. A 40% 
increase in maximal amount of thapsigargin-induced Ca2+ release and 27% decrease 
in maximal amount of histamine-induced change in cytosolic Ca2+ levels were 
observed in the present study. These values suggest RGN can increase both the Ca2+ 
storage capacity and Ca2+ uptake efficiency of the ER. Furthermore, average SERCA 
protein levels in human RGN-over-expressing cells were found to be higher than 
those in control COS-7 cells by a mean average of 20.8 ± 7.3%, which indicated RGN 
over-expression had promoted an increase in SERCA expression. This change in 
SERCA protein levels would certainly correspond well with the idea that ER Ca2+ 
storage efficiency had improved in the event of RGN over-expression, which would 
explain the observations made in intact cells regards to their thapsigargin and 
histamine responses in the absence of extracellular Ca2+. Changes in SERCA 
expression levels caused by RGN over-expression have not been demonstrated before. 
Although one past study has shown RGN over-expression in a rat kidney epithelial 
cell-line (NRK52E) can increase or decrease the mRNA expression levels of their 
endogenous L-type Ca2+ channel and Ca2+-sensing receptor (CaR) (Nakagawa and 
Yamaguchi, 2006).  
 
Two previous studies that used similar RGN over-expression experimental models 
have suggested RGN increases PMCA activity (Fujita et al., 1998, Son et al., 2008), 
which may also be the case for the present study and it is possible that increased 
PMCA activity would have caused a decreased peak height of Ca2+-mediated 
response to histamine. However, increased PMCA activity would not account for an 
increased peak height of Ca2+ release from thapsigargin treatment. The absence of 
visible difference in intensity, shape and duration of Ca2+-mediated responses 
between RGN-over-expressing and control COS-7 cells in the presence of 
  211 
extracellular Ca2+, for both response to thapsigargin and histamine, would also argue 
against PMCA having any significant effect in the event of RGN over-expression in 
COS-7 cells. However, an influx of extracellular Ca2+ (possibly by, for example, 
store-operated Ca2+ entry) from Ca2+-supplemented media could have obscured the 
effects of PMCA. This would make higher than normal PMCA activity detectable, in 
the form of a decreased height in Ca2+-mediated response to histamine, only in the 
absence of extracellular Ca2+.  
 
It should also be noted that one of these two past studies also showed RGN over-
expression does not affect cellular response to thapsigargin (Son et al., 2008), which 
would conflict to observations from the present study. This discrepancy is likely to be 
attributed to a difference in experimental procedures, whereby the past study in 
question had only monitored the first 60 seconds of thapsigargin response in 
population-based studies, whereas the present study monitored thapsigargin-
stimulated Ca2+-transients from single cells for 4 minutes after thapsigargin was 
added to them. It should also be noted that past studies have shown RGN can increase 
SERCA activity in kidney (Kurota and Yamaguchi, 1997), liver (Yamaguchi and 
Mori, 1989) and heart (Yamaguchi and Nakajima, 2002). Observations made of over-
expressed RGN’s ability to weaken Ca2+-mediated hormone response and strengthen 
Ca2+ uptake by up-regulating SERCA connect well with RGN’s age-dependent 
pattern of expression. This is because SERCA expression has also been shown to be 
age-dependent (Periasamy and Kalyanasundaram, 2007).  
  
In light of recent determination of human RGN’s Kd value for Ca2+, which has been 
stated to be 0.57mM, it is unlikely RGN mediates its effects at the cytosol because 
cytosolic Ca2+ levels would only reach this concentration in the event of apoptotic cell 
death and not when responding to hormone stimulation. However, Ca2+ 
concentrations in the ER and mitochondria can reach up to 0.5mM in stimulated cells 
(at least in HeLa cells) (Pinton et al., 1998, Vay et al., 2009). RGN has not been 
previously been shown to localise in the ER, though would exist in this organelle 
during its synthesis. This is in contrast to the mitochondria (Yamaguchi et al., 2008b). 
However, any effects that RGN over-expression may have had on mitochondrial Ca2+ 
storage is most likely to have been indirect (for example via its linkage with the ER) 
at least according to the present study because immunofluorescence experiments were 
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unable to detect specific RGN localisation at the mitochondria. It should be noted that 
RGN has been shown to be able to increase mitochondrial Ca2+ uptake (Takahashi 
and Yamaguchi, 2000) and that aging leads to a decrease in this activity of the 
mitochondria (Beal, 2005), which would correlate well with age-dependent decrease 
in RGN expression (Fujita et al., 1996). 
 
According to past studies, it is possible for RGN to localise in the lumen of the 
nucleus (Nakagawa and Yamaguchi, 2008) and influence gene transcription levels 
(Yamaguchi, 2000b). This would correspond well with the observation of both RGN 
localisation at the nucleus and increased SERCA protein levels in RGN-over-
expressing cells. However, for any effects of RGN on SERCA expression to be Ca2+-
related, the over-expression of RGN must have had to increase the Ca2+-storage 
capacity of the nucleus because a past study has shown the nuclear luminal free Ca2+ 
level is 0.1µM (at least in HeLa cells) (Badminton et al., 1996), which is 5700 times 
lower than RGN’s Kd for Ca2+-binding. Otherwise, alteration of SERCA expression 
levels caused by RGN over-expression is unlikely to have been caused by increased 
Ca2+ storage capacity at the nucleus. An increase in Ca2+-storage capacity at the 
nucleus could have also meant this organelle contributed to the effects of Ca2+-
mediated responses seen for thapsigargin and histamine.  
 
To aid future studies, the availability of a fully functional recombinant rat RGN 
would be useful in, for example, studies with isolated membranes to test RGN’s 
ability to directly interact with SERCA or PMCA. This would certainly help to further 
define the details associated with the observations made on RGN-over-expressing 
COS-7 cells discussed above. Thus the next step in the present study was to attempt to 
refold the inclusion bodies produced of recombinant rat RGN, which was used for 
anti-RGN production. To date, a Hisx6-tagged recombinant rat RGN that has been 
folded to contain all the same secondary structures of those shown to exist in the 
crystal structure of human RGN (Chakraborti and Bahnson, 2010) has yet to be 
obtained from the present study.  
 
It has been shown in past studies with recombinant forms of both human RGN (Choi 
et al., 2010b) and a diisopropylfluorophosphatase (DFP) from squid (Loligo vulgaris), 
(the latter of which is both functionally related to rat RGN (Kondo et al., 2004) and 
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also has the same tertiary fold as human RGN, (Scharff et al., 2001)) that the six-β-
propeller fold is difficult to achieve and these proteins often form inclusion bodies if 
expression in BL21 cells is not supported by either the use of protein-folding 
chaperones or an expression vector that promotes slow protein expression, 
respectively. Furthermore, it should be noted that both the crystal structure of human 
RGN and squid DFPase were produced with recombinant RGN protein that had Ca2+ 
bound to them, whereas the present study did not use refolding buffers that were 
supplemented with Ca2+ and thus the CD spectra presented here show the features of 
RGN protein not bound to Ca2+.  
 
Ca2+ has been noted to be able to alter the α-helical content of rat liver RGN 
(Yamaguchi, 1988), whereby adding Ca2+ to the protein reduces its α-helical content, 
which would support the idea that Ca2+ is required to promote the formation of β-
sheets in RGN. Though the amount of decrease in α-helical content of rat liver RGN 
in this past study was calculated to only be 4.5% in the presence of 1mM CaCl2, 
which was the same concentration of CaCl2 used throughout the purification process 
of recombinant human RGN that was used to obtain its crystal structure. This minor 
Ca2+-induced change of α-helical content in rat liver RGN would still not have 
represented a structure that was the same as that of the human RGN structure, the 
latter of which has an α-helical content of 1.3%. This difference between the two 
RGN structures may have been caused by differences in structural analysis methods 
used (modern X-ray crystallography vs. early CD spectroscopy).  
 
In conclusion, the data presented here supports past studies made on RGN expression, 
which have shown it is widely distributed across different organs, but is not expressed 
in all organs with the same abundance and it is possible the pattern of RGN 
distribution is different between mice and rats. The present study has shown RGN 
mRNA is expressed in a number of specialised cell types from the male reproductive 
system, which have not been shown previously, and suggests RGN plays a role in 
male fertility. Over-expression of human RGN has been shown, for the first time, to 
significantly influence the maximal strength of Ca2+-mediated responses to SERCA 
inhibition by thapsigargin and hormone stimulation in intact single cells. It is possible 
that this nuclear localisation of over-expressed RGN can influence SERCA 
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expression levels, which is an effect that would correlate well with the age-
dependence of both RGN and SERCA expression. Furthermore, the integrity of 
RGN’s structure is suggested to be dependent on the presence of Ca2+, whereby the 
absence of Ca2+ potentially hinders the formation of β-sheets in RGN. Further 
research will be required to refine the details behind RGN’s role in Ca2+ homeostasis, 
which may be assisted with the use of recombinant rat RGN and anti-RGN antibody 
that have been produced as part of this study.  
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CHAPTER 6.  
FINAL DISCUSSION 
 
6.1. Final Discussion – SPCA 
 
SPCA provides Ca2+ to the Golgi apparatus by acting as a Ca2+-ATPase specific to 
this organelle. The luminal Ca2+ supply of the Golgi apparatus is required for the 
modulation of activities from its contents of Ca2+-dependent enzymes, which play a 
role in post-translational modification of proteins en-route through the secretory 
pathway. Secreted proteins potentially cannot function correctly without there being 
Ca2+ present and its levels precisely regulated by SPCA in the Golgi apparatus. This is 
demonstrated in the form of HHD in human skin pathology, which is caused by 
mutations in the ATP2C1 gene that encodes SPCA. Recently, changes in SPCA 
expression levels have also been suggested to contribute to diabetes (Mitchell et al., 
2004) and neurodegenerative diseases (Sepulveda et al., 2007). 
 
SPCA1 has now been demonstrated to be sensitive to glucose homeostasis in VSMCs, 
whereby experimental glucose concentrations used to resemble those in tissues in the 
diabetic condition were able to increase both the expression and activity levels of this 
Ca2+-ATPase. How this occurs has not been elucidated, but one possibility is that 
SPCA1 expression levels can be altered by the glycosylation of its transcription 
factors. The observation of SPCA1 being sensitive to glucose levels in VSMCs fits 
well with the secretory phenotype of VSMCs in the diabetic disease state. If SPCA1 
expression and activity is also affected in the same way in diabetic humans, this could 
provide a novel drug target for treatment of this condition. 
 
Known inhibitors of SPCA now include TFP, TBBPA, 2-APB and BPA. Here it has 
been demonstrated that bis-phenol is the most potent inhibitor of human SPCA 
(isoform 1d) because it is effective at sub-micromolar concentrations and can inhibit 
100% activity of SPCA without affecting human SERCA (isoform 2b) activity at the 
same concentrations. With the knowledge of how bis-phenol is believed to affect 
SERCA and the kinetic differences between these two Ca2+-ATPases, it is possible to 
suggest bis-phenol inhibits SPCA better than SERCA because it binds to the E2 
conformation with stronger affinity in SPCA. Studies on the binding kinetics of bis-
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phenol for SPCA will be required to ascertain this. The concentration of bis-phenol 
effective at specifically inhibiting SPCA in intact cells needs to be optimised. It 
remains promising that bis-phenol can be used as a tool for future research on SPCA 
and possibly be used as a template for drug design for diseases associated with SPCA, 
such as diabetes (as suggested above). 
 
6.2. Final Discussion – RGN 
 
The importance of RGN in Ca2+ homeostasis has been debated. Past studies have 
demonstrated its ability to affect the activities of proteins involved in Ca2+ signalling, 
including Ca2+-ATPases, at the cytosol and even in organelles that store Ca2+ (nucleus 
and mitochondria). RGN has also been suggested to have other roles, including DNA-
binding (Tsurusaki and Yamaguchi, 2004) and controlling oxidative stress (Ichikawa 
and Yamaguchi, 2004). It was research associated with RGN’s role in vitamin C 
biosynthesis by acting as a gluconolactonase that brought up the argument against 
RGN’s ability to bind Ca2+. However, RGN is expressed in organisms that do not 
synthesise their own supply of vitamin C, including humans. RGN was first 
demonstrated to be able to bind Ca2+ (using early biochemical methods) at the same 
time it was presented as a novel protein. The Ca2+-binding role of RGN has also 
recently been elucidated from its crystal structure, along with its Kd for Ca2+-binding 
(0.57mM) taking away the debate of whether or not it can bind Ca2+. However, this 
low affinity for Ca2+-binding indicates this role of RGN is not important in resting 
cells when in the cytosol. 
 
It has now been further emphasised that RGN is not expressed in all tissue types. To 
add to this observation, it has also been suggested that RGN mRNA and protein levels 
in rat testis may not directly correlate with each other due to a possible difference in 
their turnover rates, and that RGN expression in this tissue type may be age-
dependent like in liver, kidney, heart and brain. Further studies on RGN expression in 
testicular tissue will be required to ascertain this. As RGN expression does occur in a 
number of different specialised cell types of the male reproductive system (in addition 
to testes and prostate), it could be involved in male fertility and therefore requires 
further research.  
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To add to the support of RGN having a role in Ca2+ homeostasis, it has now been 
shown that RGN can influence Ca2+ mobilisation in cells and is likely to do so by 
acting on SERCA. RGN over-expression experiments using COS-7 cells also indicate 
that RGN could be increasing SERCA expression levels, by acting to enhance 
transcription or remove gene repressor activity. Further studies will be required to 
refine the details behind RGN’s ability to apparently increase the capacity of ER Ca2+ 
stores and weaken Ca2+-mediated responses to hormone stimulation.   
 
6.3. Final Discussion – Future Studies on SPCA & RGN 
 
The research that has been discussed here in detail has explored SPCA’s role in Ca2+ 
homeostasis, with regards to its ability to regulate Ca2+-mediated hormone response 
(by providing the Golgi apparatus with a thapsigargin-insensitive releaseable Ca2+ 
store) in VSMCs under experimental conditions that mimic the diabetic state. For 
SPCA, the work discussed here has also shown its own activity can be specifically 
regulated, with the use of bis-phenol, in experimental systems that include the 
presence of the closely related SERCA. Though there are still plenty of questions that 
can be asked about the regulation of SPCA activity, which is an area of research that 
has yet to be fully explored. How is SPCA activity controlled endogenously in the 
cell? NAADP and cADPR have now been shown to not have any direct effects on 
SPCA. Other second messengers and even proteins, such as phospholamban and 
calmodulin, should also be tried in the future to see whether they regulate SPCA 
activity in the same way that they do for SERCA and PMCA, respectively. Can SPCA 
be post-translationally modified by, for example, by phosphorylation or nitrosylation?  
 
In the present study, the expression of RGN mRNA has now been shown for the first 
time in specialised cell types of the male reproductive system. RGN’s influence of 
Ca2+-mediated hormone response in intact cells has also now been demonstrated for 
the first time. Furthermore, both a recombinant rat RGN and anti-RGN antibody are 
now made available for future use. The former can be used to further explore the 
folding kinetics of RGN and, if successfully folded, can be used to demonstrate 
whether or not it can directly interact with proteins involved in Ca2+ homeostasis 
through direct binding experiments. The latter can be used to screen more samples 
from different cell and tissue types that have still yet to be tested for their ability to 
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express RGN in an age-dependent manner, as well as be used in experiments such as 
affinity chromatography and pull-down assays to purify RGN and study its ability to 
bind other proteins or be post-translationally modified. RGN’s ability to directly 
interact with other proteins or be subject to post-translational modification has yet to 
be demonstrated in past publications. 
 
Another point of interest with RGN is its role in humans. RGN is known to participate 
in vitamin C synthesis as a gluconolactonase in mice. However, humans have been 
shown to express RGN even though they do not synthesise their own vitamin C. So 
what is the role of RGN in humans? RGN has been demonstrated to have the ability 
to function as a gluconolactonase (Kondo et al., 2006) and thus this enzymatic activity 
of RGN may still be relevant in humans, though not for the purpose of vitamin C 
synthesis. The present study with human RGN showed it can control intracellular 
Ca2+ stores when abundantly expressed, which may make an important contributor to 
the age-dependent loss of control in Ca2+ homeostasis that has been well documented 
in past studies (Periasamy and Kalyanasundaram, 2007). However, this is an activity 
of RGN that is unlikely to require its ability to act as a gluconolactonase.  
 
Where RGN’s enzymatic activity would fit in and be of use in humans is in the 
pentose phosphate pathway, where there is a possibility that it is the equivalent of a 6-
phosphogluconolactonase that has been described previously to be expressed in 
human erythrocytes (Bauer et al., 1983). Its molecular weight has been determined to 
be approximately 31kDa and its isoelectric point is pH 6.0, which are both features 
very similar to those of RGN. 6-phosphogluconolactonase hydrolyses 6-
phosphoglucono-δ-lactone to 6-phosphogluconate, which is a reaction that is the 
second step of the hexose monophosphate shunt and part of the pentose phosphate 
pathway (Moir and Stokes, 1988). It is also a reaction similar to that catalysed by 
RGN, which is the hydrolysis of D-glucono-δ-lactone to gluconic acid. Hence RGN 
potentially plays a role in supporting NADPH production, which would fit well with 
the anti-oxidative effects of RGN that have been noted in mice. This will have to be 
tested in the future with enzymatic experiments using human RGN and 6-
phosphoglucono-δ-lactone, although it should be noted that recombinant human RGN 
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has been previously shown to be able to hydrolyse D-glucono-δ-lactone (Chakraborti 
and Bahnson, 2010).  
 
The effects of over-expressing human RGN on SERCA protein levels shown in the 
present study also indicate another possible role for RGN. It has been suggested in the 
past that RGN can alter the expression levels of other proteins, such as L-type Ca2+ 
channel (Nakagawa and Yamaguchi, 2006), PI3K (Nakashima and Yamaguchi, 
2007), p53 (Tsurusaki and Yamaguchi, 2004) and leptin (Yamaguchi and Nakagawa, 
2007). Co-incidentally, RGN’s six-β-propeller structure strongly resembles that of 
three gene transcription repressor proteins, Tup1 (Sprague et al., 2000), UNC-37 
(Pflugrad et al., 1997) and Keap1 (Padmanabhan et al., 2008). From this, it can be 
suggested that RGN may alter the expression of some proteins by acting as a gene 
transcription repressor, which may or may not be a function that would be linked to 
its ability to bind Ca2+, and future experiments with RGN will be needed to explore 
this possibility further.  
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Abstract 
Diabetes mellitus-related vascular disease is often associated with both a 
dysregulation of Ca2+ homoeostasis and enhanced secretory activity in VSMCs 
(vascular smooth muscle cells). Here, we employ a commonly used rat cell line for 
VSMCs (A7r5 cells) to investigate the effects of glucose on the expression and 
activity of the SPCA1 (secretory pathway Ca2+-ATPase 1; also known as ATP2C1), 
which is a P-type Ca2+ pump located in the Golgi apparatus that plays a key role in 
the secretory pathway. Our results show that mRNA expression levels of SPCA1 are 
significantly increased in A7r5 cells cultured in high glucose (25.0 mM)-
supplemented medium compared with normal glucose (5.55 mM)-supplemented 
medium. SPCA1 protein expression levels and thapsigargin-insensitive Ca2+-
dependent ATPase activity were also consistent with a higher than normal expression 
level of SPCA1 in high-glucose-cultured A7r5 cells. Analysis of AVP (arginine-
vasopressin)-induced cytosolic Ca2+ transients in A7r5 cells (after pre-treatment with 
thapsigargin) showed faster rise and decay phases in cells grown in high glucose 
medium compared with cells grown in normal glucose medium, supporting the 
observation of increased SPCA expression/activity. The significant levels of both 
Ca2+-ATPase activity and AVP-induced Ca2+ transients, in the presence of 
thapsigargin, indicate that SPCA must play a significant role in Ca2+ uptake within 
VSMCs. We therefore propose that, if such increases in SPCA expression and activity 
also occur in primary VSMCs, this may play a substantial role in the aetiology of 
diabetes mellitus-associated vascular disease, due to alterations in Ca2+ homoeostasis 
within the Golgi apparatus. 
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